0001580149 2025-07-01 2026-03-31 0001580149 2025-06-30 0001580149 2024-06-30 0001580149 2026-03-31 0001580149 2024-07-01 2025-06-30 0001580149 2023-07-01 2024-06-30 0001580149 2026-01-01 2026-03-31 0001580149 2025-01-01 2025-03-31 0001580149 2024-07-01 2025-03-31 0001580149 us-gaap:CommonStockMember 2023-06-30 0001580149 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001580149 bivi:TreasuryStocksMember 2023-06-30 0001580149 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001580149 us-gaap:RetainedEarningsMember 2023-06-30 0001580149 2023-06-30 0001580149 us-gaap:CommonStockMember 2024-06-30 0001580149 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001580149 bivi:TreasuryStocksMember 2024-06-30 0001580149 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001580149 us-gaap:RetainedEarningsMember 2024-06-30 0001580149 us-gaap:CommonStockMember 2024-09-30 0001580149 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001580149 bivi:TreasuryStocksMember 2024-09-30 0001580149 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0001580149 us-gaap:RetainedEarningsMember 2024-09-30 0001580149 2024-09-30 0001580149 us-gaap:CommonStockMember 2024-12-31 0001580149 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001580149 bivi:TreasuryStocksMember 2024-12-31 0001580149 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001580149 us-gaap:RetainedEarningsMember 2024-12-31 0001580149 2024-12-31 0001580149 us-gaap:CommonStockMember 2025-06-30 0001580149 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001580149 bivi:TreasuryStocksMember 2025-06-30 0001580149 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-06-30 0001580149 us-gaap:RetainedEarningsMember 2025-06-30 0001580149 us-gaap:CommonStockMember 2025-09-30 0001580149 us-gaap:AdditionalPaidInCapitalMember 2025-09-30 0001580149 bivi:TreasuryStocksMember 2025-09-30 0001580149 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-09-30 0001580149 us-gaap:RetainedEarningsMember 2025-09-30 0001580149 2025-09-30 0001580149 us-gaap:CommonStockMember 2025-12-31 0001580149 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001580149 bivi:TreasuryStocksMember 2025-12-31 0001580149 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-12-31 0001580149 us-gaap:RetainedEarningsMember 2025-12-31 0001580149 2025-12-31 0001580149 us-gaap:CommonStockMember 2023-07-01 2024-06-30 0001580149 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2024-06-30 0001580149 bivi:TreasuryStocksMember 2023-07-01 2024-06-30 0001580149 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-01 2024-06-30 0001580149 us-gaap:RetainedEarningsMember 2023-07-01 2024-06-30 0001580149 us-gaap:CommonStockMember 2024-07-01 2025-06-30 0001580149 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2025-06-30 0001580149 bivi:TreasuryStocksMember 2024-07-01 2025-06-30 0001580149 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-01 2025-06-30 0001580149 us-gaap:RetainedEarningsMember 2024-07-01 2025-06-30 0001580149 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001580149 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001580149 bivi:TreasuryStocksMember 2024-07-01 2024-09-30 0001580149 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-01 2024-09-30 0001580149 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001580149 2024-07-01 2024-09-30 0001580149 us-gaap:CommonStockMember 2024-10-01 2024-12-31 0001580149 us-gaap:AdditionalPaidInCapitalMember 2024-10-01 2024-12-31 0001580149 bivi:TreasuryStocksMember 2024-10-01 2024-12-31 0001580149 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-10-01 2024-12-31 0001580149 us-gaap:RetainedEarningsMember 2024-10-01 2024-12-31 0001580149 2024-10-01 2024-12-31 0001580149 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001580149 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001580149 bivi:TreasuryStocksMember 2025-01-01 2025-03-31 0001580149 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-03-31 0001580149 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001580149 us-gaap:CommonStockMember 2025-07-01 2025-09-30 0001580149 us-gaap:AdditionalPaidInCapitalMember 2025-07-01 2025-09-30 0001580149 bivi:TreasuryStocksMember 2025-07-01 2025-09-30 0001580149 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-07-01 2025-09-30 0001580149 us-gaap:RetainedEarningsMember 2025-07-01 2025-09-30 0001580149 2025-07-01 2025-09-30 0001580149 us-gaap:CommonStockMember 2025-10-01 2025-12-31 0001580149 us-gaap:AdditionalPaidInCapitalMember 2025-10-01 2025-12-31 0001580149 bivi:TreasuryStocksMember 2025-10-01 2025-12-31 0001580149 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-10-01 2025-12-31 0001580149 us-gaap:RetainedEarningsMember 2025-10-01 2025-12-31 0001580149 2025-10-01 2025-12-31 0001580149 us-gaap:CommonStockMember 2026-01-01 2026-03-31 0001580149 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-03-31 0001580149 bivi:TreasuryStocksMember 2026-01-01 2026-03-31 0001580149 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-01-01 2026-03-31 0001580149 us-gaap:RetainedEarningsMember 2026-01-01 2026-03-31 0001580149 us-gaap:CommonStockMember 2025-03-31 0001580149 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001580149 bivi:TreasuryStocksMember 2025-03-31 0001580149 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0001580149 us-gaap:RetainedEarningsMember 2025-03-31 0001580149 2025-03-31 0001580149 us-gaap:CommonStockMember 2026-03-31 0001580149 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0001580149 bivi:TreasuryStocksMember 2026-03-31 0001580149 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-03-31 0001580149 us-gaap:RetainedEarningsMember 2026-03-31 0001580149 us-gaap:StockOptionMember 2024-07-01 2025-06-30 0001580149 us-gaap:StockOptionMember 2023-07-01 2024-06-30 0001580149 us-gaap:WarrantMember 2024-07-01 2025-06-30 0001580149 us-gaap:WarrantMember 2023-07-01 2024-06-30 0001580149 us-gaap:RestrictedStockUnitsRSUMember 2024-07-01 2025-06-30 0001580149 us-gaap:RestrictedStockUnitsRSUMember 2023-07-01 2024-06-30 0001580149 bivi:NotespayableConversionOptionMember 2024-07-01 2025-06-30 0001580149 bivi:NotespayableConversionOptionMember 2023-07-01 2024-06-30 0001580149 us-gaap:StockOptionMember 2025-07-01 2026-03-31 0001580149 us-gaap:StockOptionMember 2024-07-01 2025-03-31 0001580149 us-gaap:WarrantMember 2025-07-01 2026-03-31 0001580149 us-gaap:WarrantMember 2024-07-01 2025-03-31 0001580149 us-gaap:RestrictedStockUnitsRSUMember 2025-07-01 2026-03-31 0001580149 us-gaap:RestrictedStockUnitsRSUMember 2024-07-01 2025-03-31 0001580149 bivi:AcuitasGroupHoldingsLLCMember 2022-07-15 0001580149 bivi:WarrantsMember 2024-06-30 0001580149 srt:MaximumMember bivi:WarrantsMember 2024-06-30 0001580149 srt:MinimumMember bivi:WarrantsMember 2024-06-30 0001580149 bivi:WarrantsMember 2023-07-01 2024-06-30 0001580149 bivi:WarrantsMember 2024-09-30 0001580149 srt:MinimumMember bivi:WarrantsMember 2024-09-30 0001580149 srt:MaximumMember bivi:WarrantsMember 2024-09-30 0001580149 bivi:WarrantsMember 2024-07-01 2024-09-30 0001580149 bivi:WarrantsMember 2024-10-22 0001580149 srt:MaximumMember bivi:WarrantsMember 2024-10-22 0001580149 srt:MinimumMember bivi:WarrantsMember 2024-10-22 0001580149 bivi:WarrantsMember 2024-10-01 2024-10-22 0001580149 us-gaap:PrimeRateMember 2024-07-01 2025-06-30 0001580149 bivi:DerivativeLiabilityWarrantsMember us-gaap:FairValueInputsLevel3Member 2023-06-30 0001580149 bivi:DerivativeLiabilityConversionOptionMember us-gaap:FairValueInputsLevel3Member 2023-06-30 0001580149 bivi:DerivativeLiabilityWarrantsMember us-gaap:FairValueInputsLevel3Member 2023-07-01 2024-06-30 0001580149 bivi:DerivativeLiabilityConversionOptionMember us-gaap:FairValueInputsLevel3Member 2023-07-01 2024-06-30 0001580149 bivi:DerivativeLiabilityWarrantsMember us-gaap:FairValueInputsLevel3Member 2024-06-30 0001580149 bivi:DerivativeLiabilityConversionOptionMember us-gaap:FairValueInputsLevel3Member 2024-06-30 0001580149 bivi:DerivativeLiabilityWarrantsMember us-gaap:FairValueInputsLevel3Member 2024-07-01 2025-06-30 0001580149 bivi:DerivativeLiabilityConversionOptionMember us-gaap:FairValueInputsLevel3Member 2024-07-01 2025-06-30 0001580149 bivi:DerivativeLiabilityWarrantsMember us-gaap:FairValueInputsLevel3Member 2025-06-30 0001580149 bivi:DerivativeLiabilityConversionOptionMember us-gaap:FairValueInputsLevel3Member 2025-06-30 0001580149 bivi:DerivativeLiabilityConversionOptionOnConvertibleDebentureMember us-gaap:FairValueInputsLevel3Member 2024-06-30 0001580149 bivi:DerivativeLiabilityConversionOptionOnConvertibleDebentureMember us-gaap:FairValueInputsLevel3Member 2023-07-01 2024-06-30 0001580149 us-gaap:CashMember us-gaap:FairValueInputsLevel1Member 2025-06-30 0001580149 us-gaap:CashMember us-gaap:FairValueInputsLevel2Member 2025-06-30 0001580149 us-gaap:CashMember us-gaap:FairValueInputsLevel3Member 2025-06-30 0001580149 us-gaap:CashMember 2025-06-30 0001580149 us-gaap:FairValueInputsLevel1Member us-gaap:USTreasuryBillSecuritiesMember 2025-06-30 0001580149 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasuryBillSecuritiesMember 2025-06-30 0001580149 us-gaap:FairValueInputsLevel3Member us-gaap:USTreasuryBillSecuritiesMember 2025-06-30 0001580149 us-gaap:USTreasuryBillSecuritiesMember 2025-06-30 0001580149 us-gaap:FairValueInputsLevel1Member 2025-06-30 0001580149 us-gaap:FairValueInputsLevel2Member 2025-06-30 0001580149 us-gaap:FairValueInputsLevel3Member 2025-06-30 0001580149 us-gaap:CashMember us-gaap:FairValueInputsLevel1Member 2024-06-30 0001580149 us-gaap:CashMember us-gaap:FairValueInputsLevel2Member 2024-06-30 0001580149 us-gaap:CashMember us-gaap:FairValueInputsLevel3Member 2024-06-30 0001580149 us-gaap:CashMember 2024-06-30 0001580149 us-gaap:FairValueInputsLevel1Member us-gaap:USTreasuryBillSecuritiesMember 2024-06-30 0001580149 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasuryBillSecuritiesMember 2024-06-30 0001580149 us-gaap:FairValueInputsLevel3Member us-gaap:USTreasuryBillSecuritiesMember 2024-06-30 0001580149 us-gaap:USTreasuryBillSecuritiesMember 2024-06-30 0001580149 us-gaap:FairValueInputsLevel1Member 2024-06-30 0001580149 us-gaap:FairValueInputsLevel2Member 2024-06-30 0001580149 us-gaap:FairValueInputsLevel3Member 2024-06-30 0001580149 us-gaap:CashMember us-gaap:FairValueInputsLevel1Member 2026-03-31 0001580149 us-gaap:CashMember us-gaap:FairValueInputsLevel2Member 2026-03-31 0001580149 us-gaap:CashMember us-gaap:FairValueInputsLevel3Member 2026-03-31 0001580149 us-gaap:CashMember 2026-03-31 0001580149 us-gaap:FairValueInputsLevel1Member us-gaap:USTreasuryBillSecuritiesMember 2026-03-31 0001580149 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasuryBillSecuritiesMember 2026-03-31 0001580149 us-gaap:FairValueInputsLevel3Member us-gaap:USTreasuryBillSecuritiesMember 2026-03-31 0001580149 us-gaap:USTreasuryBillSecuritiesMember 2026-03-31 0001580149 us-gaap:FairValueInputsLevel1Member 2026-03-31 0001580149 us-gaap:FairValueInputsLevel2Member 2026-03-31 0001580149 us-gaap:FairValueInputsLevel3Member 2026-03-31 0001580149 us-gaap:CommonClassAMember bivi:SalesAgreementMember 2023-07-01 2024-06-30 0001580149 us-gaap:CommonClassAMember bivi:SalesAgreementMember 2024-07-01 2025-06-30 0001580149 2024-03-06 0001580149 bivi:PrefundedWarrantsMember 2024-03-06 0001580149 bivi:CommonWarrantsMember 2024-03-06 0001580149 2024-03-01 2024-03-06 0001580149 bivi:PlacementAgentsWarrantsMember 2024-03-06 0001580149 bivi:PrefundedWarrantsMember 2023-07-01 2024-06-30 0001580149 2024-09-25 0001580149 bivi:PrefundedWarrantsMember 2024-09-25 0001580149 bivi:CommonWarrantsMember 2024-09-25 0001580149 2024-09-01 2024-09-25 0001580149 bivi:PlacementAgentsWarrantsMember 2024-09-25 0001580149 2024-10-01 2024-10-31 0001580149 2024-10-31 0001580149 bivi:OctoberCommonWarrantsMember 2024-10-01 2024-10-31 0001580149 srt:MinimumMember bivi:OctoberCommonWarrantsMember 2024-10-31 0001580149 srt:MaximumMember bivi:OctoberCommonWarrantsMember 2024-10-31 0001580149 bivi:OctoberPlacementAgentsWarrantsMember 2024-10-01 2024-10-31 0001580149 bivi:September2024OfferingMember 2024-07-01 2025-06-30 0001580149 bivi:PrefundedWarrantsMember 2024-07-01 2025-06-30 0001580149 bivi:SeptemberPlacementAgentsWarrantsMember 2024-07-01 2025-06-30 0001580149 bivi:VendorMember 2024-05-01 2024-05-10 0001580149 bivi:VendorMember 2024-05-10 0001580149 bivi:VendorMember 2024-08-01 2024-08-12 0001580149 bivi:VendorMember 2024-08-12 0001580149 bivi:VendorMember 2025-04-01 2025-04-24 0001580149 bivi:VendorMember 2025-04-24 0001580149 bivi:NewEmployeeMember bivi:StockOptionsMember 2023-10-01 2023-10-03 0001580149 bivi:NewEmployeeMember srt:MinimumMember bivi:StockOptionsMember 2023-10-01 2023-10-03 0001580149 bivi:NewEmployeeMember srt:MaximumMember bivi:StockOptionsMember 2023-10-01 2023-10-03 0001580149 bivi:EmployeeMember bivi:StockOptionsMember 2024-06-01 2024-06-30 0001580149 bivi:EmployeeMember srt:MinimumMember bivi:StockOptionsMember 2024-06-01 2024-06-30 0001580149 bivi:EmployeeMember srt:MaximumMember bivi:StockOptionsMember 2024-06-01 2024-06-30 0001580149 bivi:EmployeeMember bivi:StockOptionsMember 2024-12-01 2024-12-20 0001580149 srt:DirectorMember bivi:StockOptionsMember 2024-12-01 2024-12-20 0001580149 bivi:StockOptionsMember 2024-07-01 2025-06-30 0001580149 bivi:StockOptionsMember 2023-07-01 2024-06-30 0001580149 bivi:FourDirectorMember us-gaap:RestrictedStockUnitsRSUMember 2023-11-01 2023-11-09 0001580149 bivi:TwoDirectorsMember us-gaap:RestrictedStockUnitsRSUMember 2023-11-01 2023-11-09 0001580149 us-gaap:RestrictedStockUnitsRSUMember 2023-07-01 2024-06-30 0001580149 us-gaap:RestrictedStockUnitsRSUMember 2024-07-01 2025-06-30 0001580149 srt:BoardOfDirectorsChairmanMember 2024-07-01 2025-06-30 0001580149 bivi:EmployeesMember us-gaap:RestrictedStockUnitsRSUMember 2024-06-01 2024-06-30 0001580149 bivi:TwoDirectorsMember us-gaap:RestrictedStockUnitsRSUMember 2024-11-01 2024-11-20 0001580149 bivi:ThreeDirectorsMember us-gaap:RestrictedStockUnitsRSUMember 2024-11-01 2024-11-20 0001580149 bivi:VendorMember 2024-12-28 2025-01-02 0001580149 bivi:VendorMember 2025-01-02 0001580149 bivi:AdvisoryBoardMember us-gaap:RestrictedStockUnitsRSUMember 2025-01-01 2025-01-21 0001580149 bivi:WarrantsMember 2024-10-01 2024-12-31 0001580149 bivi:WarrantsMember 2024-12-31 0001580149 srt:MaximumMember bivi:WarrantsMember 2024-12-31 0001580149 srt:MinimumMember bivi:WarrantsMember 2024-12-31 0001580149 bivi:WarrantsMember 2024-01-01 2024-12-31 0001580149 bivi:WarrantsMember 2025-07-01 2025-09-30 0001580149 srt:MaximumMember bivi:WarrantsMember 2025-09-30 0001580149 srt:MinimumMember bivi:WarrantsMember 2025-09-30 0001580149 bivi:WarrantsMember 2025-09-30 0001580149 2025-08-01 2025-08-11 0001580149 2025-08-11 0001580149 bivi:StockOptionsMember 2026-01-01 2026-03-31 0001580149 bivi:StockOptionsMember 2025-01-01 2025-03-31 0001580149 bivi:StockOptionsMember 2025-07-01 2026-03-31 0001580149 bivi:StockOptionsMember 2024-07-01 2025-03-31 0001580149 srt:DirectorMember bivi:StockOptionsMember 2025-12-30 2026-01-05 0001580149 srt:DirectorMember bivi:StockOptionsMember 2026-01-05 0001580149 srt:DirectorMember bivi:StockOptionsMember 2026-01-02 2026-01-05 0001580149 bivi:EmployeesMember bivi:StockOptionsMember 2026-01-02 2026-01-05 0001580149 bivi:EmployeesMember bivi:StockOptionsMember 2025-12-30 2026-01-05 0001580149 bivi:ConsultantMember 2025-09-01 2025-09-02 0001580149 us-gaap:RestrictedStockUnitsRSUMember 2026-01-01 2026-03-31 0001580149 us-gaap:RestrictedStockUnitsRSUMember 2025-01-01 2025-03-31 0001580149 us-gaap:RestrictedStockUnitsRSUMember 2025-07-01 2026-03-31 0001580149 us-gaap:RestrictedStockUnitsRSUMember 2024-07-01 2025-03-31 0001580149 us-gaap:WarrantMember 2025-07-01 2026-03-31 0001580149 us-gaap:WarrantMember 2026-03-31 0001580149 bivi:StockOptionsMember 2023-06-30 0001580149 bivi:StockOptionsMember 2022-07-01 2023-06-30 0001580149 bivi:StockOptionsMember 2024-06-30 0001580149 bivi:StockOptionsMember 2025-06-30 0001580149 bivi:StockOptionsMember 2026-03-31 0001580149 us-gaap:WarrantMember 2023-06-30 0001580149 us-gaap:WarrantMember 2022-07-01 2023-06-30 0001580149 us-gaap:WarrantMember 2023-07-01 2024-06-30 0001580149 us-gaap:WarrantMember 2024-06-30 0001580149 us-gaap:WarrantMember 2024-07-01 2025-06-30 0001580149 us-gaap:WarrantMember 2025-06-30 0001580149 bivi:Year2025Member 2025-06-30 0001580149 bivi:Year2026Member 2025-06-30 0001580149 bivi:Year2027Member 2025-06-30 0001580149 bivi:Year2028Member 2025-06-30 0001580149 bivi:Year2029Member 2025-06-30 0001580149 bivi:Year2030Member 2025-06-30 0001580149 bivi:Year2027Member 2026-03-31 0001580149 bivi:Year2028Member 2026-03-31 0001580149 bivi:Year2029Member 2026-03-31 0001580149 bivi:Year2030Member 2026-03-31 0001580149 bivi:Year2031Member 2026-03-31 0001580149 bivi:OfficeLeasesMember 2024-07-01 2025-06-30 0001580149 bivi:OfficeLeasesMember 2022-10-02 0001580149 bivi:OfficeLeasesMember 2024-02-12 0001580149 bivi:OfficeLeasesMember 2024-02-01 2024-02-12 0001580149 2024-02-12 0001580149 2024-02-01 2024-02-12 0001580149 bivi:OfficeLeasesMember 2025-07-01 2026-03-31 0001580149 2026-12-31 0001580149 bivi:LongCOVIDProgramMember 2025-07-01 2026-03-31 0001580149 bivi:LongCOVIDProgramMember 2026-05-01 2026-05-04 0001580149 bivi:LongCOVIDProgramMember 2026-01-01 2026-03-31 0001580149 bivi:LongCOVIDProgramMember 2025-01-01 2025-03-31 0001580149 bivi:LongCOVIDProgramMember 2024-07-01 2025-03-31 iso4217:USD shares iso4217:USD shares pure false 0001580149 S-1 BioVie Inc. NV 46-2510769 680 W Nye Lane Suite 201 Carson City NV 89703 775 888-3162 Non-accelerated Filer true false 17544547 23843798 2104050 1049897 204392 20698494 24048190 339653 406726 178341 407718 345711 345711 21562199 25208345 2200320 3586912 74464 60343 701210 5701210 3771 2274784 9352236 275430 349894 2550214 9702130 0.001 0.001 10000000 10000000 0 0 0 0 0.0001 0.0001 800000000 800000000 1917061 1914224 621641 619008 6229 349732674 -352144246 -334232661 29 27 19011985 15506215 21562199 25208345 229377 229377 9266734 23100394 8570089 8849814 18066200 32179585 -18066200 -32179585 3771 1816271 332720 2893922 853029 1136703 524080 59052 -17542120 -32120533 369465 886423 -17911585 -33006956 -12.12 -73.05 -12.12 -73.05 1477372 451853 1477372 451853 -17911585 -33006956 -176591 -176591 -17911585 -33183547 364519 3643 316385759 -229 -2 176591 -301225705 15340286 2823764 2823764 1763450 1763450 243375 2449 27800490 27802939 12240 122 -97 -2404 -25 1500 15 72885 72900 886423 -886423 -176591 -176591 7 -32120533 -32120533 6229 349732674 -2633 -27 -334232661 15506215 1195447 1195447 1202809 1202809 988395 989 15673624 15674613 11314 11 -9 -204 -2 6000 6 73674 73680 223130 224 2901117 2901341 422 369465 -369465 66159 17 -17 -17542120 -17542120 7476 371148784 -29 -352144246 19011985 -17542120 -32120533 229377 229377 1202809 1763450 1195447 2823764 73680 72900 11820 108751 -111212 -1023145 25758 236970 223865 67073 49346 5215 3771 1816271 2104050 845505 101866 -1386592 110653 -60343 -47245 -48385 -19025205 -27945024 -14525000 14525000 15674613 27802939 2901341 -10000000 850000 5000000 12725954 17802939 -6299251 4382915 23843798 19460883 17544547 23843798 183930 1525056 432192 -176591 369465 886423 <p id="xdx_808_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zEyZ7uWyKlxc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.5in; font-size: 10pt"><b>1.</b></td> <td style="font-size: 10pt"><b><span id="xdx_825_z83EAuLWT9ki">Background Information</span></b></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">BioVie Inc. (the “Company” or “we” or “our”) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Neurodegenerative Disease Programs</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company acquired the biopharmaceutical assets of NeurMedix, Inc. (“NeurMedix”) a privately held clinical-stage pharmaceutical company and a related party in June 2021. The acquired assets included NE3107 (or “bezisterim”). Bezisterim, the approved generic name for NE3107 is an investigational, novel, orally administered small molecule that is thought to inhibit inflammation-driven insulin resistance and major pathological inflammatory cascades with a novel mechanism of action. There is emerging scientific consensus that both inflammation and insulin resistance may play fundamental roles in the development of Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), and bezisterim could, if approved by the U.S. Food and Drug Administration (“FDA”), represent an entirely new medical approach to treating these devastating conditions affecting an estimated 6 million Americans suffering from AD, 1 million Americans suffering from PD and Long COVID affects approximately 20 million adults in the US, and millions more worldwide.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In neurodegenerative disease, the Company’s drug candidate bezisterim is an orally bioavailable, Blood Brain Barrier (“BBB”)-permeable, insulin-sensitizer that is also anti-inflammatory. In addition, it is not immunosuppressive and has a low risk of drug-drug interaction. Bezisterim inhibits activation of inflammatory action extracellular single regulated kinase (“ERK”) and nuclear factor kappa-light-chain-enhancer of activated B cells (“NFκB”) (including interactions with tumor necrosis factor (“TNF”) signaling and other relevant inflammatory pathways) that lead to neuroinflammation and insulin resistance. By binding to ERK and selectively modulating NFκB activation and TNF-α production and not interfere with their homeostatic functions, BioVie believes that bezisterim may offer clinical improvements in several disease indications, including PD, AD and long COVID.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Parkinson’s Disease </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company designed a new Phase 2b study of bezisterim as a potential first line therapy to treat patients with new onset PD. This trial will be evaluating the safety and efficacy of bezisterim on motor and non-motor symptoms in patients with PD who haven’t been treated with carbidopa/levodopa. The PD Phase 2b study, multicenter, randomized, double-blind, placebo-controlled trial with a hybrid decentralized design will last 20 weeks from the initial screening phase to the safety follow up. In July 2024, the Company submitted the new protocol and received a response from the FDA permitting the Company to proceed with the study. The trial commenced in April 2025.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Phase 2 study of bezisterim for the treatment of PD (NCT05083260) that completed in December 2022, was a double-blind, placebo-controlled, safety, tolerability, and pharmacokinetics study in PD participants treated with carbidopa/levodopa and bezisterim. Forty-five patients with a defined L-dopa “off state” were randomized 1:1 to placebo: bezisterim 20 mg twice daily for 28 days. This trial was launched with two design objectives: 1) the primary objective was safety and a drug-drug interaction study as requested by the FDA to measure the potential for adverse interactions of bezisterim with carbidopa/ levodopa; and 2) the secondary objective was to determine if preclinical indications of promotoric activity and apparent enhancement of levodopa activity could be seen in humans. Both objectives were met.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Long COVID Program</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Long COVID is a condition in which symptoms of COVID-19, the acute respiratory disease caused by the SARS-CoV-2 virus, persist for an extended period, generally three months or more. Common symptoms include lingering loss of smell and taste, extreme fatigue, and “brain fog,” though persistent cardiovascular and respiratory problems, muscle weakness, and neurologic issues have also been documented.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In April 2024, the Company was awarded a clinical trial grant of $13.1 million from the U.S. Department of Defense (“DOD”), awarded through the Peer Reviewed Medical Research Program of the Congressionally Directed Medical Research Programs. In August 2024, U.S. Army Medical Research and Development Command, Office of Human Research Oversight (“OHRO”) approved the Company’s plan to evaluate bezisterim for the treatment of neurological symptoms that are associated with long COVID and the FDA authorized our Investigational New Drug (“IND”) application for bezisterim allowing the Company to study a novel, anti-inflammatory approach or the treatment of the debilitating neurocognitive symptoms associated with long COVID.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Phase 2 ADDRESS-LC study is a randomized (1:1), placebo-controlled, multicenter trial evaluating the efficacy, safety and tolerability of bezisterim in adult participants with long COVID who have cognitive impairment sequelae and fatigue. Individuals who have been diagnosed with long COVID and have neurocognitive dysfunction and self-reported fatigue may meet qualification criteria.<span style="font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The trial commenced in May 2025. As of June 30, 2025, the total cost incurred was approximately $5.3 million and as of August 4, 2025 approximately $5.3 million was reimbursed.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Alzheimer’s Disease</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 29, 2023, the Company announced the analysis of its unblinded, topline efficacy data from its Phase 3 clinical trial (NCT04669028) of bezisterim in the treatment of mild to moderate AD. The study had co-primary endpoints looking at cognition using the Alzheimer’s Disease Assessment Scale-Cognitive Scale (ADAS-Cog 12) and function using the Clinical Dementia Rating-Sum of Boxes (CDR-SB). Patients were randomly assigned, 1:1 versus placebo, to receive sequentially 5 mg of bezisterim orally twice a day for 14 days, then 10 mg orally twice a day for 14 days, followed by 26 weeks of 20 mg orally twice daily.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon trial completion, as the Company began the process of unblinding the trial data, the Company found significant deviation from protocol and current good clinical practices (“cGCPs”) violations at 15 study sites (virtually all of which were from one geographic area). This highly unusual level of suspected improprieties led the Company to exclude all patients from these sites and to refer the sites to the FDA Office of Scientific Investigations (“OSI”) for potential further action. After the patient exclusions, 81 patients remained in the Modified Intent to Treat population, 57 of whom were in the Per-Protocol population which included those who completed the trial and were verified to take study drug from pharmacokinetic data.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The trial was originally designed to be 80% powered with 125 patients in each of the treatment and placebo arms. The unplanned exclusion of so many patients left the trial underpowered for the primary endpoints. In the Per-Protocol population, which included those patients who completed the trial and who were further verified to have taken the study drug (based on pharmacokinetic data), an observed descriptive change from baseline appeared to suggest a slowing of cognitive loss; these same patients experienced an advantage in age deceleration vs. placebo as measured by DNA epigenetic change. Age deceleration is used by longevity researchers to measure the difference between the patient’s biological age, in this case as measured by the Horvath DNA methylation Skin Blood Clock, relative to the patient’s actual chronological age. This test was a non-primary/secondary endpoint, other-outcome measure, done via blood test collected at week 30 (end of study). Additional DNA methylation data continues to be collected and analyzed.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Liver Cirrhosis Program</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In liver disease, our investigational drug candidate BIV201 (continuous infusion terlipressin), which was granted both FDA Fast Track designation status and FDA Orphan Drug Status, is being evaluated as a treatment option for patients suffering from ascites and other life-threatening complications of advanced liver cirrhosis caused by non-alcoholic steatohepatitis (NASH), hepatitis, and alcoholism. The initial target for BIV201 therapy was refractory ascites. These patients suffer from frequent life-threatening complications, generate more than $5 billion in annual treatment costs, and have an estimated 50% mortality rate within 6 to 12 months.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">After receiving guidance from the FDA regarding the design of Phase 3 clinical testing of BIV201 for the treatment of patients with cirrhosis and ascites, the Company is now targeting a broader ascites patient population. The Company is currently finalizing the protocol design for the Phase 3 study of BIV201 with a focus on demonstrating clinical benefit through a composite primary endpoint of complications and disease progression in patients with cirrhosis and ascites who have recently recovered from acute kidney injury (“AKI”). This patient population is not limited to those having refractory ascites. Ascites is a common complication of advanced liver cirrhosis involving the accumulation of large volumes of fluid in the abdomen, often exceeding five liters, due to liver and kidney dysfunction. BIV201 is administered in a continuous infusion of terlipressin as a patent-pending liquid formulation with patents issued in the U.S., China, Japan, Chile and India to date. Terlipressin, the drug is used in over 40 countries to treat related complications of liver cirrhosis (Type 1 hepatorenal syndrome and bleeding esophageal varices) that was approved in the U.S. in 2022 (to improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function) but is not approved in Japan.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The BIV201 development program was initiated by LAT Pharma LLC. On April 11, 2016, BioVie acquired LAT Pharma LLC and the rights to its BIV201 development program and currently owns all development and marketing rights to this drug candidate. Pursuant to the Agreement and Plan of Merger entered into on April 11, 2016, between predecessor entities, LAT Pharma LLC and NanoAntibiotics, Inc., BioVie is obligated to pay a low single digit royalty on net sales of BIV201 (continuous infusion terlipressin) to be shared among LAT Pharma Members, PharmaIn Corporation, and The Barrett Edge, Inc. Pursuant to the separation agreement to be entered into between the Company and BioVie, the Company will assume the royalty agreement and will be obligated to pay 5.0% on net sales of BIV201 (continuous infusion terlipressin) to be shared among LAT Pharma Members, PharmaIn Corporation, and The Barrett Edge, Inc.</p> <p id="xdx_801_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_z9bIoXoDiEQ7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.5in; font-size: 10pt; text-align: justify"><b>2.</b></td> <td style="font-size: 10pt; text-align: justify"><b><span id="xdx_82C_zJ9XfUBHsUDk">Liquidity and Going Concern</span></b></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s operations are subject to a number of factors that can affect its operating results and financial conditions. Such factors include, but are not limited to: the results of clinical testing and trial activities of the Company’s products, the Company’s ability to obtain regulatory approval to market its products; competition from products manufactured and sold or being developed by other companies; the price of, and demand for, Company products; the Company’s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products; and the Company’s ability to raise capital. The Company’s financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As of June 30, 2025, the Company had working capital of approximately $<span id="xdx_903_ecustom--WorkingCapital_iI_pp0n6_c20250630_z9BfVzx9RCU" title="Working capital">18.4</span> million, cash and cash equivalents of approximately $<span id="xdx_902_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0n6_c20250630_zKyiK9keTT19" title="Cash and cash equivalent">17.5</span> million, stockholders’ equity of approximately $<span id="xdx_90E_ecustom--StockholderEquities_iI_pp0n6_c20250630_z7RwWvcHrYz5" title="Stockholders' equity">19.0</span> million, and an accumulated deficit of approximately $<span id="xdx_903_ecustom--AccumulatedDeficit_iI_pp0n6_c20250630_zuusBY0yLgBe" title="Accumulated deficit">352.1</span> million. The Company is in the pre-revenue stage and no revenues are expected in the foreseeable future. The Company’s future operations are dependent on the success of the Company’s ongoing development and commercialization efforts, as well as its ability to secure additional financing as needed. Projected cash flows could be extended if further measures are taken to delay planned expenditures in our research protocols and slow the progress in the Company’s development and launch of next phase clinical programs.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The future viability of the Company is largely dependent upon its ability to raise additional capital to finance its operations. Management expects that future sources of funding may include sales of equity, obtaining loans, or other strategic transactions.<span style="font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Although management continues to pursue the Company’s strategic plans, there is no assurance that the Company will be successful in obtaining sufficient financing on terms acceptable to the Company, if at all, to fund continuing operations. These circumstances raise substantial doubt on the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p> 18400000 17500000 19000000.0 352100000 <p id="xdx_806_eus-gaap--SignificantAccountingPoliciesTextBlock_zSrnPsAG1oX9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.5in; font-size: 10pt; text-align: justify"><b>3.</b></td> <td style="font-size: 10pt; text-align: justify"><b><span id="xdx_825_zQPQFJwu4AEf">Significant Accounting Policies</span></b></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_84E_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zkzYaSw9zUg6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span id="xdx_869_zifGcXVAs4r3">Basis of Presentation</span> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and include all adjustments necessary for the fair presentation of the Company’s financial position for the periods presented.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_844_ecustom--ReverseStockSpliteUpPolicyTextBlock_zOoptissNEzc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span id="xdx_866_zMoI9Mw9G6Z1">Reverse stock split up</span> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company effected a <span id="xdx_902_eus-gaap--StockholdersEquityReverseStockSplit_c20240701__20250630_zfczJPCMFNha" title="Reverse split">1:10 reverse split</span> of the issued and outstanding shares of its Common Stock which was approved by the board of directors after the approval obtained from shareholders at a special meeting on June 23, 2025 which became effective on July 7, 2025. All historical share and earnings per share amounts have been retroactively adjusted to reflect the split. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_84C_eus-gaap--UseOfEstimates_zft2QJf5f5Za" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span id="xdx_86D_zkezlhSravc1">Use of Estimates</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company bases its estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances. The amounts of assets and liabilities reported in the Company’s balance sheets and the amounts of expenses reported for each of the periods presented in the statements of operations and comprehensive loss are affected by estimates and assumptions, which are used for, but not limited to, accounting for clinical accruals, share-based compensation, assumptions used in recording leases, the inputs used in the valuation of goodwill and intangible assets in connection with impairment testing and accounting for income taxes. Actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_84A_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zttVwgEEYHoc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span id="xdx_86A_zfMSUMokmem2">Cash and cash equivalents</span> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash and cash equivalents consisted of cash deposits and money market funds held at a bank and funds held in a brokerage account which included a U.S. treasury money market fund and U.S. Treasury Bills with original maturities of three months or less.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_840_ecustom--InvestmentsUSTreasuryBillsPolicyTextBlock_zHg8AMyLozy8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span id="xdx_86D_zKP2ijSlKuX9">Investments in U.S. Treasury Bills</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Investments in U.S. Treasury Bills with maturities greater than three months, are accounted for as available-for-sale and are recorded at fair value. Unrealized gains were included in other comprehensive income in the accompanying statements of operations and comprehensive loss.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_84B_ecustom--ConcentrationOfCreditRiskinTheFinancialServiceIndustryPolicyTextBlock_zfshjIl1M355" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span id="xdx_861_zUWx9aDKC5R">Concentration of Credit Risk in the Financial Service Industry</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 30, 2025, the Company had cash deposited in a certain financial institution in excess of federally insured levels. The Company regularly monitors the financial stability of these financial institutions and believes that it is not exposed to any significant credit risk in cash and cash equivalents. However, if liquidity and financial stability concerns arise with respect to banks and financial institutions, either nationally or in specific regions, the Company’s ability to access cash or enter into new financing arrangements may be threatened, which could have a material adverse effect on its business, financial condition and results of operations. <span style="font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <p id="xdx_846_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zMc7KVeXB8fc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span id="xdx_86C_zcRcgQ8Ov8Xc">Fair value measurement of assets and liabilities</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We determine the fair values of our financial instruments based on the fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value assumes that the transaction to sell the asset or transfer the liability occurs in the principal or most advantageous market for the asset or liability and establishes that the fair value of an asset or liability shall be determined based on the assumptions that market participants would use in pricing the asset or liability. The classification of a financial asset or liability within the hierarchy is based upon the lowest level input that is significant to the fair value measurement. The fair value hierarchy prioritizes the inputs into three levels that may be used to measure fair value:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 1 - Inputs are unadjusted quoted prices in active markets for identical assets or liabilities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 2 - Inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 3 - Inputs are unobservable inputs based on our assumptions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s financial instruments include cash, accounts payable, the carrying value of the operating lease liabilities and notes payable. The carrying amounts of cash and accounts payable approximate their fair value, due to the short-term nature of these items. The carrying amounts of notes payable and operating lease liabilities approximate their fair values since they bear interest at rates which approximate market rates for similar debt instruments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_842_ecustom--PrepaidAndOtherAssetsPolicyTextBlock_z6HLAvF3LRh4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span id="xdx_865_zlWmMMS1X0Hf">Prepaid and other assets</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prepaid and other assets consist of prepayments of certain expenses such as cost related to capital raise activities; and a security deposit paid in connection with a lease agreement.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_84E_eus-gaap--LesseeLeasesPolicyTextBlock_z7mDsR5bpgDg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span id="xdx_867_zLx8fB7gjTwf">Leases</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company determines whether an arrangement contains a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, current portion of operating lease liabilities, and operating lease liabilities, net of current portion on our balance sheets. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. As the Company’s leases do not provide an implicit rate, an incremental borrowing rate is used based on the information available at the commencement date in determining the present value of lease payments. The Company does not include options to extend or terminate the lease term in its calculation unless it is reasonably certain that the Company will exercise any such options. Rent expense is recognized under the operating leases on a straight-line basis. The Company does not recognize right-of-use assets or lease liabilities for short-term leases, which have a lease term of 12 months or less at inception, and instead will recognize lease payments as expense on a straight-line basis over the lease term.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_847_eus-gaap--ResearchAndDevelopmentExpensePolicy_zh5fq8Zxtrpf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span id="xdx_866_zr6iAwMm3UIf">Research and Development</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development expenses consist primarily of costs associated with the preclinical and/or clinical trials of drug candidates, compensation and other expenses for research and development, personnel, supplies and development materials, costs for consultants and related contracted research costs.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_840_eus-gaap--IncomeTaxPolicyTextBlock_za6o1LOnWFGb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span id="xdx_86E_zlA35HbKZNt7">Income Taxes</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company uses the asset and liability method of accounting for deferred income taxes. Deferred income taxes are measured by applying enacted statutory rates to net operating loss carryforwards and to the differences between the financial reporting and tax bases of assets and liabilities. Deferred tax assets are reduced, by a valuation allowance if it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company decided to apply a full valuation allowance against its deferred tax assets due to the continuing losses. <span style="font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognizes uncertainty in income taxes in the financial statements using a recognition threshold and measurement attribute of a tax position taken or expected to be taken in a tax return. The Company applies the “more-likely-than-not” recognition threshold to all tax positions, commencing at the adoption date of the applicable accounting guidance, which resulted in no unrecognized tax benefits as of such date. Additionally, there have been no unrecognized tax benefits subsequent to adoption. The Company has opted to classify interest and penalties that would accrue, if any, according to the provisions of relevant tax law as general and administrative expenses, in the Statements of Operations and Comprehensive Loss. For the years ended June 30, 2025 and 2024, there was no such interest or penalties.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p id="xdx_84B_eus-gaap--EarningsPerSharePolicyTextBlock_zffV0Mtnfhf2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span><span id="xdx_86E_zklmtLEkJkl">Net Loss per Common Share</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic net loss per common share is computed by dividing the net loss attributable to Common Stockholders by the weighted average number of shares of Common Stock outstanding during the period. Diluted net loss per common share is computed by dividing the net loss attributable to Common Stockholders by the weighted average number of shares of Common Stock outstanding and potentially outstanding shares of Common Stock during the period to reflect the potential dilution that could occur from common shares issuable through stock options, warrants, and convertible debentures. For the years ended June 30, 2025 and 2024, such amounts were excluded from the diluted loss since their effect was considered anti-dilutive due to the net loss for the periods presented.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The table below shows the potential shares of common stock, presented based on amounts outstanding at each year end, that were excluded from the computation of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_88F_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zdpo3kinTvZf" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Significant Accounting Policies (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td><span id="xdx_8BD_zYGPeaX5Jsee" style="display: none">Schedule of dilutive securities were excluded from the computation of diluted loss per share</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">June 30, 2025</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">June 30, 2024</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%; text-align: left">Stock Options</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240701__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zWVBjy6hEBM9" style="width: 14%; text-align: right" title="Total">84,872</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_pdd" style="width: 14%; text-align: right" title="Total">51,808</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240701__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zEQ8n4P6OQbf" style="text-align: right" title="Total">960,098</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="text-align: right" title="Total">193,203</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Restricted Stock Units</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240701__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zN6dmbntRVOa" style="text-align: right" title="Total">7,212</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" style="text-align: right" title="Total">4,030</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Notes payable conversion option</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240701__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--NotespayableConversionOptionMember_zeYYl8VFXG73" style="border-bottom: Black 1pt solid; text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0574">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--NotespayableConversionOptionMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Total">7,164</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240701__20250630_zG1h1MUrgkEe" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Total">1,052,182</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20240630_pdd" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Total">256,205</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_843_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zSdZy4JNKjch" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i><span id="xdx_862_ziG9U2YABppa">Stock-based Compensation</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has accounted for stock-based compensation under the provisions of Accounting Standards Codification (“ASC”) Topic 718 – “Stock Compensation” (“ASC 718”) which requires the use of the fair-value based method to determine compensation for all arrangements under which employees and others receive shares of stock or equity instruments (stock options and Common Stock purchase warrants). For employees and non-employees awards, the fair value of each stock option award is estimated on the date of grant using the Black-Scholes valuation model that uses assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate, and is generally recognized as an expense over the requisite service period, net of forfeitures which are recorded as they occur. Expected volatilities are based on historical volatility of peer companies and other factors estimated over the expected term of the stock options. For employee and non-employee awards, the expected term of options granted is derived using the “simplified method” which computes expected term as the average of the sum of the vesting term plus the contract term. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the period of the expected term. The Company recognizes forfeitures as they occur.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_846_eus-gaap--GoodwillAndIntangibleAssetsGoodwillPolicy_zFbhG8uEqhcj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span id="xdx_86B_zShJSMz34Pzf">Goodwill</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Goodwill is recorded when the purchase price paid for an acquisition exceeds the fair value of the net identified tangible and intangible assets acquired. The Company performs an annual impairment test of goodwill and further periodic tests to the extent indicators of impairment develop between annual impairment tests. The Company’s impairment review process compares the fair value of the reporting unit to its carrying value, including the goodwill related to the reporting unit. To determine the fair value of the reporting unit, the Company may use various approaches including an asset or cost approach, market approach or income approach or any combination thereof. These approaches may require the Company to make certain estimates and assumptions including future cash flows, revenue and expenses. These estimates and assumptions are reviewed each time the Company tests goodwill for impairment and are typically developed as part of the Company’s routine business planning and forecasting process. While the Company believes its estimates and assumptions are reasonable, variations from those estimates could produce materially different results. The Company did not recognize any goodwill impairments for the years ended June 30, 2025 and 2024. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <p id="xdx_847_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_znyIoTK9cYZe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span id="xdx_86C_zJK0NIsDDHi1">Impairment of Long-Lived Assets</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Long-lived assets, including intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the carrying amount of an asset exceeds its undiscounted estimated future cash flows, an impairment review is performed. An impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset. Generally, fair value is determined using valuation techniques such as expected discounted cash flows or appraisals, as appropriate. Assets to be disposed of would be separately presented in the balance sheet and reported at the lower of the carrying amount or fair value less costs to sell, and are no longer depreciated or amortized. The assets and liabilities of a disposed group classified as held for sale would be presented separately in the appropriate asset and liability sections of the balance sheets. The Company did not recognize any long-lived asset impairments for the years ended June 30, 2025 and 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_84F_ecustom--GrantProgramPolicyTextBlock_zkWrpYsDfbid" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span id="xdx_869_zeTw3csE4ARb">Grant program</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company records expenses related to the DOD Long Covid Program as such expenses are incurred. The reimbursement of such expenses is recognized upon receipt of the reimbursement, or when it is probable the reimbursement will be received, as a credit against the respective expense account.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_84D_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zec7Y7DAfIV5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span id="xdx_86E_zPoC4EnIesAh">Segment Reporting</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company operates as one operating segment with a focus on its efforts to develop drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. The Company's Chief Executive Officer (“CEO”), as the chief operating decision maker, manages and allocates resources to the operations of the Company based on the line items included within these financial statements. This enables the CEO to assess the overall level of available resources and determine how best to deploy these resources across functions, clinical trials, and development projects in line with the long-term company-wide strategic goals. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_844_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zhTOoBiezSCf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span id="xdx_86D_zCimpUh7MHEj">Recent Accounting Pronouncements</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company considers the applicability and impact of all Accounting Standards Updates (“ASU’s”).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2023, the FASB issued ASU 2023-09, "Income Taxes (Topic 740): Improvements in Income Tax Disclosures" to enhance the transparency and decision usefulness of income tax disclosures. This amendment requires public companies to disclose specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold. Additionally, under the amendment entities are required to disclose the amount of income taxes paid disaggregated by federal, state and foreign taxes, as well as disaggregated by material individual jurisdictions. Finally, the amendment requires entities to disclose income from continuing operations before income tax expense disaggregated between domestic and foreign and income tax expense from continuing operations disaggregated by federal, state and foreign. The new rules are effective for annual periods beginning after December 15, 2024. The standard will be adopted on a prospective basis and is not expected to have a material impact to our financial statements or disclosures.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ASU 2023-07: Segment Reporting Topic 280 - Improvements to Reportable Segment Disclosures. This update requires expanded annual and interim disclosures for significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss. This update is effective for fiscal years beginning after December 15, 2023. The Company adopted ASU 2023-07 in the current fiscal year.</p> <p id="xdx_84E_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zkzYaSw9zUg6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span id="xdx_869_zifGcXVAs4r3">Basis of Presentation</span> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and include all adjustments necessary for the fair presentation of the Company’s financial position for the periods presented.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_844_ecustom--ReverseStockSpliteUpPolicyTextBlock_zOoptissNEzc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span id="xdx_866_zMoI9Mw9G6Z1">Reverse stock split up</span> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company effected a <span id="xdx_902_eus-gaap--StockholdersEquityReverseStockSplit_c20240701__20250630_zfczJPCMFNha" title="Reverse split">1:10 reverse split</span> of the issued and outstanding shares of its Common Stock which was approved by the board of directors after the approval obtained from shareholders at a special meeting on June 23, 2025 which became effective on July 7, 2025. All historical share and earnings per share amounts have been retroactively adjusted to reflect the split. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 1:10 reverse split <p id="xdx_84C_eus-gaap--UseOfEstimates_zft2QJf5f5Za" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span id="xdx_86D_zkezlhSravc1">Use of Estimates</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company bases its estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances. The amounts of assets and liabilities reported in the Company’s balance sheets and the amounts of expenses reported for each of the periods presented in the statements of operations and comprehensive loss are affected by estimates and assumptions, which are used for, but not limited to, accounting for clinical accruals, share-based compensation, assumptions used in recording leases, the inputs used in the valuation of goodwill and intangible assets in connection with impairment testing and accounting for income taxes. Actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_84A_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zttVwgEEYHoc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span id="xdx_86A_zfMSUMokmem2">Cash and cash equivalents</span> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash and cash equivalents consisted of cash deposits and money market funds held at a bank and funds held in a brokerage account which included a U.S. treasury money market fund and U.S. Treasury Bills with original maturities of three months or less.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_840_ecustom--InvestmentsUSTreasuryBillsPolicyTextBlock_zHg8AMyLozy8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span id="xdx_86D_zKP2ijSlKuX9">Investments in U.S. Treasury Bills</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Investments in U.S. Treasury Bills with maturities greater than three months, are accounted for as available-for-sale and are recorded at fair value. Unrealized gains were included in other comprehensive income in the accompanying statements of operations and comprehensive loss.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_84B_ecustom--ConcentrationOfCreditRiskinTheFinancialServiceIndustryPolicyTextBlock_zfshjIl1M355" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span id="xdx_861_zUWx9aDKC5R">Concentration of Credit Risk in the Financial Service Industry</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 30, 2025, the Company had cash deposited in a certain financial institution in excess of federally insured levels. The Company regularly monitors the financial stability of these financial institutions and believes that it is not exposed to any significant credit risk in cash and cash equivalents. However, if liquidity and financial stability concerns arise with respect to banks and financial institutions, either nationally or in specific regions, the Company’s ability to access cash or enter into new financing arrangements may be threatened, which could have a material adverse effect on its business, financial condition and results of operations. <span style="font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <p id="xdx_846_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zMc7KVeXB8fc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span id="xdx_86C_zcRcgQ8Ov8Xc">Fair value measurement of assets and liabilities</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We determine the fair values of our financial instruments based on the fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value assumes that the transaction to sell the asset or transfer the liability occurs in the principal or most advantageous market for the asset or liability and establishes that the fair value of an asset or liability shall be determined based on the assumptions that market participants would use in pricing the asset or liability. The classification of a financial asset or liability within the hierarchy is based upon the lowest level input that is significant to the fair value measurement. The fair value hierarchy prioritizes the inputs into three levels that may be used to measure fair value:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 1 - Inputs are unadjusted quoted prices in active markets for identical assets or liabilities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 2 - Inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 3 - Inputs are unobservable inputs based on our assumptions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s financial instruments include cash, accounts payable, the carrying value of the operating lease liabilities and notes payable. The carrying amounts of cash and accounts payable approximate their fair value, due to the short-term nature of these items. The carrying amounts of notes payable and operating lease liabilities approximate their fair values since they bear interest at rates which approximate market rates for similar debt instruments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_842_ecustom--PrepaidAndOtherAssetsPolicyTextBlock_z6HLAvF3LRh4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span id="xdx_865_zlWmMMS1X0Hf">Prepaid and other assets</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prepaid and other assets consist of prepayments of certain expenses such as cost related to capital raise activities; and a security deposit paid in connection with a lease agreement.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_84E_eus-gaap--LesseeLeasesPolicyTextBlock_z7mDsR5bpgDg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span id="xdx_867_zLx8fB7gjTwf">Leases</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company determines whether an arrangement contains a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, current portion of operating lease liabilities, and operating lease liabilities, net of current portion on our balance sheets. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. As the Company’s leases do not provide an implicit rate, an incremental borrowing rate is used based on the information available at the commencement date in determining the present value of lease payments. The Company does not include options to extend or terminate the lease term in its calculation unless it is reasonably certain that the Company will exercise any such options. Rent expense is recognized under the operating leases on a straight-line basis. The Company does not recognize right-of-use assets or lease liabilities for short-term leases, which have a lease term of 12 months or less at inception, and instead will recognize lease payments as expense on a straight-line basis over the lease term.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_847_eus-gaap--ResearchAndDevelopmentExpensePolicy_zh5fq8Zxtrpf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span id="xdx_866_zr6iAwMm3UIf">Research and Development</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development expenses consist primarily of costs associated with the preclinical and/or clinical trials of drug candidates, compensation and other expenses for research and development, personnel, supplies and development materials, costs for consultants and related contracted research costs.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_840_eus-gaap--IncomeTaxPolicyTextBlock_za6o1LOnWFGb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span id="xdx_86E_zlA35HbKZNt7">Income Taxes</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company uses the asset and liability method of accounting for deferred income taxes. Deferred income taxes are measured by applying enacted statutory rates to net operating loss carryforwards and to the differences between the financial reporting and tax bases of assets and liabilities. Deferred tax assets are reduced, by a valuation allowance if it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company decided to apply a full valuation allowance against its deferred tax assets due to the continuing losses. <span style="font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognizes uncertainty in income taxes in the financial statements using a recognition threshold and measurement attribute of a tax position taken or expected to be taken in a tax return. The Company applies the “more-likely-than-not” recognition threshold to all tax positions, commencing at the adoption date of the applicable accounting guidance, which resulted in no unrecognized tax benefits as of such date. Additionally, there have been no unrecognized tax benefits subsequent to adoption. The Company has opted to classify interest and penalties that would accrue, if any, according to the provisions of relevant tax law as general and administrative expenses, in the Statements of Operations and Comprehensive Loss. For the years ended June 30, 2025 and 2024, there was no such interest or penalties.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p id="xdx_84B_eus-gaap--EarningsPerSharePolicyTextBlock_zffV0Mtnfhf2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span><span id="xdx_86E_zklmtLEkJkl">Net Loss per Common Share</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic net loss per common share is computed by dividing the net loss attributable to Common Stockholders by the weighted average number of shares of Common Stock outstanding during the period. Diluted net loss per common share is computed by dividing the net loss attributable to Common Stockholders by the weighted average number of shares of Common Stock outstanding and potentially outstanding shares of Common Stock during the period to reflect the potential dilution that could occur from common shares issuable through stock options, warrants, and convertible debentures. For the years ended June 30, 2025 and 2024, such amounts were excluded from the diluted loss since their effect was considered anti-dilutive due to the net loss for the periods presented.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The table below shows the potential shares of common stock, presented based on amounts outstanding at each year end, that were excluded from the computation of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_88F_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zdpo3kinTvZf" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Significant Accounting Policies (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td><span id="xdx_8BD_zYGPeaX5Jsee" style="display: none">Schedule of dilutive securities were excluded from the computation of diluted loss per share</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">June 30, 2025</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">June 30, 2024</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%; text-align: left">Stock Options</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240701__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zWVBjy6hEBM9" style="width: 14%; text-align: right" title="Total">84,872</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_pdd" style="width: 14%; text-align: right" title="Total">51,808</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240701__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zEQ8n4P6OQbf" style="text-align: right" title="Total">960,098</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="text-align: right" title="Total">193,203</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Restricted Stock Units</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240701__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zN6dmbntRVOa" style="text-align: right" title="Total">7,212</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" style="text-align: right" title="Total">4,030</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Notes payable conversion option</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240701__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--NotespayableConversionOptionMember_zeYYl8VFXG73" style="border-bottom: Black 1pt solid; text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0574">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--NotespayableConversionOptionMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Total">7,164</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240701__20250630_zG1h1MUrgkEe" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Total">1,052,182</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20240630_pdd" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Total">256,205</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_88F_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zdpo3kinTvZf" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Significant Accounting Policies (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td><span id="xdx_8BD_zYGPeaX5Jsee" style="display: none">Schedule of dilutive securities were excluded from the computation of diluted loss per share</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">June 30, 2025</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">June 30, 2024</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%; text-align: left">Stock Options</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240701__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zWVBjy6hEBM9" style="width: 14%; text-align: right" title="Total">84,872</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_pdd" style="width: 14%; text-align: right" title="Total">51,808</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240701__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zEQ8n4P6OQbf" style="text-align: right" title="Total">960,098</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="text-align: right" title="Total">193,203</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Restricted Stock Units</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240701__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zN6dmbntRVOa" style="text-align: right" title="Total">7,212</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" style="text-align: right" title="Total">4,030</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Notes payable conversion option</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240701__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--NotespayableConversionOptionMember_zeYYl8VFXG73" style="border-bottom: Black 1pt solid; text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0574">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--NotespayableConversionOptionMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Total">7,164</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240701__20250630_zG1h1MUrgkEe" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Total">1,052,182</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20240630_pdd" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Total">256,205</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table> 84872 51808 960098 193203 7212 4030 7164 1052182 256205 <p id="xdx_843_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zSdZy4JNKjch" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i><span id="xdx_862_ziG9U2YABppa">Stock-based Compensation</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has accounted for stock-based compensation under the provisions of Accounting Standards Codification (“ASC”) Topic 718 – “Stock Compensation” (“ASC 718”) which requires the use of the fair-value based method to determine compensation for all arrangements under which employees and others receive shares of stock or equity instruments (stock options and Common Stock purchase warrants). For employees and non-employees awards, the fair value of each stock option award is estimated on the date of grant using the Black-Scholes valuation model that uses assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate, and is generally recognized as an expense over the requisite service period, net of forfeitures which are recorded as they occur. Expected volatilities are based on historical volatility of peer companies and other factors estimated over the expected term of the stock options. For employee and non-employee awards, the expected term of options granted is derived using the “simplified method” which computes expected term as the average of the sum of the vesting term plus the contract term. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the period of the expected term. The Company recognizes forfeitures as they occur.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_846_eus-gaap--GoodwillAndIntangibleAssetsGoodwillPolicy_zFbhG8uEqhcj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span id="xdx_86B_zShJSMz34Pzf">Goodwill</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Goodwill is recorded when the purchase price paid for an acquisition exceeds the fair value of the net identified tangible and intangible assets acquired. The Company performs an annual impairment test of goodwill and further periodic tests to the extent indicators of impairment develop between annual impairment tests. The Company’s impairment review process compares the fair value of the reporting unit to its carrying value, including the goodwill related to the reporting unit. To determine the fair value of the reporting unit, the Company may use various approaches including an asset or cost approach, market approach or income approach or any combination thereof. These approaches may require the Company to make certain estimates and assumptions including future cash flows, revenue and expenses. These estimates and assumptions are reviewed each time the Company tests goodwill for impairment and are typically developed as part of the Company’s routine business planning and forecasting process. While the Company believes its estimates and assumptions are reasonable, variations from those estimates could produce materially different results. The Company did not recognize any goodwill impairments for the years ended June 30, 2025 and 2024. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <p id="xdx_847_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_znyIoTK9cYZe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span id="xdx_86C_zJK0NIsDDHi1">Impairment of Long-Lived Assets</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Long-lived assets, including intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the carrying amount of an asset exceeds its undiscounted estimated future cash flows, an impairment review is performed. An impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset. Generally, fair value is determined using valuation techniques such as expected discounted cash flows or appraisals, as appropriate. Assets to be disposed of would be separately presented in the balance sheet and reported at the lower of the carrying amount or fair value less costs to sell, and are no longer depreciated or amortized. The assets and liabilities of a disposed group classified as held for sale would be presented separately in the appropriate asset and liability sections of the balance sheets. The Company did not recognize any long-lived asset impairments for the years ended June 30, 2025 and 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_84F_ecustom--GrantProgramPolicyTextBlock_zkWrpYsDfbid" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span id="xdx_869_zeTw3csE4ARb">Grant program</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company records expenses related to the DOD Long Covid Program as such expenses are incurred. The reimbursement of such expenses is recognized upon receipt of the reimbursement, or when it is probable the reimbursement will be received, as a credit against the respective expense account.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_84D_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zec7Y7DAfIV5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span id="xdx_86E_zPoC4EnIesAh">Segment Reporting</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company operates as one operating segment with a focus on its efforts to develop drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. The Company's Chief Executive Officer (“CEO”), as the chief operating decision maker, manages and allocates resources to the operations of the Company based on the line items included within these financial statements. This enables the CEO to assess the overall level of available resources and determine how best to deploy these resources across functions, clinical trials, and development projects in line with the long-term company-wide strategic goals. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_844_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zhTOoBiezSCf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span id="xdx_86D_zCimpUh7MHEj">Recent Accounting Pronouncements</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company considers the applicability and impact of all Accounting Standards Updates (“ASU’s”).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2023, the FASB issued ASU 2023-09, "Income Taxes (Topic 740): Improvements in Income Tax Disclosures" to enhance the transparency and decision usefulness of income tax disclosures. This amendment requires public companies to disclose specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold. Additionally, under the amendment entities are required to disclose the amount of income taxes paid disaggregated by federal, state and foreign taxes, as well as disaggregated by material individual jurisdictions. Finally, the amendment requires entities to disclose income from continuing operations before income tax expense disaggregated between domestic and foreign and income tax expense from continuing operations disaggregated by federal, state and foreign. The new rules are effective for annual periods beginning after December 15, 2024. The standard will be adopted on a prospective basis and is not expected to have a material impact to our financial statements or disclosures.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ASU 2023-07: Segment Reporting Topic 280 - Improvements to Reportable Segment Disclosures. This update requires expanded annual and interim disclosures for significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss. This update is effective for fiscal years beginning after December 15, 2023. The Company adopted ASU 2023-07 in the current fiscal year.</p> <p id="xdx_809_eus-gaap--IntangibleAssetsDisclosureTextBlock_zKGVceX0A5Gk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.5in; font-size: 10pt"><b>4.</b></td> <td style="font-size: 10pt"><b><span id="xdx_825_zgEf4ZhXGTJ4">Intangible Assets</span></b></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company’s intangible assets consist of intellectual property acquired from LAT Pharma, Inc. and are amortized over their estimated useful lives. The following is a summary of the intangible assets as of June 30, 2025 and 2024: </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_88A_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zdMvdrhPv9Dh" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Intangible Assets (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt"><span id="xdx_8B7_zj2j2wS34Jxb" style="display: none">Schedule of intangible assets</span></td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td id="xdx_492_20250630_zE3KljjVsTMc" style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td id="xdx_496_20240630_z65Qk9x5ElSh" style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0d_maFLIANzRD2_z0BSvInn2Nx8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%; text-align: left">Intellectual Property</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">2,293,770</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">2,293,770</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0d_di_msFLIANzRD2_zoQ6MKfXPiNi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less: Accumulated Amortization</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,115,429</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,886,052</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pp0d_mtFLIANzRD2_zxWYDLK2DZ81" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Intellectual Property, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">178,341</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">407,718</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Amortization expense amounted to $<span id="xdx_906_eus-gaap--AmortizationOfIntangibleAssets_c20240701__20250630_pp0p" title="Amortization expenses"><span id="xdx_900_eus-gaap--AmortizationOfIntangibleAssets_c20230701__20240630_pp0p" title="Amortization expenses">229,377</span></span> for each of the years ended June 30, 2025 and 2024, respectively. The Company amortized intellectual property over the expected original useful lives of <span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20250630_zfdT2SmwWg6b" title="Useful life">10</span> years and the remaining amortization expense for the year ending June 30, 2026 is $<span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20250630_z56jS06DyjCi" title="Remaining amortization expense">178,341</span>.</p> <table cellpadding="0" cellspacing="0" id="xdx_88A_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zdMvdrhPv9Dh" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Intangible Assets (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt"><span id="xdx_8B7_zj2j2wS34Jxb" style="display: none">Schedule of intangible assets</span></td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td id="xdx_492_20250630_zE3KljjVsTMc" style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td id="xdx_496_20240630_z65Qk9x5ElSh" style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0d_maFLIANzRD2_z0BSvInn2Nx8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%; text-align: left">Intellectual Property</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">2,293,770</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">2,293,770</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0d_di_msFLIANzRD2_zoQ6MKfXPiNi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less: Accumulated Amortization</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,115,429</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,886,052</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pp0d_mtFLIANzRD2_zxWYDLK2DZ81" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Intellectual Property, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">178,341</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">407,718</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 2293770 2293770 2115429 1886052 178341 407718 229377 229377 P10Y 178341 <p id="xdx_803_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zXe7q9J9Bo78" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.5in; font-size: 10pt"><b>5.</b></td> <td style="font-size: 10pt"><b><span id="xdx_82B_zHOq7xIuAlBg">Related Party Transactions</span></b></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Equity Transactions with Acuitas</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 15, 2022, the Company entered into a securities purchase agreement with Acuitas Group Holdings, LLC (“Acuitas”), the Company’s largest stockholder, pursuant to which Acuitas agreed to purchase from the Company, in a private placement, (i) an aggregate of <span id="xdx_904_eus-gaap--CommonStockSharesIssued_iI_c20220715__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AcuitasGroupHoldingsLLCMember_zkvPuWXq1z1h" title="Common stock, shares issued">36,364</span> shares of the Company’s Common Stock, at a price of $165.00 per share (the “PIPE Shares”), and (ii) a warrant to purchase 72,728 shares of Common Stock (“PIPE Warrant Shares”), at an original exercise price of $182.00, with a term of exercise of five years.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As results of the Company’s capital raises further described in Note 8, the warrants’ down round features (the “rachet adjustment”) resulted in deemed dividends of $<span id="xdx_90B_eus-gaap--Dividends_c20240701__20250630_pp0p" title="Deemed dividend">369,465</span> and $<span id="xdx_904_eus-gaap--Dividends_c20230701__20240630_pp0p" title="Deemed dividend">886,423</span> recognized in the accompanying statement of changes in stockholders’ equity for the years ended June 30, 2025 and 2024, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the year ended June 30, 2024, the deemed dividend of $886,423 recognized from the rachet adjustment resulting from the March 6, 2024 capital raise, reduced the exercise price to $100 per share. The fair value of the PIPE Warrant Shares was estimated using the Black Scholes Method with the following inputs, the stock price of $<span id="xdx_902_eus-gaap--SharePrice_iI_c20240630__us-gaap--AwardTypeAxis__custom--WarrantsMember_zJYWpH3G9mq" title="Stock price">106.50</span>, exercise price of $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240630__us-gaap--AwardTypeAxis__custom--WarrantsMember__srt--RangeAxis__srt--MaximumMember_zF1Ur3Ct8h58" title="Exercise price">182.00</span> and reduced exercise price of $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240630__us-gaap--AwardTypeAxis__custom--WarrantsMember__srt--RangeAxis__srt--MinimumMember_z8ksVYQW0xwj" title="Exercise price">100.00</span>, remaining term of <span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240630__us-gaap--AwardTypeAxis__custom--WarrantsMember_zTumpYtCPsZa" title="Remaining term">3.5</span> years, risk free rate of <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20230701__20240630__us-gaap--AwardTypeAxis__custom--WarrantsMember_zttZdNUGijDi" title="Risk free rate">4.4%</span> and volatility of <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20230701__20240630__us-gaap--AwardTypeAxis__custom--WarrantsMember_pd" title="Volatility">95.0%</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the year ended June 30, 2025, the deemed dividend of $369,465 was recognized based on rachet adjustments from the September 25, 2024 and October 22, 2024 capital raises, that reduced the exercise prices to $15.30 per share and $13.70 per share, respectively. The fair value of the PIPE Warrant Shares were estimated using the Black Scholes Method with the following inputs at September 2024, the stock price of $<span id="xdx_906_eus-gaap--SharePrice_iI_c20240930__us-gaap--AwardTypeAxis__custom--WarrantsMember_zOLnm77n8KSi" title="Stock price">12.00</span>, exercise price of $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240930__us-gaap--AwardTypeAxis__custom--WarrantsMember__srt--RangeAxis__srt--MinimumMember_zluIGlOmJy08" title="Exercise price">15.30</span> and $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240930__us-gaap--AwardTypeAxis__custom--WarrantsMember__srt--RangeAxis__srt--MaximumMember_zeLc39kNG13i" title="Exercise price">100.00</span>, remaining term of <span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240930__us-gaap--AwardTypeAxis__custom--WarrantsMember_z98xiINF1s81" title="Remaining term">2.9</span> years, risk free rate of <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20240701__20240930__us-gaap--AwardTypeAxis__custom--WarrantsMember_zZdlk5CqZVek" title="Risk free rate">3.5%</span> and volatility of <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20240701__20240930__us-gaap--AwardTypeAxis__custom--WarrantsMember_zD4O604K5MZi" title="Volatility">93.0%</span>, resulting in a $<span id="xdx_909_eus-gaap--Dividends_pp0p0_c20240701__20240930__us-gaap--AwardTypeAxis__custom--WarrantsMember_zVof2Ei48Lme" title="Deemed dividend">325,041</span> deemed dividend; and the following inputs at October 22, 2024, the stock price of $<span id="xdx_90E_eus-gaap--SharePrice_c20241022__us-gaap--AwardTypeAxis__custom--WarrantsMember_pd" title="Stock price">33.60</span>, exercise price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20241022__us-gaap--AwardTypeAxis__custom--WarrantsMember__srt--RangeAxis__srt--MaximumMember_pd" title="Exercise price">15.30</span> and $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20241022__us-gaap--AwardTypeAxis__custom--WarrantsMember__srt--RangeAxis__srt--MinimumMember_pd" title="Exercise price">13.70</span>, remaining term of <span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241022__us-gaap--AwardTypeAxis__custom--WarrantsMember_z2k55p5MIf11" title="Remaining term">2.8</span> years, risk free rate of <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20241001__20241022__us-gaap--AwardTypeAxis__custom--WarrantsMember_pd" title="Risk free rate">4.0%</span> and volatility of <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20241001__20241022__us-gaap--AwardTypeAxis__custom--WarrantsMember_pd" title="Volatility">94.0%</span>, resulting in a $<span id="xdx_90D_eus-gaap--Dividends_pp0p0_c20241001__20241022__us-gaap--AwardTypeAxis__custom--WarrantsMember_zXYcYLz3ld97" title="Deemed dividend">44,424</span> deemed dividend..</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Consulting expenses</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended June 30, 2025, the Company paid a Director of the Company $50,000 for consulting services which are reflected as a component of selling, general and administrative expenses on the accompanying statement of operations and comprehensive loss. <span style="font-size: 10pt"> </span></p> 36364 369465 886423 106.50 182.00 100.00 P3Y6M 0.044 0.950 12.00 15.30 100.00 P2Y10M24D 0.035 0.930 325041 33.60 15.30 13.70 P2Y9M18D 0.040 0.940 44424 <p id="xdx_800_eus-gaap--DebtDisclosureTextBlock_zcUK4tXnnCJk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.5in; font-size: 10pt"><b>6.</b></td> <td style="font-size: 10pt"><b><span id="xdx_823_zcyAE4QPoNZ8">Notes Payable</span></b></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 30, 2021 (the “Closing Date”), the Company entered into a Loan and Security Agreement and the Supplement to the Loan and Security Agreement and Promissory Notes (together, the “Loan Agreement”) with Avenue Venture Opportunities Fund, L.P. (“AVOPI”) and Avenue Venture Opportunities Fund II, L.P. (“AVOPII,” and together with AVOPI, “Avenue”) for growth capital loans in an aggregate commitment amount of up to $20 million (the “Loan”). On the Closing Date, $15 million of the Loan was funded (“Tranche 1”). The Loan bore interest at an annual rate equal to the greater of (a) the sum of <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateDuringPeriod_c20240701__20250630__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember_pd" title="Interest rate">7.00%</span> plus the prime rate as reported in The Wall Street Journal and (b) 10.75%. The Loan was secured by a lien upon and security interest in all of the Company’s assets, including intellectual property, subject to agreed exceptions. The Loan was paid in full on its maturity date of December 1, 2024 along with a final payment equal to <span id="xdx_908_eus-gaap--DebtInstrumentInterestRateDuringPeriod_c20240701__20250630_pd" title="Interest rate">4.25%</span> of the Loan commitment amount, or $850,000, the (“Loan Premium”) and the lien upon and security interest in all of the Company’s assets was released.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Loan Agreement included a conversion option to convert up to $5.0 million of the principal amount of the Loan outstanding at the option of Avenue, into shares of the Company’s Common Stock at a conversion price of $698.00 per share (the “Conversion Option”).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On the Closing Date, the Company also issued to Avenue warrants to purchase 3,611 shares of Common Stock of the Company (the “Avenue Warrants”) at an exercise price per share equal to $582.00. The Avenue Warrants are exercisable until November 30, 2026.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The amount of the carrying value of the notes payable was determined by allocating portions of the outstanding principal of the notes, resulting in approximately $<span id="xdx_90D_eus-gaap--FairValueAdjustmentOfWarrants_pp0n6_c20240701__20250630_zbHOInMyTZt6" title="Fair value of warrants">1.4</span> million allocated to the fair value of the Avenue Warrants, and approximately $<span id="xdx_901_ecustom--FairValueOfEmbeddedConversionOption_pp0n6_c20240701__20250630_zm1YByTDlGge" title="Fair value of embedded conversion option">2.2</span> million allocated to the fair value of the embedded Conversion Option. Accordingly, the total amount of unearned discount of approximately $3.6 million, the total direct financing cost of approximately $<span id="xdx_904_ecustom--DirectFinancingCost_c20240701__20250630_pp0n" title="Direct financing cost">390,000</span> and the Loan Premium of $<span id="xdx_90F_eus-gaap--DebtInstrumentUnamortizedPremium_c20250630_pp0n" title="Unamortized premium recognized">850,000</span> were amortized using the effective interest method over the term of the Loan.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Total interest expense associated with the Loan was approximately $<span id="xdx_909_eus-gaap--InterestExpenseDebt_c20240701__20250630_pp0n" title="Interest expense">312,000</span>, which is reflected as a component of interest expense on the accompanying statements of operations and comprehensive loss for the year ended June 30, 2025. Interest expense associated with this loan was comprised of interest incurred on the outstanding principal of the loan of approximately $<span id="xdx_901_eus-gaap--DebtInstrumentPeriodicPaymentInterest_c20240701__20250630_pp0n" title="Interest payment">163,000</span>, amortization of financing costs of approximately $<span id="xdx_905_eus-gaap--AmortizationOfFinancingCosts_c20240701__20250630_pp0n" title="Amortization of financing costs">12,000</span>, amortization of the unearned discount of approximately $<span id="xdx_909_ecustom--UnearnedDiscount_c20240701__20250630_pp0n" title="Unearned discount">111,000</span>, and the accretion of the Loan Premium of approximately $<span id="xdx_905_ecustom--AccretionsOfLoanPremium_c20240701__20250630_pp0n" title="Accretion of loan premium">26,000</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Total interest expense for the year ended June 30, 2024 was approximately $<span id="xdx_909_eus-gaap--InterestExpenseDebt_pp0n6_c20230701__20240630_zVkhRXRh8hH9" title="Interest expense">2.9</span> million on the accompanying statement of operations and comprehensive loss. Interest expense was comprised of interest incurred on the outstanding principal of the loan of approximately $<span id="xdx_907_eus-gaap--DebtInstrumentPeriodicPaymentInterest_pp0n6_c20230701__20240630_zC6wJoQYIN9e" title="Interest payment">1.5</span> million, amortization of financing costs of approximately $<span id="xdx_907_eus-gaap--AmortizationOfFinancingCosts_c20230701__20240630_pp0n" title="Amortization of financing costs">109,000</span>, amortization of the unearned discount of $<span id="xdx_90F_ecustom--UnearnedDiscount_pp0n6_c20230701__20240630_zROrH0arp3Yc" title="Unearned discount">1.0</span> million, and the accretion of the Loan Premium of approximately $<span id="xdx_90A_ecustom--AccretionsOfLoanPremium_c20230701__20240630_pp0n" title="Accretion of loan premium">237,000</span>. <span style="font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following is a summary of the Notes Payable as of June 30, 2025 and 2024:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_88A_eus-gaap--ScheduleOfDebtTableTextBlock_zJvDzgraWKn5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Notes Payable (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td id="xdx_8BD_zMiZ9Ub7MyDc" style="display: none; text-align: left">Schedule of note payable</td><td> </td> <td style="text-align: left"> </td><td id="xdx_49E_20250630_zxWNEpi06Ttc" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49D_20240630_zivV1q6PWM0b" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_406_ecustom--CurrentPortionOfNotesPayable_iI_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%; text-align: left">Current portion of Notes Payable</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0701">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">5,000,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_ecustom--DebtFinancingCosts_iNI_pp0d_di_zzNp96KwMUC4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Less: debt financing costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0704">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(11,820</td><td style="text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--DeferredDiscountsFinanceChargesAndInterestIncludedInReceivables_iNI_pp0d_di_zIZ379GBPlRc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Less: unearned discount</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0707">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(111,212</td><td style="text-align: left">)</td></tr> <tr id="xdx_40D_ecustom--AccretionOfLoanPremiums_iI_pp0p" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Plus: accretion of Loan Premium</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0710">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">824,242</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--NotesPayableCurrent_iI_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Current portion of Notes Payable, net of financing costs, unearned premium and discount</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0713">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,701,210</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 0.0700 0.0425 1400000 2200000 390000 850000 312000 163000 12000 111000 26000 2900000 1500000 109000 1000000.0 237000 <table cellpadding="0" cellspacing="0" id="xdx_88A_eus-gaap--ScheduleOfDebtTableTextBlock_zJvDzgraWKn5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Notes Payable (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td id="xdx_8BD_zMiZ9Ub7MyDc" style="display: none; text-align: left">Schedule of note payable</td><td> </td> <td style="text-align: left"> </td><td id="xdx_49E_20250630_zxWNEpi06Ttc" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49D_20240630_zivV1q6PWM0b" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_406_ecustom--CurrentPortionOfNotesPayable_iI_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%; text-align: left">Current portion of Notes Payable</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0701">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">5,000,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_ecustom--DebtFinancingCosts_iNI_pp0d_di_zzNp96KwMUC4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Less: debt financing costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0704">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(11,820</td><td style="text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--DeferredDiscountsFinanceChargesAndInterestIncludedInReceivables_iNI_pp0d_di_zIZ379GBPlRc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Less: unearned discount</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0707">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(111,212</td><td style="text-align: left">)</td></tr> <tr id="xdx_40D_ecustom--AccretionOfLoanPremiums_iI_pp0p" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Plus: accretion of Loan Premium</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0710">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">824,242</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--NotesPayableCurrent_iI_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Current portion of Notes Payable, net of financing costs, unearned premium and discount</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0713">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,701,210</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 5000000 11820 111212 824242 5701210 <p id="xdx_800_eus-gaap--FairValueDisclosuresTextBlock_zaJlUR3QXgdk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.5in; font-size: 10pt"><b>7.</b></td> <td style="font-size: 10pt"><b><span id="xdx_82C_zInbY3zg2KZg">Fair Value Measurements</span></b></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At June 30, 2025, there was no value ascribed to the derivative liabilities and as of June 30, 2024 the derivative liability related to warrants that was measured on a recurring basis was a level 3 liability and totaled $3,771. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table presents the activity for level 3 liabilities measured at fair value using unobservable inputs for the years ended June 30, 2025 and 2024:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zQ1igMbJPbb4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Fair Value Measurements (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td id="xdx_8BF_znoCrrhWDZx" style="display: none; text-align: left">Schedule of derivative liabilities at fair value</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Derivative liability - Avenue Warrants</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Derivative liability - Conversion Option</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%">Balance at June 30, 2023</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span id="xdx_903_ecustom--DerivativeLiability_iS_pp0d_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zOMQpCBojbck" title="Balance at beginning">894,280</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span id="xdx_90A_ecustom--DerivativeLiability_iS_pp0d_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z0sFd5X1CGgh" title="Balance at beginning">925,762</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Additions to level 3 liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_pp0d_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z2zlf12LAZVa" title="Additions to level 3 liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0725">-</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_pp0d_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z1cDva6RCwva" title="Additions to level 3 liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0727">-</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Change in fair value of level 3 liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_pp0d_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zz1LnOfap8O2" title="Change in in fair value of level 3 liabilities">(890,509</span></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_pp0d_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z0h9v69Pt4f9" title="Change in in fair value of level 3 liabilities">(925,762</span></td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Transfer in and/or out of level 3</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_901_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_pp0d_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zPeRGMKZplal" title="Transfer in and/or out of Level 3"><span style="-sec-ix-hidden: xdx2ixbrl0733">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_904_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_pp0d_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zAFRfhvW3Lab" title="Transfer in and/or out of Level 3"><span style="-sec-ix-hidden: xdx2ixbrl0735">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance at June 30, 2024</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90A_ecustom--DerivativeLiability_iS_pp0d_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zvkXVSI07SHa" title="Balance at beginning">3,771</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_901_ecustom--DerivativeLiability_iS_pp0d_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zhLogunzJjK1" title="Balance at beginning"><span style="-sec-ix-hidden: xdx2ixbrl0739">-</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Additions to level 3 liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_pp0d_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zpupPVJExuBc" title="Additions to level 3 liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0741">-</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_pp0d_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zBYsH1Ap5Vl8" title="Additions to level 3 liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0743">-</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Change in fair value of level 3 liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_pp0d_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zpdRngpnT3Bc" title="Change in in fair value of level 3 liabilities">(3,771</span></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_pp0d_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zX251mn6xhCc" title="Change in in fair value of level 3 liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0747">-</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Transfer in and/or out of Level 3</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_pp0d_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z6mUTNxUDzQh" title="Transfer in and/or out of Level 3"><span style="-sec-ix-hidden: xdx2ixbrl0749">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_909_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_pp0d_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zHKLLC2u0LW4" title="Transfer in and/or out of Level 3"><span style="-sec-ix-hidden: xdx2ixbrl0751">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance at June 30, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_ecustom--DerivativeLiability_iE_pp0d_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zh4Cd9kHYiD7" title="Balance at ending"><span style="-sec-ix-hidden: xdx2ixbrl0753">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_ecustom--DerivativeLiability_iE_pp0d_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zCdC21ACRt6j" title="Balance at ending"><span style="-sec-ix-hidden: xdx2ixbrl0755">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A9_ziyB7tjcsI78" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair values of derivative liabilities for the Avenue Warrants and Conversion Option at June 30, 2024 in the accompanying balance sheet, were approximately $3,800 and zero, respectively. The total change in the fair value of the derivative liabilities totaled approximately $<span id="xdx_905_ecustom--FairValueOfDerivativeLiabilities_c20240701__20250630_pp0p" title="Fair value of the derivative liabilities">3,800</span> and $<span id="xdx_909_ecustom--FairValueOfDerivativeLiabilities_pp0n6_c20230701__20240630_zUdI5Ti4s4p6" title="Fair value of the derivative liabilities">1.8</span> million for the years ended June 30, 2025, and 2024, respectively; and accordingly, was recorded in the accompanying statements of operations and comprehensive loss.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The assumptions used in the Black Scholes model to value the Avenue Warrants at June 30, 2025 included the closing stock price of $<span id="xdx_909_eus-gaap--SharePrice_c20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pd" title="Share Price">9.25</span> per share; the exercise price of $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pd" title="Exercise Price">582.00</span>, remaining term <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zIkuTbDcdyP5" title="Term">1.4</span> years, risk free rate of <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pd" title="Risk Free Interest Rate">3.9%</span> and volatility of <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zTiyBGA2kEAl" title="Volatility Rate">81.0%</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Conversion Option was nil as of June 30, 2025 and June 30, 2024 as the corresponding debt matured and was repaid in December 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The assumptions used in the Black Scholes model to value the derivative liabilities at June 30, 2024 included the closing stock price of $<span id="xdx_908_eus-gaap--SharePrice_c20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pd" title="Share Price">40.00</span> per share; for the Avenue Warrants, the exercise price of $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pd" title="Exercise Price">582.00</span>, remaining term <span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zIsW6KAODb9e" title="Term">2.4</span> years, risk free rate of <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pd" title="Risk Free Interest Rate">4.6%</span> and volatility of <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pd" title="Volatility Rate">82.0%</span>; and for the Conversion Option, the conversion price of $<span id="xdx_906_eus-gaap--SharePrice_iI_c20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionOnConvertibleDebentureMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zpsX0vRW8iDl" title="Share Price">698.00</span>; remaining term of <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtM_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionOnConvertibleDebentureMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z82iA5P38cpg" title="Term">5</span> months, risk free rate of <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionOnConvertibleDebentureMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z0iJQxBeILNa" title="Risk Free Interest Rate">5.38%</span> and volatility of <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionOnConvertibleDebentureMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zMYO4SOFwlzk" title="Volatility Rate">91.0%</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Financial assets</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of June 30, 2025, investments in U.S. Treasury Bills were valued through use of quoted prices and are classified as Level 1. The following table presents information about our assets that are measured at fair value on a recurring basis using the above input categories.</p> <table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zRmdg1iZzMa4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Fair Value Measurements (Details 1)"> <tr style="vertical-align: bottom; background-color: White"> <td id="xdx_8B2_zIVpfSLY2z53" style="display: none; text-align: left">Measured at fair value on a recurring basis</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="14" style="font-weight: bold; text-align: center">Fair Value Measurements at</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Level 1</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Level 2</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Level 3</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Total</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Cash</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_90A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20250630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p" title="Total">3,978,271</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_90B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20250630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0794">-</span></span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_904_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20250630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0796">-</span></span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_90A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20250630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_pp0p" title="Total">3,978,271</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">U.S. Treasury Bills due in 3 months or less at purchase</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20250630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p" title="Total">13,566,276</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20250630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0802">-</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20250630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0804">-</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20250630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember_pp0p" title="Total">13,566,276</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; padding-left: 9pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p" title="Total">17,544,547</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0810">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0812">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20250630_pp0p" title="Total">17,544,547</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="14" style="font-weight: bold; text-align: center">Fair Value Measurements at</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Level 1</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Level 2</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Level 3</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Total</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Cash</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_909_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20240630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p" title="Total">12,763,941</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_90A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20240630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0818">-</span></span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_90B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20240630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0820">-</span></span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_909_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20240630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_pp0p" title="Total">12,763,941</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">U.S. Treasury Bills due in 3 months or less at purchase</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20240630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p" title="Total">11,079,857</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20240630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0826">-</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20240630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0828">-</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20240630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember_pp0p" title="Total">11,079,857</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; padding-left: 9pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p" title="Total">23,843,798</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0834">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0836">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iI_pp0d_c20240630_zMlu0p8UOge8" title="Total">23,843,798</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zQ1igMbJPbb4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Fair Value Measurements (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td id="xdx_8BF_znoCrrhWDZx" style="display: none; text-align: left">Schedule of derivative liabilities at fair value</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Derivative liability - Avenue Warrants</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Derivative liability - Conversion Option</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%">Balance at June 30, 2023</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span id="xdx_903_ecustom--DerivativeLiability_iS_pp0d_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zOMQpCBojbck" title="Balance at beginning">894,280</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span id="xdx_90A_ecustom--DerivativeLiability_iS_pp0d_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z0sFd5X1CGgh" title="Balance at beginning">925,762</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Additions to level 3 liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_pp0d_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z2zlf12LAZVa" title="Additions to level 3 liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0725">-</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_pp0d_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z1cDva6RCwva" title="Additions to level 3 liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0727">-</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Change in fair value of level 3 liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_pp0d_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zz1LnOfap8O2" title="Change in in fair value of level 3 liabilities">(890,509</span></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_pp0d_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z0h9v69Pt4f9" title="Change in in fair value of level 3 liabilities">(925,762</span></td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Transfer in and/or out of level 3</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_901_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_pp0d_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zPeRGMKZplal" title="Transfer in and/or out of Level 3"><span style="-sec-ix-hidden: xdx2ixbrl0733">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_904_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_pp0d_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zAFRfhvW3Lab" title="Transfer in and/or out of Level 3"><span style="-sec-ix-hidden: xdx2ixbrl0735">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance at June 30, 2024</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90A_ecustom--DerivativeLiability_iS_pp0d_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zvkXVSI07SHa" title="Balance at beginning">3,771</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_901_ecustom--DerivativeLiability_iS_pp0d_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zhLogunzJjK1" title="Balance at beginning"><span style="-sec-ix-hidden: xdx2ixbrl0739">-</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Additions to level 3 liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_pp0d_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zpupPVJExuBc" title="Additions to level 3 liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0741">-</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_pp0d_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zBYsH1Ap5Vl8" title="Additions to level 3 liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0743">-</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Change in fair value of level 3 liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_pp0d_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zpdRngpnT3Bc" title="Change in in fair value of level 3 liabilities">(3,771</span></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_pp0d_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zX251mn6xhCc" title="Change in in fair value of level 3 liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0747">-</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Transfer in and/or out of Level 3</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_pp0d_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z6mUTNxUDzQh" title="Transfer in and/or out of Level 3"><span style="-sec-ix-hidden: xdx2ixbrl0749">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_909_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_pp0d_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zHKLLC2u0LW4" title="Transfer in and/or out of Level 3"><span style="-sec-ix-hidden: xdx2ixbrl0751">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance at June 30, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_ecustom--DerivativeLiability_iE_pp0d_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zh4Cd9kHYiD7" title="Balance at ending"><span style="-sec-ix-hidden: xdx2ixbrl0753">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_ecustom--DerivativeLiability_iE_pp0d_c20240701__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zCdC21ACRt6j" title="Balance at ending"><span style="-sec-ix-hidden: xdx2ixbrl0755">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 894280 925762 -890509 -925762 3771 -3771 3800 1800000 9.25 582.00 P1Y4M24D 0.039 0.810 40.00 582.00 P2Y4M24D 0.046 0.820 698.00 P5M 0.0538 0.910 <table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zRmdg1iZzMa4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Fair Value Measurements (Details 1)"> <tr style="vertical-align: bottom; background-color: White"> <td id="xdx_8B2_zIVpfSLY2z53" style="display: none; text-align: left">Measured at fair value on a recurring basis</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="14" style="font-weight: bold; text-align: center">Fair Value Measurements at</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Level 1</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Level 2</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Level 3</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Total</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Cash</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_90A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20250630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p" title="Total">3,978,271</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_90B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20250630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0794">-</span></span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_904_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20250630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0796">-</span></span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_90A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20250630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_pp0p" title="Total">3,978,271</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">U.S. Treasury Bills due in 3 months or less at purchase</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20250630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p" title="Total">13,566,276</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20250630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0802">-</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20250630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0804">-</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20250630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember_pp0p" title="Total">13,566,276</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; padding-left: 9pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p" title="Total">17,544,547</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0810">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0812">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20250630_pp0p" title="Total">17,544,547</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="14" style="font-weight: bold; text-align: center">Fair Value Measurements at</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Level 1</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Level 2</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Level 3</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Total</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Cash</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_909_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20240630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p" title="Total">12,763,941</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_90A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20240630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0818">-</span></span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_90B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20240630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0820">-</span></span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_909_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20240630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_pp0p" title="Total">12,763,941</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">U.S. Treasury Bills due in 3 months or less at purchase</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20240630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p" title="Total">11,079,857</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20240630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0826">-</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20240630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0828">-</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20240630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember_pp0p" title="Total">11,079,857</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; padding-left: 9pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p" title="Total">23,843,798</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0834">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0836">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iI_pp0d_c20240630_zMlu0p8UOge8" title="Total">23,843,798</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 3978271 3978271 13566276 13566276 17544547 17544547 12763941 12763941 11079857 11079857 23843798 23843798 <p id="xdx_80D_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zYGKHmLAWQYj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.5in; font-size: 10pt"><b>8.</b></td> <td style="font-size: 10pt"><b><span id="xdx_820_zkAEsoCRPiA1">Equity Transactions</span></b></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Issuance of common stock for cash</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 31, 2022, the Company entered into a Controlled Equity Offering Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald &amp; Co. and B. Riley Securities, Inc. (collectively, the “Agents”), pursuant to which the Company may issue and sell from time-to-time shares of the Company’s common stock through the Agents, subject to the terms and conditions of the Sales Agreement. On April 6, 2023, the Company and B. Riley Securities, Inc. mutually agreed to terminate B. Riley Securities, Inc.’s role as a sales agent under the Sales Agreement. During the year ended June 30, 2024, the Company sold <span id="xdx_90C_ecustom--IssuanceOfCommonStockForCashShares_c20230701__20240630__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_pd" title="Issuance of common stock for cash, shares">33,375</span> shares of common stock under the Sales Agreement for total net proceeds of approximately $<span id="xdx_909_ecustom--IssuanceOfCommonStockForCash_pp0n6_c20230701__20240630__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zb6TfNAceDHe" title="Issuance of common stock for cash">9.3</span> million after deducting <span id="xdx_90B_ecustom--CommissionsPercentage_c20230701__20240630__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zMt2Pi0h8236" title="Commissions percentage">3%</span> commissions and expenses of approximately $<span id="xdx_90E_eus-gaap--PaymentsOfStockIssuanceCosts_c20230701__20240630__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_pp0n" title="Issuance costs">377,000</span>. During the year ended June 30, 2025, the Company sold <span id="xdx_90E_ecustom--IssuanceOfCommonStockForCashShares_c20240701__20250630__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_pd" title="Issuance of common stock for cash, shares">215</span> shares of common stock under the Sales Agreement for total net proceeds of $<span id="xdx_901_ecustom--IssuanceOfCommonStockForCash_c20240701__20250630__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_pp0n" title="Issuance of common stock for cash">6,400</span> after <span><span id="xdx_902_ecustom--CommissionsPercentage_c20240701__20250630__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zMkB4TYgjf7c" title="Commissions percentage">3%</span></span> commissions and expenses of approximately $<span id="xdx_90C_eus-gaap--PaymentsOfStockIssuanceCosts_c20240701__20250630__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_pp0n" title="Issuance costs">200</span>. On September 25, 2024, the Company suspended the sales agreement and terminated the continuous offering by us under the effective Prospectus Supplement filed January 19, 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 6, 2024, the Company closed a best efforts public offering (the “Offering”) of <span id="xdx_90B_eus-gaap--CommonStockSharesIssued_c20240306_pd" title="Common stock shares">150,000</span> shares (the “Shares”) of its common stock, par value $0.0001 per share (the “Common Stock”), pre-funded warrants (the “Pre-funded Warrants”) to purchase <span id="xdx_90F_ecustom--PurchaseOfCommonStockShares_c20240306__us-gaap--StatementClassOfStockAxis__custom--PrefundedWarrantsMember_pd" title="Purchase of shares">60,000</span> shares of Common Stock, and warrants to purchase up to <span id="xdx_901_ecustom--PurchaseOfCommonStockShares_c20240306__us-gaap--StatementClassOfStockAxis__custom--CommonWarrantsMember_pd" title="Purchase of shares">105,000</span> shares of Common Stock (the “Common Warrants”) at a combined public offering price of $<span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_c20240306__us-gaap--StatementClassOfStockAxis__custom--CommonWarrantsMember_pd" title="Common stock par value">100.00</span> per Share, or Pre-funded Warrant, and the associated Common Warrant. <span style="background-color: white">The Common Warrants have an exercise price of $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20240306_pd" title="Class of warrant or right, exercise price of warrants or rights">150.00</span> per share and are immediately exercisable upon issuance for a period of five years following the date of issuance. </span>The gross proceeds to the Company from the Offering were approximately $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pp0n6_c20240301__20240306_zmC7JnCG98o8" title="Proceeds from offering">21.0</span> million, before deducting placement agent fees and offering expenses of approximately $2.5 million, resulting in net proceeds of approximately $18.5 million. Additionally, upon closing the Company issued the placement agent warrants (“Placement Agent’s warrants”) to purchase <span id="xdx_90E_eus-gaap--TemporaryEquitySharesIssued_c20240306__us-gaap--AwardTypeAxis__custom--PlacementAgentsWarrantsMember_pd" title="Warrant issued">10,500</span> shares of Common Stock exercisable at a per share price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20240306__us-gaap--AwardTypeAxis__custom--PlacementAgentsWarrantsMember_pd" title="Class of warrant or right, exercise price of warrants or rights">125.00</span>, which was equal to 125% of the public offering price per share. The Placement Agent’s Warrants are exercisable during a five-year period commencing 180 days from March 6, 2024. The Pre-Funded Warrants were exercised shortly after issuance and the <span id="xdx_90B_ecustom--StockExercised_c20230701__20240630__us-gaap--AwardTypeAxis__custom--PrefundedWarrantsMember_pd" title="Number of stock exercised">60,000</span> shares of Common Stock were issued during the year ended June 30, 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 25, 2024, the Company closed a best efforts public offering (the “September 2024 Offering”) of <span id="xdx_90C_eus-gaap--CommonStockSharesIssued_c20240925_pd" title="Common stock shares">136,080</span> shares of its common stock, par value $<span id="xdx_90F_eus-gaap--CommonStockParOrStatedValuePerShare_c20240925_pd" title="Common stock par value">0.0001</span> per share, pre-funded warrants (the “September Pre-funded Warrants”) to purchase <span id="xdx_901_ecustom--PurchaseOfCommonStockShares_c20240925__us-gaap--StatementClassOfStockAxis__custom--PrefundedWarrantsMember_pd" title="Purchase of shares">60,000</span> shares of Common Stock, and warrants to purchase up to <span id="xdx_908_ecustom--PurchaseOfCommonStockShares_c20240925__us-gaap--StatementClassOfStockAxis__custom--CommonWarrantsMember_pd" title="Purchase of shares">196,080</span> shares of Common Stock (the “September Common Warrants”) at a combined public offering price of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20240925_pd" title="Class of warrant or right, exercise price of warrants or rights">15.30</span> per share, or September Pre-funded Warrant, and the associated September Common Warrant. 26,500 September Pre-funded Warrants were exercised shortly thereafter and reflected on the statement of changes in stockholders’ equity as a component of proceeds from issuance of common stock. <span style="background-color: white">The September Common Warrants have an exercise price of $<span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_c20240925__us-gaap--StatementClassOfStockAxis__custom--CommonWarrantsMember_pd" title="Common stock par value">15.30</span> per share and were immediately exercisable upon issuance and will expire on the fifth anniversary date of the original issuance date. </span>The gross proceeds to the Company from the September 2024 Offering was approximately $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pp0n6_c20240901__20240925_zsOOkWlQXd1i" title="Proceeds from offering">3.0</span> million, before deducting placement agent fees and offering expenses of approximately $747,000. Additionally, upon closing, the Company issued the placement agent warrants (“September Placement Agent’s Warrants”) to purchase <span id="xdx_906_eus-gaap--TemporaryEquitySharesIssued_c20240925__us-gaap--AwardTypeAxis__custom--PlacementAgentsWarrantsMember_pd" title="Warrant issued">981</span> shares of Common Stock exercisable at a per share price of $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20240925__us-gaap--AwardTypeAxis__custom--PlacementAgentsWarrantsMember_pd" title="Class of warrant or right, exercise price of warrants or rights">19.10</span>, which was equal to 125% of the public offering price per share. The September Placement Agent’s Warrants are exercisable during a five-year period commencing 180 days from September 25, 2024. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In October 2024, the Company closed three registered direct offerings totaling <span id="xdx_905_ecustom--OfferingShares_c20241001__20241031_pd" title="Offering shares">825,600</span> shares of its common stock, par value $<span id="xdx_902_ecustom--OfferingPricePerShare_c20241031_pd" title="Offering price per share">0.0001</span> per share, and two concurrent private placements of warrants to purchase up to <span id="xdx_90B_ecustom--NumbersOfWarrantsPurchase_c20241001__20241031__us-gaap--ClassOfWarrantOrRightAxis__custom--OctoberCommonWarrantsMember_pd" title="Numbers of warrants purchase">711,000</span> shares of Common Stock (the “October Common Warrants”) priced at-the-market under Nasdaq rules at prices ranging from $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20241031__us-gaap--ClassOfWarrantOrRightAxis__custom--OctoberCommonWarrantsMember__srt--RangeAxis__srt--MinimumMember_pd" title="Class of warrant or right, exercise price of warrants or rights">15.00</span> to $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20241031__us-gaap--ClassOfWarrantOrRightAxis__custom--OctoberCommonWarrantsMember__srt--RangeAxis__srt--MaximumMember_pd" title="Class of warrant or right, exercise price of warrants or rights">28.30</span> per share (the “October Offerings”)<span style="background-color: white">. The October Common Warrants have exercise prices ranging from $<span id="xdx_90D_eus-gaap--WarrantExercisePriceDecrease_c20241001__20241031__us-gaap--ClassOfWarrantOrRightAxis__custom--OctoberCommonWarrantsMember_pd" title="Warrant, exercise price, decrease">13.70</span> to $<span id="xdx_907_eus-gaap--WarrantExercisePriceIncrease_c20241001__20241031__us-gaap--ClassOfWarrantOrRightAxis__custom--OctoberCommonWarrantsMember_pd" title="Warrant, exercise price, increase">21.20</span> per share and are exercisable beginning six months following issuance and will expire on the fifth anniversary date of the original issuance dates. </span>The gross proceeds to the Company from the October Offerings totaled approximately $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pp0n6_c20241001__20241031__us-gaap--ClassOfWarrantOrRightAxis__custom--OctoberCommonWarrantsMember_zSXC6rMWRcn4" title="Proceeds from offering">15.9</span> million, before deducting placement agent fees and offering expenses of approximately $<span id="xdx_904_ecustom--AgentFeesAndOfferingExpenses_pp0n6_c20241001__20241031__us-gaap--ClassOfWarrantOrRightAxis__custom--OctoberCommonWarrantsMember_zWUNeDZlFDIj" title="Agent fees and offering expenses">2.5 </span>million. Additionally, upon closing of the October Offerings, the Company issued placement agent warrants (the “October Placement Agent’s Warrants”) to purchase 41,321 shares of Common Stock in the aggregate exercisable at a per share price ranging from $<span id="xdx_908_eus-gaap--WarrantExercisePriceDecrease_c20241001__20241031__us-gaap--ClassOfWarrantOrRightAxis__custom--OctoberPlacementAgentsWarrantsMember_pd" title="Warrant, exercise price, decrease">18.80</span> to $<span id="xdx_90F_eus-gaap--WarrantExercisePriceIncrease_c20241001__20241031__us-gaap--ClassOfWarrantOrRightAxis__custom--OctoberPlacementAgentsWarrantsMember_pd" title="Warrant, exercise price, increase">35.40</span>, which was equal to 125% of the offering price per share in the applicable October Offering. The October Placement Agent’s Warrants are exercisable during a five-year period commencing 180 days from each of the respective closing dates of the October Offerings.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended June 30, 2025, <span id="xdx_908_ecustom--WarrantsExercised_c20240701__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--September2024OfferingMember_pd" title="Warrants exercised">189,630</span> of common warrants from the September 2024 Offering were exercised at $<span id="xdx_903_eus-gaap--WarrantExercisePriceIncrease_c20240701__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--September2024OfferingMember_pd" title="Warrant, exercise price, increase">15.30</span> per share for proceeds totaling approximately $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pp0n6_c20240701__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--September2024OfferingMember_zu62mWG7QrMd" title="Proceeds from offering">2.9</span> million, and <span id="xdx_905_ecustom--WarrantsExercised_c20240701__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--PrefundedWarrantsMember_pd" title="Warrants exercised">33,500</span> September Pre-funded Warrants were also exercised. In addition, <span id="xdx_90B_ecustom--WarrantsExercised_c20240701__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--SeptemberPlacementAgentsWarrantsMember_pd" title="Warrants exercised">667</span> September Placement Agent’s Warrants were exercised on a cashless exercise basis and <span id="xdx_902_ecustom--CommonStockIssued_c20240701__20250630_pd" title="Common stock issued">422</span> common shares were issued.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i> Issuance of common stock for services</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 10, 2024, the Company awarded <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240501__20240510__srt--TitleOfIndividualAxis__custom--VendorMember_pd" title="Stock issued for services, shares">1,500</span> shares of Common Stock to a vendor as part of their fees in exchange for services. The fair value of the Common Stock at the date of issuance was $<span id="xdx_906_eus-gaap--SharePrice_c20240510__srt--TitleOfIndividualAxis__custom--VendorMember_pd" title="Share price">48.60</span> per share. The stock-based compensation expense related to this Common Stock issuance was $<span id="xdx_90C_eus-gaap--ShareBasedCompensation_c20240501__20240510__srt--TitleOfIndividualAxis__custom--VendorMember_pp0n" title="Stock-based compensation expense">72,900 </span>for the year ended June 30, 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 12, 2024, the Company awarded <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240801__20240812__srt--TitleOfIndividualAxis__custom--VendorMember_pd" title="Stock issued for services, shares">1,500</span> shares of Common Stock to a vendor as part of their fees in exchange for services. The fair value of the Common Stock at the date of issuance was $<span id="xdx_903_eus-gaap--SharePrice_c20240812__srt--TitleOfIndividualAxis__custom--VendorMember_pd" title="Share price">22.30</span> per share. The stock-based compensation expense related to this Common Stock issuance was $<span id="xdx_904_eus-gaap--ShareBasedCompensation_c20240801__20240812__srt--TitleOfIndividualAxis__custom--VendorMember_pp0n" title="Stock-based compensation expense">33,450</span> for the year ended June 30, 2025.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 24, 2025, the Company awarded <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20250401__20250424__srt--TitleOfIndividualAxis__custom--VendorMember_zGGer9IcYFVi" title="Stock issued for services, shares">4,500</span> shares of Common Stock to a vendor as part of their fees in exchange for services. The fair value of the Common Stock at the date of issuance was $<span id="xdx_906_eus-gaap--SharePrice_iI_c20250424__srt--TitleOfIndividualAxis__custom--VendorMember_zEUvhmzc1ASi" title="Share price">8.94</span> per share. The stock-based compensation expense related to this Common Stock issuance was $<span id="xdx_90D_eus-gaap--ShareBasedCompensation_pp0d_c20250401__20250424__srt--TitleOfIndividualAxis__custom--VendorMember_zPmXuQmHCaMf" title="Stock-based compensation expense">40,230</span> for the year ended June 30, 2025.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Stock Options</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table summarizes the activity relating to the Company’s stock options for the years ended June 30, 2025 and 2024:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zFbQiugH3X86" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity Transactions (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td id="xdx_8BA_zuTqguAY0Npc" style="display: none">Schedule of summarizes the activity relating to the Company’s stock options</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-Average Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Remaining Average Contractual Term</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Outstanding at June 30, 2023</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230701__20240603__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zetEpyM7Vtc2" title="Options outstanding at beginning">39,529</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zO6Fufyn9E9h" title="Weighted average exercise price, options outstanding at beginning">710.00</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zfrlqAbvMiPa" title="Weighted remaining average contractual term, beginning">6.3</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_pp0d_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_z0bGfd0GL4ib" title="Aggregate intrinsic value, outstanding at beginning">1,067,966</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pd" title="Options granted">15,525</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pd" title="Weighted average exercise price, options granted">117.00</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zZDqmz4EqJg5" title="Weighted remaining average contractual term, options granted">9.8</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Options Expired</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zv1OvtJ2xm9d" title="Options expired">(64</span></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pd" title="Weighted average exercise price, Options expired">460.90</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Options Canceled</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zBTaVJ0ZeuNh" title="Options Canceled">(3,182</span></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExerciseCanceledPrice_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zR1qH91H5ix9" title="Weighted average exercise price, Options Canceled">571.90</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding at June 30, 2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240701__20250603__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zc9OiyOK1zY" title="Options outstanding at beginning">51,808</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240701__20250630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zrEwMuGVbaU8" title="Weighted average exercise price, options outstanding at beginning">541.10</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zU74ysvcAirc" title="Weighted remaining average contractual term, beginning">6.1</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_pp0d_c20240701__20250630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zi95o9qqEr9k" title="Aggregate intrinsic value, outstanding at beginning"><span style="-sec-ix-hidden: xdx2ixbrl0977">-</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Options Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20240701__20250630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pd" title="Options granted">49,031</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240701__20250630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pd" title="Weighted average exercise price, options granted">24.01</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20240701__20250630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zyjWQjfOyji6" title="Weighted remaining average contractual term, options granted">7.1</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Options Expired</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20240701__20250630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zWXqJsXv1jJ9" title="Options expired">(7,725</span></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20240701__20250630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pd" title="Weighted average exercise price, Options expired">553.23</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Options Canceled</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20240701__20250630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_z1Us9nz154Zf" title="Options Canceled">(8,242</span></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90E_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExerciseCanceledPrice_c20240701__20250630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zHlxAC2u5nia" title="Weighted average exercise price, Options Canceled">(78.75</span></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding at June 30, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20240701__20250630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_ze9HtSYAC28a" title="Options outstanding at ending">84,872</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240701__20250630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_z8izUO5iOogd" title="Weighted average exercise price, options outstanding at ending">286.20</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240701__20250630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zqOV1HzxGGx" title="Weighted remaining average contractual term, beginning">6.2</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iE_pp0d_c20240701__20250630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_z9b59OB7VHfi" title="Aggregate intrinsic value, outstanding at ending"><span style="-sec-ix-hidden: xdx2ixbrl0999">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercisable at June 30, 2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_c20250630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pd" title="Options exercisable">49,920</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20250630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pd" title="Weighted average exercise price, options exercisable">387.85</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240701__20250630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_z4DN4PgDnGyd" title="Weighted average remaining contractual term, options exercisable">5.4</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c20250630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pp0p" title="Aggregate intrinsic value. options exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1007">-</span></span></td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8AD_zYNl9XYuyPwk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of each option grant on the date of grant is estimated using the Black-Scholes model. The following weighted-average assumptions were utilized for the years ended:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_znlQG4zTtITd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity Transactions (Details 1)"> <tr style="vertical-align: bottom; background-color: White"> <td id="xdx_8BE_zWmafmncsZ07" style="display: none; text-align: left">Schedule of assumptions used</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left">Expected life of options (in years)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240701__20250630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zDiCLLwBSsq8" title="Expected life of options (in years)">4</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zvhMeoXsUGVa" title="Expected life of options (in years)">6</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20240701__20250630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zfdhJY8mUCU2" title="Expected volatility">93.44</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zRRsKEl1oTG7" title="Expected volatility">86.28</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20240701__20250630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zNJBy8ZpHOs9" title="Risk free interest rate">4.34</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_z6v4cUCksWX9" title="Risk free interest rate">4.40</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Dividend Yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20240701__20250630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zeVW0Q5QArq7" title="Dividend Yield">0</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zRBL1AThAaQh" title="Dividend Yield">0</span></td><td style="text-align: left">%</td></tr> </table> <p id="xdx_8A1_zgeVWmDBmnpe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 3, 2023, the Company granted stock options to purchase <span id="xdx_906_ecustom--NumberOfStockOptionsPurchased_c20231001__20231003__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember__srt--CounterpartyNameAxis__custom--NewEmployeeMember_pd" title="Number of stock options purchased">2,112</span> shares of Common Stock to new hire employees. <span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_c20231001__20231003__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember__srt--CounterpartyNameAxis__custom--NewEmployeeMember__srt--RangeAxis__srt--MinimumMember_pd" title="Awarded vested rights, percentage">20%</span> of the shares underlying the options awarded vest on the one-year anniversary of the grant date, and the remaining <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_c20231001__20231003__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember__srt--CounterpartyNameAxis__custom--NewEmployeeMember__srt--RangeAxis__srt--MaximumMember_pd" title="Awarded vested rights, percentage">80%</span> will vest in equal monthly installments over 48 months each month thereafter. The exercise price of the options is $<span id="xdx_90C_eus-gaap--StockOptionExercisePriceIncrease_c20231001__20231003__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember__srt--CounterpartyNameAxis__custom--NewEmployeeMember_pd" title="Exercise price">341.00</span>, the grant date fair value, and the options terminate on the earlier of the tenth grant date anniversary or the date of which the options are fully exercised.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In June 2024, the Company granted stock options to purchase <span id="xdx_903_ecustom--NumberOfStockOptionsPurchased_c20240601__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember__srt--CounterpartyNameAxis__custom--EmployeeMember_pd" title="Number of stock options purchased">11,580</span> shares of Common Stock to employees. <span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_c20240601__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember__srt--CounterpartyNameAxis__custom--EmployeeMember__srt--RangeAxis__srt--MinimumMember_pd" title="Awarded vested rights, percentage">33%</span> of the shares underlying the options awarded vest on the grant date, and the remaining <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_c20240601__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember__srt--CounterpartyNameAxis__custom--EmployeeMember__srt--RangeAxis__srt--MaximumMember_pd" title="Awarded vested rights, percentage">67%</span> will vest over 2 years on first and second anniversary of the grant date. The exercise price of the options is $<span id="xdx_907_eus-gaap--StockOptionExercisePriceIncrease_c20240601__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember__srt--CounterpartyNameAxis__custom--EmployeeMember_pd" title="Exercise price">47.00</span>, the grant date fair value, and the options terminate on the earlier of the tenth grant date anniversary or the date of which the options are fully exercised.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 20, 2024, the Company granted to employees and directors stock options to purchase <span id="xdx_90B_ecustom--NumberOfStockOptionsPurchased_c20241201__20241220__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember__srt--CounterpartyNameAxis__custom--EmployeeMember_pd" title="Number of stock options purchased">20,893</span> and <span id="xdx_906_ecustom--NumberOfStockOptionsPurchased_c20241201__20241220__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember__srt--CounterpartyNameAxis__srt--DirectorMember_pd" title="Number of stock options purchased">11,308</span> shares of Common Stock, respectively. The options have an exercise price of $<span id="xdx_90E_eus-gaap--StockOptionExercisePriceIncrease_c20241201__20241220__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember__srt--CounterpartyNameAxis__custom--EmployeeMember_pd" title="Exercise price"><span id="xdx_90E_eus-gaap--StockOptionExercisePriceIncrease_c20241201__20241220__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember__srt--CounterpartyNameAxis__srt--DirectorMember_pd" title="Exercise price">19.00</span></span> per share equal to the Company’s stock price at the close on December 20, 2024, the grant date. The fair value of the stock options issued to Directors were $<span id="xdx_90F_ecustom--FairValueOfStockOptions_c20241201__20241220__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember__srt--CounterpartyNameAxis__srt--DirectorMember_pd" title="Fair value of stock options">12.00</span> per share. The fair value of the stock options issued to Management was $<span id="xdx_90F_ecustom--FairValueOfStockOptions_c20241201__20241220__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember__srt--CounterpartyNameAxis__custom--EmployeeMember_pd" title="Fair value of stock options">14.30</span> per share.<span style="font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recorded stock based compensation expense relating to the vesting of stock options of approximately $<span id="xdx_908_eus-gaap--ShareBasedCompensation_pp0n6_c20240701__20250630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zcowOYDwT5e8" title="Stock-based compensation expense">1.2</span> million and $<span id="xdx_900_eus-gaap--ShareBasedCompensation_pp0n6_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zKodFsi841qa" title="Stock-based compensation expense">2.8</span> million for the years ended June 30, 2025 and 2024, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Issuance and modification of restricted stock units, restricted shares and stock options:</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 9, 2023, the Company granted equity awards for the board of directors’ annual compensation. Four directors received <span id="xdx_908_ecustom--RsuGranted_c20231101__20231109__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--FourDirectorMember_zP3eM7AW18Wi" title="Rsu granted">1,827</span> Restricted Stock Units (“RSUs”) with a grant date fair value of $<span id="xdx_90D_eus-gaap--StockOptionExercisePriceIncrease_c20231101__20231109__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--TwoDirectorsMember_zXuKIidE4812" title="Exercise price">301.00</span> per share. In addition, two directors received stock options to purchase <span id="xdx_905_ecustom--RsuGranted_c20231101__20231109__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--TwoDirectorsMember_zl5Lzxty5KA5" title="Rsu granted">1,833</span> shares of common stock at an exercise price of $<span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue1_c20231101__20231109__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--FourDirectorMember_ziNIhNtJw681" title="Rsu granted, grant date fair value">301.00</span> per share with a grant date fair value of $<span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue1_c20231101__20231109__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--TwoDirectorsMember_zHRGcM7Ibwr9" title="Rsu granted, grant date fair value">183.00</span> per share. The equity awards vest quarterly on February 9, 2024, May 9, 2024, August 9, 2024 and earlier of November 9, 2024 or the next annual shareholders’ meeting. During the year ended June 30, 2024, <span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20230701__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pd" title="RSUs vested">457</span> of these RSUs vested. During the year ended June 30, 2025, <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20240701__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pd" title="RSUs vested">682</span> of these RSUs vested and <span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardRSUsForfeituresInPeriod_c20240701__20250630__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_pd" title="RSUs cancelled">232</span> RSUs were cancelled due to Mr. Gorlin resigning from the Board of Directors.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2023, the Company terminated five employees and as part of their severance agreement modified their equity awards that had been granted pursuant to the 2019 Omnibus Plan. The modifications included the acceleration of certain stock option awards to purchase a total of 563 shares of common stock (“Accelerated Options”), effective on the December Separation Date, as defined in severance agreement (“Separation Date”), and extended the expiration date for one year from the Separation Date for both the Accelerated Options and any vested and unexercised stock options held by the terminated employees as of the Separation Date. Accordingly, the Company remeasured the Accelerated Options based on the stock price of $154.00 per share at the close on the Separation Date and a one-year extension of the term. The net adjustment for the modification was a net credit of $127,199 and was recognized as an adjustment to stock compensation expense during the year ended June 30, 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additionally, 103 vesting RSUs were accelerated as of the Separation date. The modified RSUs were remeasured based on the stock price of $154.00 per share at close on the Separation Date and $15,865, was recorded to additional in stock-based compensation for the year ended June 30, 2024 as a result of the modification.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On the Separation date, December 2023, the Company canceled 1,840 unvested stock options and 103 unvested RSUs. Additionally, the Company canceled an additional 1,342 unvested stock options for employees that voluntarily left the company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 24, 2024, the Company granted a total of <span id="xdx_90B_ecustom--RsuGranted_c20240601__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_pd" title="Rsu granted">8,580</span> RSUs to employees, with a grant date fair value of $<span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue1_c20240601__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_pd" title="Rsu granted, grant date fair value">47.40</span> per share. The RSUs vested on the grant date. The Company delivered the vested portion of the RSU’s and issued <span id="xdx_90B_ecustom--SharesIssuedOverVestingPeriod_c20240601__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_pd" title="Shares issued over the vesting period">8,580</span> shares of Common Stock, of which <span id="xdx_908_eus-gaap--RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_c20240601__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_pd" title="Shares for tax withholdings">2,145</span> shares were withheld in Treasury stock in exchange for payment of withholding tax on behalf of the employees.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 20, 2024, the Company granted equity awards as part of the board of directors’ annual compensation. Two directors received <span id="xdx_908_ecustom--RsuGranted_c20241101__20241120__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--TwoDirectorsMember_zuNt5Pj0763" title="Rsu granted">6,690</span> RSUs with a grant date fair value of $<span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue1_c20241101__20241120__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--TwoDirectorsMember_z7UguYhuXOPf" title="Rsu granted, grant date fair value">33.60</span> per share and three directors received stock options to purchase <span id="xdx_900_ecustom--RsuGranted_c20241101__20241120__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--ThreeDirectorsMember_zdxF66vkLWji" title="Rsu granted">16,830</span> shares of Common Stock at an exercise price of $<span id="xdx_90D_eus-gaap--StockOptionExercisePriceIncrease_c20241101__20241120__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--ThreeDirectorsMember_zjwrYbwel70d" title="Exercise price">33.60</span> per share with a grant date fair value of $<span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue1_c20241101__20241120__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--ThreeDirectorsMember_zI5GJg0qrQN6" title="Rsu granted, grant date fair value">21.10</span> per share. The RSUs vest quarterly on February 8, 2025, May 8, 2025, August 8, 2025 and the earlier of November 8, 2025 or the next annual shareholders’ meeting. During the year ended June 30, 2025, <span id="xdx_906_ecustom--SharesIssuedOverVestingPeriod_c20240701__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pd" title="Shares issued over the vesting period">2,528</span> shares were issued related to the RSUs that vested and <span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardRSUsForfeituresInPeriod_c20240701__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pd" title="RSUs cancelled">2,415</span> shares were canceled due to departures.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 1, 2025, the Company awarded <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20241228__20250102__srt--CounterpartyNameAxis__custom--VendorMember_pd" title="Stock issued for services, shares">4,500</span> shares of restricted common stock as part of a service agreement to a vendor. The restricted common shares fully vest on the first anniversary of the effective date. The total cost of the award was based on $<span id="xdx_906_eus-gaap--SharePrice_c20250102__srt--CounterpartyNameAxis__custom--VendorMember_pd" title="Share price">21.80</span> per share as of the date of the award and related stock-based compensation expense for the year ended June 30, 2025 was $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20241228__20250102__srt--CounterpartyNameAxis__custom--VendorMember_pp0n" title="Stock issued for services, amount">49,050</span>.<i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 21, 2025, the Company granted a total of <span id="xdx_904_ecustom--RsuGranted_c20250101__20250121__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--CounterpartyNameAxis__custom--AdvisoryBoardMember_pd" title="Rsu granted">10,500</span> RSUs to Advisory board members at the grant date fair value of $<span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue1_c20250101__20250121__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--CounterpartyNameAxis__custom--AdvisoryBoardMember_pd" title="Rsu granted, grant date fair value">20.50</span>. Vesting of the RSUs are in five equal installments at the grant date and each calendar quarter end beginning March 31, 2025.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes vesting of restricted stock units:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i> </i></p> <table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_zrf0Y4OoMkPj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity Transactions (Details 2)"> <tr style="vertical-align: bottom; background-color: White"> <td id="xdx_8B5_z6XVXcZu22Ql" style="display: none">Schedule of vested of restricted stock units</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Grant Date Fair Value Per Share</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%">Unvested at June 30, 2023</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_c20230701__20240630_zqicqyuvz0qh" title="Number of shares unvested at beginning">5,965</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20230701__20240630_z7g5UqQkHC4i" title="Weighted average grant date fair value per share unvested at beginning">524.00</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Issued</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230701__20240630_pd" title="Number of shares, issued">10,407</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230701__20240630_pd" title="Weighted average grant date fair value per share, issued">91.60</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Vested</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_di_c20230701__20240630_zaF0PEepmxgg" title="Number of shares, vested">(12,240</span></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20230701__20240630_pd" title="Weighted average grant date fair value per share, vested">169.40</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Canceled</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_di_c20230701__20240630_zfHP6wJkEzj6" title="Number of shares, canceled">(103</span></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20230701__20240630_pd" title="Weighted average grant date fair value per share, canceled">612.00</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Unvested at June 30, 2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_c20240701__20250630_zkhW1i4vGxri" title="Number of shares unvested at beginning">4,029</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20240701__20250630_zW5yIWwc79c8" title="Weighted average grant date fair value per share unvested at beginning">445.90</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Issued</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240701__20250630_pd" title="Number of shares, issued">17,190</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240701__20250630_pd" title="Weighted average grant date fair value per share, issued">25.60</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Vested</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_di_c20240701__20250630_zQVqI5pSZfQa" title="Number of shares, vested">(11,314</span></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20240701__20250630_pd" title="Weighted average grant date fair value per share, vested">107.60</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Canceled</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_di_c20240701__20250630_zNQlQRLQCEp3" title="Number of shares, canceled">(2,693</span></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20240701__20250630_pd" title="Weighted average grant date fair value per share, canceled">70.75</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Unvested at June 30, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_c20240701__20250630_ztPI6wxO3j94" title="Number of shares unvested at ending">7,212</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20240701__20250630_zckgQX7ubd5g" title="Weighted average grant date fair value per share unvested at ending">116.41</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A7_zEszDx334ng1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The total stock-based compensation expense from restricted stock units and restricted shares for the year ended June 30, 2025 and 2024 was approximately $<span id="xdx_907_eus-gaap--ShareBasedCompensation_pp0n6_c20240701__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zDEasZtbrl08" title="Stock-based compensation expense">1.2</span> million and $<span id="xdx_902_eus-gaap--ShareBasedCompensation_pp0n6_c20230701__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zlEFoCHpkaoi" title="Stock-based compensation expense">1.8</span> million, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Stock Warrants</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table summarizes the warrants activity during the years ended June 30, 2025 and 2024:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_zCVQNfzCRbZ8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity Transactions (Details 3)"> <tr style="vertical-align: bottom; background-color: White"> <td id="xdx_8B5_z9K2dNBDeNf" style="display: none">Summary of warrants activity</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Life (Years)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Outstanding and exercisable at June 30, 2023</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJFgNzg3VOI8" title="Number of shares, beginning">77,703</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_iS_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znogU8febSqa" title="Weighted average exercise price, beginning">206.00</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20220701__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zAdNsl2YPIE8" title="Weighted average remaining life (Years)">4.0</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_pp0d_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zBGBHHWjlInl" title="Aggregate intrinsic value, beginning">18,318,954</span>.00</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pd" title="Number of shares, granted">175,500</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pd" title="Weighted average exercise price, granted">131.40</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zvxWP9KAkWqb" title="Weighted average remaining life (Years), granted">5.0</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Exercised</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIssuedNumberOfShares_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pd" title="Number of shares, exercised">(60,000</span></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pd" title="Weighted average exercise price, exercised">100.00</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Outstanding and exercisable at June 30, 2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20240701__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zN3rTHzqJ8M4" title="Number of shares, beginning">193,203</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_iS_c20240701__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zIwFLgavoWq7" title="Weighted average exercise price, beginning">140.30</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zH0RHGK0TM32" title="Weighted average remaining life (Years)">4.0</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_pp0d_c20240701__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zeYPPsrgZkJh" title="Aggregate intrinsic value, beginning"><span style="-sec-ix-hidden: xdx2ixbrl1177">-</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20240701__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pd" title="Number of shares, granted">1,018,210</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240701__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pd" title="Weighted average exercise price, granted">16.54</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20240701__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zNSlfwfEvdxg" title="Weighted average remaining life (Years), granted">4.8</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIssuedNumberOfShares_c20240701__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pd" title="Number of shares, exercised">(250,297</span></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue_c20240701__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pd" title="Weighted average exercise price, exercised">15.31</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_c20240701__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pd" title="Number of shares, expired">(1,018</span></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20240701__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pd" title="Weighted average exercise price, expired">218.81</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Outstanding and exercisable at June 30, 2025</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240701__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zjcl4oSVHgE5" title="Number of shares, ending">960,098</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_iE_c20240701__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zn7POmwCG80j" title="Weighted average exercise price, ending">35.02</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20240701__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zlXcI6tC5Vaf" title="Weighted average remaining life (Years)">4.1</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iE_pp0d_c20240701__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zk6R7pVX7vwl" title="Aggregate intrinsic value, ending"><span style="-sec-ix-hidden: xdx2ixbrl1199">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> <p id="xdx_8A5_zJowN5IcItCd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The table below shows the expiration of the warrants outstanding as of June 30, 2025:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zaKyjkRIQvSc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity Transactions (Details 4)"> <tr style="vertical-align: bottom; background-color: White"> <td id="xdx_8BC_zNCTbXnbux8k" style="display: none; text-align: left">Schedule of warrants outstanding</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Warrants</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expiring June 30,</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250630__us-gaap--AwardDateAxis__custom--Year2025Member_z1oTP8idvbN" title="Total outstanding warrants"><span style="-sec-ix-hidden: xdx2ixbrl1203">-</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 85%; text-align: left">2026</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_907_eus-gaap--ClassOfWarrantOrRightOutstanding_c20250630__us-gaap--AwardDateAxis__custom--Year2026Member_pd" title="Total outstanding warrants">360</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_c20250630__us-gaap--AwardDateAxis__custom--Year2027Member_pd" title="Total outstanding warrants">3,610</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2028</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--ClassOfWarrantOrRightOutstanding_c20250630__us-gaap--AwardDateAxis__custom--Year2028Member_pd" title="Total outstanding warrants">72,728</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2029</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--ClassOfWarrantOrRightOutstanding_c20250630__us-gaap--AwardDateAxis__custom--Year2029Member_pd" title="Total outstanding warrants">115,509</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">2030</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightOutstanding_c20250630__us-gaap--AwardDateAxis__custom--Year2030Member_pd" title="Total outstanding warrants">767,891</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Total outstanding warrants</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightOutstanding_c20250630_pd" title="Total outstanding warrants">960,098</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> 33375 9300000 0.03 377000 215 6400 0.03 200 150000 60000 105000 100.00 150.00 21000000.0 10500 125.00 60000 136080 0.0001 60000 196080 15.30 15.30 3000000.0 981 19.10 825600 0.0001 711000 15.00 28.30 13.70 21.20 15900000 2500000 18.80 35.40 189630 15.30 2900000 33500 667 422 1500 48.60 72900 1500 22.30 33450 4500 8.94 40230 <table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zFbQiugH3X86" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity Transactions (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td id="xdx_8BA_zuTqguAY0Npc" style="display: none">Schedule of summarizes the activity relating to the Company’s stock options</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-Average Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Remaining Average Contractual Term</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Outstanding at June 30, 2023</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230701__20240603__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zetEpyM7Vtc2" title="Options outstanding at beginning">39,529</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zO6Fufyn9E9h" title="Weighted average exercise price, options outstanding at beginning">710.00</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zfrlqAbvMiPa" title="Weighted remaining average contractual term, beginning">6.3</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_pp0d_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_z0bGfd0GL4ib" title="Aggregate intrinsic value, outstanding at beginning">1,067,966</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pd" title="Options granted">15,525</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pd" title="Weighted average exercise price, options granted">117.00</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zZDqmz4EqJg5" title="Weighted remaining average contractual term, options granted">9.8</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Options Expired</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zv1OvtJ2xm9d" title="Options expired">(64</span></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pd" title="Weighted average exercise price, Options expired">460.90</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Options Canceled</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zBTaVJ0ZeuNh" title="Options Canceled">(3,182</span></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExerciseCanceledPrice_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zR1qH91H5ix9" title="Weighted average exercise price, Options Canceled">571.90</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding at June 30, 2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240701__20250603__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zc9OiyOK1zY" title="Options outstanding at beginning">51,808</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240701__20250630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zrEwMuGVbaU8" title="Weighted average exercise price, options outstanding at beginning">541.10</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zU74ysvcAirc" title="Weighted remaining average contractual term, beginning">6.1</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_pp0d_c20240701__20250630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zi95o9qqEr9k" title="Aggregate intrinsic value, outstanding at beginning"><span style="-sec-ix-hidden: xdx2ixbrl0977">-</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Options Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20240701__20250630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pd" title="Options granted">49,031</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240701__20250630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pd" title="Weighted average exercise price, options granted">24.01</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20240701__20250630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zyjWQjfOyji6" title="Weighted remaining average contractual term, options granted">7.1</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Options Expired</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20240701__20250630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zWXqJsXv1jJ9" title="Options expired">(7,725</span></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20240701__20250630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pd" title="Weighted average exercise price, Options expired">553.23</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Options Canceled</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20240701__20250630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_z1Us9nz154Zf" title="Options Canceled">(8,242</span></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90E_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExerciseCanceledPrice_c20240701__20250630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zHlxAC2u5nia" title="Weighted average exercise price, Options Canceled">(78.75</span></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding at June 30, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20240701__20250630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_ze9HtSYAC28a" title="Options outstanding at ending">84,872</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240701__20250630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_z8izUO5iOogd" title="Weighted average exercise price, options outstanding at ending">286.20</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240701__20250630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zqOV1HzxGGx" title="Weighted remaining average contractual term, beginning">6.2</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iE_pp0d_c20240701__20250630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_z9b59OB7VHfi" title="Aggregate intrinsic value, outstanding at ending"><span style="-sec-ix-hidden: xdx2ixbrl0999">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercisable at June 30, 2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_c20250630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pd" title="Options exercisable">49,920</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20250630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pd" title="Weighted average exercise price, options exercisable">387.85</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240701__20250630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_z4DN4PgDnGyd" title="Weighted average remaining contractual term, options exercisable">5.4</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c20250630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pp0p" title="Aggregate intrinsic value. options exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1007">-</span></span></td><td style="text-align: left"> </td></tr> </table> 39529 710.00 P6Y3M18D 1067966 15525 117.00 P9Y9M18D 64 460.90 3182 571.90 51808 541.10 P6Y1M6D 49031 24.01 P7Y1M6D 7725 553.23 8242 -78.75 84872 286.20 P6Y2M12D 49920 387.85 P5Y4M24D <table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_znlQG4zTtITd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity Transactions (Details 1)"> <tr style="vertical-align: bottom; background-color: White"> <td id="xdx_8BE_zWmafmncsZ07" style="display: none; text-align: left">Schedule of assumptions used</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left">Expected life of options (in years)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240701__20250630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zDiCLLwBSsq8" title="Expected life of options (in years)">4</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zvhMeoXsUGVa" title="Expected life of options (in years)">6</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20240701__20250630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zfdhJY8mUCU2" title="Expected volatility">93.44</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zRRsKEl1oTG7" title="Expected volatility">86.28</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20240701__20250630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zNJBy8ZpHOs9" title="Risk free interest rate">4.34</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_z6v4cUCksWX9" title="Risk free interest rate">4.40</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Dividend Yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20240701__20250630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zeVW0Q5QArq7" title="Dividend Yield">0</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zRBL1AThAaQh" title="Dividend Yield">0</span></td><td style="text-align: left">%</td></tr> </table> P4Y P6Y 0.9344 0.8628 0.0434 0.0440 0 0 2112 0.20 0.80 341.00 11580 0.33 0.67 47.00 20893 11308 19.00 19.00 12.00 14.30 1200000 2800000 1827 301.00 1833 301.00 183.00 457 682 232 8580 47.40 8580 2145 6690 33.60 16830 33.60 21.10 2528 2415 4500 21.80 49050 10500 20.50 <table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_zrf0Y4OoMkPj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity Transactions (Details 2)"> <tr style="vertical-align: bottom; background-color: White"> <td id="xdx_8B5_z6XVXcZu22Ql" style="display: none">Schedule of vested of restricted stock units</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Grant Date Fair Value Per Share</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%">Unvested at June 30, 2023</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_c20230701__20240630_zqicqyuvz0qh" title="Number of shares unvested at beginning">5,965</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20230701__20240630_z7g5UqQkHC4i" title="Weighted average grant date fair value per share unvested at beginning">524.00</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Issued</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230701__20240630_pd" title="Number of shares, issued">10,407</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230701__20240630_pd" title="Weighted average grant date fair value per share, issued">91.60</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Vested</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_di_c20230701__20240630_zaF0PEepmxgg" title="Number of shares, vested">(12,240</span></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20230701__20240630_pd" title="Weighted average grant date fair value per share, vested">169.40</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Canceled</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_di_c20230701__20240630_zfHP6wJkEzj6" title="Number of shares, canceled">(103</span></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20230701__20240630_pd" title="Weighted average grant date fair value per share, canceled">612.00</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Unvested at June 30, 2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_c20240701__20250630_zkhW1i4vGxri" title="Number of shares unvested at beginning">4,029</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20240701__20250630_zW5yIWwc79c8" title="Weighted average grant date fair value per share unvested at beginning">445.90</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Issued</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240701__20250630_pd" title="Number of shares, issued">17,190</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240701__20250630_pd" title="Weighted average grant date fair value per share, issued">25.60</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Vested</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_di_c20240701__20250630_zQVqI5pSZfQa" title="Number of shares, vested">(11,314</span></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20240701__20250630_pd" title="Weighted average grant date fair value per share, vested">107.60</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Canceled</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_di_c20240701__20250630_zNQlQRLQCEp3" title="Number of shares, canceled">(2,693</span></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20240701__20250630_pd" title="Weighted average grant date fair value per share, canceled">70.75</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Unvested at June 30, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_c20240701__20250630_ztPI6wxO3j94" title="Number of shares unvested at ending">7,212</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20240701__20250630_zckgQX7ubd5g" title="Weighted average grant date fair value per share unvested at ending">116.41</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 5965 524.00 10407 91.60 12240 169.40 103 612.00 4029 445.90 17190 25.60 11314 107.60 2693 70.75 7212 116.41 1200000 1800000 <table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_zCVQNfzCRbZ8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity Transactions (Details 3)"> <tr style="vertical-align: bottom; background-color: White"> <td id="xdx_8B5_z9K2dNBDeNf" style="display: none">Summary of warrants activity</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Life (Years)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Outstanding and exercisable at June 30, 2023</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJFgNzg3VOI8" title="Number of shares, beginning">77,703</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_iS_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znogU8febSqa" title="Weighted average exercise price, beginning">206.00</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20220701__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zAdNsl2YPIE8" title="Weighted average remaining life (Years)">4.0</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_pp0d_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zBGBHHWjlInl" title="Aggregate intrinsic value, beginning">18,318,954</span>.00</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pd" title="Number of shares, granted">175,500</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pd" title="Weighted average exercise price, granted">131.40</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zvxWP9KAkWqb" title="Weighted average remaining life (Years), granted">5.0</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Exercised</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIssuedNumberOfShares_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pd" title="Number of shares, exercised">(60,000</span></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pd" title="Weighted average exercise price, exercised">100.00</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Outstanding and exercisable at June 30, 2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20240701__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zN3rTHzqJ8M4" title="Number of shares, beginning">193,203</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_iS_c20240701__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zIwFLgavoWq7" title="Weighted average exercise price, beginning">140.30</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zH0RHGK0TM32" title="Weighted average remaining life (Years)">4.0</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_pp0d_c20240701__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zeYPPsrgZkJh" title="Aggregate intrinsic value, beginning"><span style="-sec-ix-hidden: xdx2ixbrl1177">-</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20240701__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pd" title="Number of shares, granted">1,018,210</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240701__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pd" title="Weighted average exercise price, granted">16.54</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20240701__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zNSlfwfEvdxg" title="Weighted average remaining life (Years), granted">4.8</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIssuedNumberOfShares_c20240701__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pd" title="Number of shares, exercised">(250,297</span></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue_c20240701__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pd" title="Weighted average exercise price, exercised">15.31</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_c20240701__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pd" title="Number of shares, expired">(1,018</span></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20240701__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pd" title="Weighted average exercise price, expired">218.81</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Outstanding and exercisable at June 30, 2025</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240701__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zjcl4oSVHgE5" title="Number of shares, ending">960,098</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_iE_c20240701__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zn7POmwCG80j" title="Weighted average exercise price, ending">35.02</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20240701__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zlXcI6tC5Vaf" title="Weighted average remaining life (Years)">4.1</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iE_pp0d_c20240701__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zk6R7pVX7vwl" title="Aggregate intrinsic value, ending"><span style="-sec-ix-hidden: xdx2ixbrl1199">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> 77703 206.00 P4Y 18318954 175500 131.40 P5Y -60000 100.00 193203 140.30 P4Y 1018210 16.54 P4Y9M18D -250297 15.31 -1018 218.81 960098 35.02 P4Y1M6D <table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zaKyjkRIQvSc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity Transactions (Details 4)"> <tr style="vertical-align: bottom; background-color: White"> <td id="xdx_8BC_zNCTbXnbux8k" style="display: none; text-align: left">Schedule of warrants outstanding</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Warrants</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expiring June 30,</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250630__us-gaap--AwardDateAxis__custom--Year2025Member_z1oTP8idvbN" title="Total outstanding warrants"><span style="-sec-ix-hidden: xdx2ixbrl1203">-</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 85%; text-align: left">2026</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_907_eus-gaap--ClassOfWarrantOrRightOutstanding_c20250630__us-gaap--AwardDateAxis__custom--Year2026Member_pd" title="Total outstanding warrants">360</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_c20250630__us-gaap--AwardDateAxis__custom--Year2027Member_pd" title="Total outstanding warrants">3,610</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2028</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--ClassOfWarrantOrRightOutstanding_c20250630__us-gaap--AwardDateAxis__custom--Year2028Member_pd" title="Total outstanding warrants">72,728</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2029</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--ClassOfWarrantOrRightOutstanding_c20250630__us-gaap--AwardDateAxis__custom--Year2029Member_pd" title="Total outstanding warrants">115,509</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">2030</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightOutstanding_c20250630__us-gaap--AwardDateAxis__custom--Year2030Member_pd" title="Total outstanding warrants">767,891</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Total outstanding warrants</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightOutstanding_c20250630_pd" title="Total outstanding warrants">960,098</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> 360 3610 72728 115509 767891 960098 <p id="xdx_807_eus-gaap--LesseeOperatingLeasesTextBlock_zXZXpsAlJNU2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.5in; font-size: 10pt"><b>9.</b></td> <td style="font-size: 10pt; text-align: justify"><b><span id="xdx_823_zXNtHSFMnso4">Leases</span></b></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Office Leases </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company pays an annual rent of $<span id="xdx_901_eus-gaap--PaymentsForRent_pp0d_c20240701__20250630__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--OfficeLeasesMember_zTreAIeE4iH1" title="Annual rent">2,200</span> for its headquarters at 680 W Nye Lane, Suite 201, Carson City Nevada 89703. The rental agreement was for a one-year <span id="xdx_901_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtY_c20221002__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--OfficeLeasesMember_zoBP7TKB4jue" style="display: none" title="Lease term">1</span> term, commenced on October 1, 2022 and has been subsequently renewed at each annual maturity date at the same rate.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s San Diego office lease at 5090 Shoreham Place Suite 212, San Diego, CA 92122 which commenced on March 1, 2022, was for a term of <span id="xdx_903_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtM_c20240212__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--OfficeLeasesMember_znJmFGGIABbe" title="Lease term">38</span> months with a base monthly rate of $4,300, and annual increases of three percent. In February 2024, the Company amended the lease agreement which allowed the Company to vacate the then current space and move to a larger space at Suite 206. The current monthly base rate for the new office space is $<span id="xdx_908_ecustom--MonthlyRent_pp0d_c20240201__20240212__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--OfficeLeasesMember_ztOVC8X4M2pg" title="Monthly rent">10,024</span>, with an annual increase of four percent. The term for the new office lease is 60 months and commenced on February 12, 2024. The lease that was in place for the 5090 Shoreham Place Suite 212 office was effectively extinguished upon the commencement of the new office space lease on February 12, 2024, resulting in the write off of the corresponding remaining right-of-use asset and operating lease liability of $<span id="xdx_903_eus-gaap--OperatingLeaseRightOfUseAsset_c20240212_pp0p" title="Right-of-use Asset">56,909</span> and $<span id="xdx_907_eus-gaap--OperatingLeaseLiability_c20240212_pp0p" title="Operating Lease Liability">62,124</span>, respectively, and a gain to selling, general and administrative expenses of $<span id="xdx_901_eus-gaap--OtherSellingGeneralAndAdministrativeExpense_c20240201__20240212_pp0p" title="Selling, general and administrative expenses">5,215</span> for the year ended June 30, 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Total operating lease expense for the years ended June 30, 2025 and 2024 of approximately $<span id="xdx_902_eus-gaap--OperatingLeaseCost_c20240701__20250630_pp0p" title="Operating lease cost">127,000</span> and $<span id="xdx_900_eus-gaap--OperatingLeaseCost_c20230701__20240630_pp0p" title="Operating lease cost">78,000</span>, respectively, were included in the accompanying statements of operations and comprehensive loss as a component of selling, general and administrative expenses.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The right-of-use asset, net and current and non-current portion of the operating lease liabilities included in the accompanying balance sheets are as follows:<span style="font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"> </p> <table cellpadding="0" cellspacing="0" id="xdx_89F_ecustom--LesseeOperatingLeaseLiabilityTableTextBlock_zWLkoi08OzG7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td id="xdx_8B9_zzLIja3NZAgi" style="display: none; text-align: left; padding-bottom: 1pt; padding-left: 9pt">Schedule of operating lease liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td id="xdx_49A_20250630_zwdduoCOyRjf" style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td id="xdx_494_20240630_zfMHyBAh6B8l" style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; font-weight: bold">Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p" style="vertical-align: bottom; background-color: White"> <td style="width: 70%; text-align: left; padding-bottom: 1pt; padding-left: 9pt">Operating lease right-of-use asset, net</td><td style="width: 1%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">339,653</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">406,726</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-decoration: underline; font-weight: bold">Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0d_maOLLzhQK_zrdJbhOp2wki" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 9pt">Current portion of operating lease liability</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">74,464</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">60,343</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0d_maOLLzhQK_zEfuHcCTNur3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Operating lease liability, net of current portion</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">275,430</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">349,894</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--OperatingLeaseLiability_iTI_pp0d_mtOLLzhQK_zZvchnODpqy1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt">Total operating lease liability</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">349,894</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">410,237</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A1_ztGne9Ke8cRl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At June 30, 2025, the future estimated minimum lease payments under non-cancelable operating leases are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_89C_ecustom--ScheduleOfFutureEstimatedMinimumLeasePaymentsUnderNonCancelableOperatingLeases_z2qo7HARgt75" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details 1)"> <tr style="vertical-align: bottom; background-color: White"> <td id="xdx_8BB_z33xTAcsWut2" style="display: none; text-align: left">Schedule of future estimated minimum lease payments under non-cancelable operating leases</td><td> </td> <td style="text-align: left"> </td><td id="xdx_495_20250630_zXx8m3GrY7e4" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">Year ending June 30</td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0d_maLOLLPzdj0_zAwfVecT7smg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 85%; text-align: left">2026</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">122,042</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0d_maLOLLPzdj0_zngFpocAmJ4h" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">126,313</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pp0d_maLOLLPzdj0_zO8dfpSgrOnb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2028</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">130,734</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pp0d_maLOLLPzdj0_zvBh6oDE6RH5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">2029</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">77,796</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0d_mtLOLLPzdj0_ziTzb2ddVKdk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total minimum lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">456,885</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0d_di_zvGzPz1Z0CR9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less amount representing interest</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(106,991</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iI_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Present value of future minimum lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">349,894</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A6_zUOddQszffki" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Total cash paid for amounts included in the measurement of lease liabilities were $<span id="xdx_900_ecustom--CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities_c20240701__20250630_pp0p" title="Cash paid for amounts included in measurement of operating lease liabilities">117,915</span> and $<span id="xdx_902_ecustom--CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities_c20230701__20240630_pp0p" title="Cash paid for amounts included in measurement of operating lease liabilities">83,910</span> for the years ended June 30, 2025 and 2024, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The weighted average remaining lease term and discount rate as of June 30, 2025 and 2024 were as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_89F_ecustom--ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock_zTh3BQQjzn0f" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details 2)"> <tr style="vertical-align: bottom; background-color: White"> <td id="xdx_8B1_zHUbRVcVOj1g" style="display: none; text-align: left; padding-left: 9pt">Schedule of weighted average remaining lease term and discount rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Weighted average remaining lease term (Years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 70%; text-align: left; padding-left: 9pt">Operating lease</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_90D_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20250630_zLJ5CF26Hf8k" title="Weighted average remaining lease term (Years) Operating leases">3.6</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_902_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20240630_zDy23010tUvf" title="Weighted average remaining lease term (Years) Operating leases">4.6</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Weighted average discount rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 9pt">Operating lease</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20250630_zi8plh7uJK79" title="Weighted average discount rate Operating leases">15.00</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20240630_zNTkeWHzVmti" title="Weighted average discount rate Operating leases">15.00</span></td><td style="text-align: left">%</td></tr> </table> <p id="xdx_8AC_zPmnK8aI2hIk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 2200 P1Y P38M 10024 56909 62124 5215 127000 78000 <table cellpadding="0" cellspacing="0" id="xdx_89F_ecustom--LesseeOperatingLeaseLiabilityTableTextBlock_zWLkoi08OzG7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td id="xdx_8B9_zzLIja3NZAgi" style="display: none; text-align: left; padding-bottom: 1pt; padding-left: 9pt">Schedule of operating lease liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td id="xdx_49A_20250630_zwdduoCOyRjf" style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td id="xdx_494_20240630_zfMHyBAh6B8l" style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; font-weight: bold">Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p" style="vertical-align: bottom; background-color: White"> <td style="width: 70%; text-align: left; padding-bottom: 1pt; padding-left: 9pt">Operating lease right-of-use asset, net</td><td style="width: 1%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">339,653</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">406,726</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-decoration: underline; font-weight: bold">Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0d_maOLLzhQK_zrdJbhOp2wki" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 9pt">Current portion of operating lease liability</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">74,464</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">60,343</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0d_maOLLzhQK_zEfuHcCTNur3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Operating lease liability, net of current portion</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">275,430</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">349,894</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--OperatingLeaseLiability_iTI_pp0d_mtOLLzhQK_zZvchnODpqy1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt">Total operating lease liability</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">349,894</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">410,237</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 339653 406726 74464 60343 275430 349894 349894 410237 <table cellpadding="0" cellspacing="0" id="xdx_89C_ecustom--ScheduleOfFutureEstimatedMinimumLeasePaymentsUnderNonCancelableOperatingLeases_z2qo7HARgt75" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details 1)"> <tr style="vertical-align: bottom; background-color: White"> <td id="xdx_8BB_z33xTAcsWut2" style="display: none; text-align: left">Schedule of future estimated minimum lease payments under non-cancelable operating leases</td><td> </td> <td style="text-align: left"> </td><td id="xdx_495_20250630_zXx8m3GrY7e4" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">Year ending June 30</td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0d_maLOLLPzdj0_zAwfVecT7smg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 85%; text-align: left">2026</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">122,042</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0d_maLOLLPzdj0_zngFpocAmJ4h" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">126,313</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pp0d_maLOLLPzdj0_zO8dfpSgrOnb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2028</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">130,734</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pp0d_maLOLLPzdj0_zvBh6oDE6RH5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">2029</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">77,796</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0d_mtLOLLPzdj0_ziTzb2ddVKdk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total minimum lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">456,885</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0d_di_zvGzPz1Z0CR9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less amount representing interest</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(106,991</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iI_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Present value of future minimum lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">349,894</td><td style="text-align: left"> </td></tr> </table> 122042 126313 130734 77796 456885 106991 349894 117915 83910 <table cellpadding="0" cellspacing="0" id="xdx_89F_ecustom--ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock_zTh3BQQjzn0f" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details 2)"> <tr style="vertical-align: bottom; background-color: White"> <td id="xdx_8B1_zHUbRVcVOj1g" style="display: none; text-align: left; padding-left: 9pt">Schedule of weighted average remaining lease term and discount rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Weighted average remaining lease term (Years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 70%; text-align: left; padding-left: 9pt">Operating lease</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_90D_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20250630_zLJ5CF26Hf8k" title="Weighted average remaining lease term (Years) Operating leases">3.6</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_902_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20240630_zDy23010tUvf" title="Weighted average remaining lease term (Years) Operating leases">4.6</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Weighted average discount rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 9pt">Operating lease</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20250630_zi8plh7uJK79" title="Weighted average discount rate Operating leases">15.00</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20240630_zNTkeWHzVmti" title="Weighted average discount rate Operating leases">15.00</span></td><td style="text-align: left">%</td></tr> </table> P3Y7M6D P4Y7M6D 0.1500 0.1500 <p id="xdx_804_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z4URowZR8Qac" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.5in; font-size: 10pt"><b>10.</b></td> <td style="font-size: 10pt"><b><span id="xdx_82A_zE9PTcLM42Fh">Commitments and Contingencies</span></b></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Royalty Agreements</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Agreement and Plan of Merger entered into on April 11, 2016, by and between our predecessor entities, LAT Pharma and NanoAntibiotics, Inc., the Company is obligated to pay a low single digit royalty on net sales of BIV201 (continuous infusion terlipressin) to be shared by the members of LAT Pharma Members, PharmaIn Corporation, and The Barrett Edge, Inc.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Technology Transfer Agreement entered into on July 25, 2016, by and between the Company and the University of Padova (Italy), the Company is obligated to pay a low single digit royalty on net sales of all terlipressin products covered by US patent no. 9,655,645 and any future foreign issuances, capped at a maximum of $200,000 per year.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Shareholder class action complaint and shareholder derivative complaints</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 19, 2024, a purported shareholder class action complaint, captioned <i>Eric Olmstead v. BioVie Inc. et al.</i>, No. 3:24-cv-00035, was filed in the U.S. District Court for the District of Nevada, naming the Company   and certain of its officers as defendants. On February 22, 2024, a second, related putative securities class action was filed in the same court asserting similar claims against the same defendants, captioned <i>Way v. BioVie Inc. et al.</i>, No. 2:24-cv-00361. On April 15, 2024, the court consolidated these two actions under the caption <i>In re BioVie Inc. Securities Litigation</i>, No. 3:24-cv-00035, appointed the lead plaintiff, and approved selection of the lead counsel. On June 21, 2024, the lead plaintiff filed an amended complaint, alleging that the defendants made material misrepresentations and/or omissions of material fact relating to the Company’s business, operations, compliance, and prospects, including information related to the NM101 Phase 3 study and trial of bezisterim (NE3107) in mild to moderate probable AD, <span style="background-color: white">in violation of Sections 10(b) and 20(a) of the  Exchange Act, and Rule 10b-5 promulgated thereunder. The class action is on behalf of purchasers of the Company’s securities during the period from December 7, 2022 through November 28, 2023, and seeks unspecified monetary damages on behalf of the putative class and an award of costs and expenses, including attorney’s fees. The defendants filed a motion to dismiss the amended complaint on August 21, 2024, and that motion was fully briefed as of December 5, 2024. On March 27, 2025, the court denied the defendants’ motion to dismiss, and the parties are now engaged in the early stages of fact discovery</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 30, 2024, a shareholder derivative lawsuit was filed in the United States District Court for the District of Nevada by putative stockholder Andrew Hulm, allegedly on behalf of the Company, that piggy-backs on the securities class action also pending in that court. The derivative complaint names certain current and former officers and directors as defendants, and generally alleges that they breached their fiduciary duties by causing or failing to prevent the securities violations alleged in the securities class action. The derivative complaint also alleges claims for unjust enrichment, waste of corporate assets, gross mismanagement, and abuse of control as against all defendants. On March 18, 2025, the court ordered the Hulm derivative lawsuit stayed, pending resolution of the motion to dismiss the securities class action described above.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 28, 2025, a second shareholder derivative lawsuit was filed in the United States District Court for the District of Nevada by putative stockholder William Settel, allegedly on behalf of the Company, that likewise piggy-backs on the securities class action. The Settel derivative complaint alleges essentially the same claims as the Hulm derivative action against the same defendants based on the same alleged conduct.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company believes that the claims are without merit and intends to defend vigorously against them, but there can be no assurances as to the outcome.</p> <p id="xdx_804_ecustom--EmployeeBenefitPlanTextBlock_zcP9eWVIMCIi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.5in; font-size: 10pt"><b>11.</b></td> <td style="font-size: 10pt"><b><span id="xdx_822_zRRpJSz52L2f">Employee Benefit Plan</span></b></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 1, 2021, the Company began sponsoring an employee benefit plan subject to Section 401(K) of the Internal Revenue Service Code (the “401K Plan”) pursuant to which, all employees meeting eligibility requirements are able to participate.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Subject to certain limitations in the Internal Revenue Code, eligible employees are permitted to make contributions to the 401K Plan on a pre-tax salary reduction basis and the Company will match 5% of the first 5% of an employee’s contributions to the 401K Plan. The Company made contributions into the plan of approximately $<span id="xdx_90D_eus-gaap--DefinedBenefitPlanContributionsByEmployer_c20240701__20250630_pp0p" title="Employee's contributions">152,400</span> and $<span id="xdx_903_eus-gaap--DefinedBenefitPlanContributionsByEmployer_c20230701__20240630_pp0p" title="Employee's contributions">153,200</span>, for the years ended June 30, 2025 and 2024, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> 152400 153200 <p id="xdx_807_eus-gaap--IncomeTaxDisclosureTextBlock_zjAkzSy4qQM2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.5in; font-size: 10pt"><b>12.</b></td> <td style="font-size: 10pt"><b><span id="xdx_826_z9el8V7B9SWd">Income Taxes</span> </b></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Significant components of the Company’s deferred tax assets (liabilities) are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zHfRvQr6zlC4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td id="xdx_8B8_z3Jho2OHa4sf" style="display: none; text-align: left">Schedule of deferred tax assets</td><td> </td> <td style="text-align: left"> </td><td id="xdx_492_20250630_zWc8sJbO8fo6" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_499_20240630_znfcZ6bVS6bb" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_409_eus-gaap--ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_iB_zX7ROAKDLuO8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Deferred tax assets (liabilities):</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsCapitalLossCarryforwards_i01I_pp0d_maDTANz3Ol_zJsYFcUhih2h" style="vertical-align: bottom; background-color: White"> <td style="width: 70%; text-align: left">Tax loss carryforward</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">58,323,950</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">51,429,074</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_i01I_pp0d_maDTANz3Ol_zNPbF7raEIU7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Intangible assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(49,935</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(114,161</td><td style="text-align: left">)</td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_i01I_pp0d_maDTANz3Ol_zDyTT5lpOcge" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Stock based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,531,784</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,860,272</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_i01I_pp0d_maDTANz3Ol_zfLp1NV53A05" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">R&amp;D capitalized</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,134,322</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,467,969</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--DeferredTaxAssetsValuationAllowance_i01NI_pp0d_di_msDTANz3Ol_zvPWMhGSz0V3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Valuation Allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(74,940,121</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(69,643,154</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsNet_i01TI_pp0d_mtDTANz3Ol_z6VIDEjHoE8f" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Net deferred tax assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1312">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1313">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> <p id="xdx_8AA_zPa7Pdp8ldQ4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At June 30, 2025 and 2024, the Company has recorded a full valuation against its net deferred tax assets of approximately $<span id="xdx_907_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iI_pp0n6_c20250630_zFDDiCbOBL5g" title="Deferred Tax Assets, Net">74.9</span> million and $<span id="xdx_909_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iI_pp0n6_c20240630_zEU3K9HHVvT6" title="Deferred Tax Assets, Net">69.6 </span>million, respectively, since in the judgement of management, these assets are not more than likely to be realized. The increase in the valuation allowance during the year ended June 30, 2025 was approximately $<span id="xdx_90E_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pp0n6_c20240701__20250630_zDBtMiH3Eg7d" title="Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount">5.3</span> million.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At June 30, 2025, the Company had a Net Operating Loss (“NOL”) carryforward of approximately $<span id="xdx_904_eus-gaap--OperatingLossCarryforwards_iI_pp0n6_c20250630_z7sXaIKg4ZX3" title="Net Operating Loss carryforward">208</span> million. NOL’s generated prior to 2018 have expiration dates ranging from <span id="xdx_90A_ecustom--ExpirationsDates_c20240701__20250630_zdsvPvyV2RLd" title="Expirations dates">2032 to 2037</span>. Utilization of the Company’s historical NOL are subject to limitations under Internal Revenue Code Section 382 as a result of multiple ownership changes through the Company’s capital raises.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company has no current tax expense due to its net losses and a full valuation allowance.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Reconciliation of the differences between income tax benefit computed at the federal and state statutory tax rates and the provision for income tax benefit for the years ended June 30, 2025 and 2024 is as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zskt5jNhZuh6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details 1)"> <tr style="vertical-align: bottom; background-color: White"> <td id="xdx_8B4_zYkQ3PqG4tH9" style="display: none; text-align: left">Schedule of effective income tax rate reconciliation</td><td> </td> <td style="text-align: left"> </td><td id="xdx_499_20240701__20250630_zmrRbcRDCTtl" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_497_20230701__20240630_znkvLNLHmVge" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_zaakmQtPGF78" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left">Income tax expense at federal statutory rate</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">21</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">21</td><td style="width: 1%; text-align: left">%</td></tr> <tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_zLpo2UV1SGH1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">State taxes, net of federal benefit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7</td><td style="text-align: left">%</td></tr> <tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_zhstcCAqh928" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Change in valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(28</td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">%)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(28</td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">%)</td></tr> <tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_zBHY1LdwHjte" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Effective tax rate</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1336">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1337">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A9_zRgOEZcjtJ82" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On July 4, 2025, the U.S. enacted the One Big Beautiful Bill Act (the “Act”), which contains a broad range of tax reform provisions affecting businesses.   The Company is currently evaluating the full effects of the Act and does not anticipate a material impact on the financial statements.</p> <table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zHfRvQr6zlC4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td id="xdx_8B8_z3Jho2OHa4sf" style="display: none; text-align: left">Schedule of deferred tax assets</td><td> </td> <td style="text-align: left"> </td><td id="xdx_492_20250630_zWc8sJbO8fo6" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_499_20240630_znfcZ6bVS6bb" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_409_eus-gaap--ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_iB_zX7ROAKDLuO8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Deferred tax assets (liabilities):</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsCapitalLossCarryforwards_i01I_pp0d_maDTANz3Ol_zJsYFcUhih2h" style="vertical-align: bottom; background-color: White"> <td style="width: 70%; text-align: left">Tax loss carryforward</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">58,323,950</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">51,429,074</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_i01I_pp0d_maDTANz3Ol_zNPbF7raEIU7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Intangible assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(49,935</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(114,161</td><td style="text-align: left">)</td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_i01I_pp0d_maDTANz3Ol_zDyTT5lpOcge" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Stock based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,531,784</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,860,272</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_i01I_pp0d_maDTANz3Ol_zfLp1NV53A05" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">R&amp;D capitalized</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,134,322</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,467,969</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--DeferredTaxAssetsValuationAllowance_i01NI_pp0d_di_msDTANz3Ol_zvPWMhGSz0V3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Valuation Allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(74,940,121</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(69,643,154</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsNet_i01TI_pp0d_mtDTANz3Ol_z6VIDEjHoE8f" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Net deferred tax assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1312">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1313">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> 58323950 51429074 -49935 -114161 6531784 5860272 10134322 12467969 74940121 69643154 74900000 69600000 5300000 208000000 2032 to 2037 <table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zskt5jNhZuh6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details 1)"> <tr style="vertical-align: bottom; background-color: White"> <td id="xdx_8B4_zYkQ3PqG4tH9" style="display: none; text-align: left">Schedule of effective income tax rate reconciliation</td><td> </td> <td style="text-align: left"> </td><td id="xdx_499_20240701__20250630_zmrRbcRDCTtl" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_497_20230701__20240630_znkvLNLHmVge" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_zaakmQtPGF78" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left">Income tax expense at federal statutory rate</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">21</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">21</td><td style="width: 1%; text-align: left">%</td></tr> <tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_zLpo2UV1SGH1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">State taxes, net of federal benefit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7</td><td style="text-align: left">%</td></tr> <tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_zhstcCAqh928" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Change in valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(28</td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">%)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(28</td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">%)</td></tr> <tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_zBHY1LdwHjte" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Effective tax rate</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1336">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1337">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 0.21 0.21 0.07 0.07 -0.28 -0.28 <p id="xdx_809_eus-gaap--SegmentReportingDisclosureTextBlock_zmFZXvwUkML1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.5in; font-size: 10pt"><b>13.</b></td> <td style="font-size: 10pt"><b><span id="xdx_829_zRLz4dGImWMg">Segment Reporting</span> </b></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company operates as one operating segment with a focus on its efforts to develop drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. The Company's CEO, as the chief operating decision maker, manages and allocates resources to the operations of the Company based on the line items included within these financial statements and segment performance is evaluated based on net loss. This enables the CEO to assess the overall level of available resources and determine how best to deploy these resources across functions, clinical trials, and development projects in line with the long-term company-wide strategic goals. The measurement of segment assets is reported on the balance sheet as total assets. All of the Company’s tangible assets are held in the United States.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The following table presents selected financial information with respect to the Company’s single operating segment and its significant segment expenses for the years ended June 30, 2025 and 2024:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_88B_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zNyNDAR8uhke" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Segment Reporting (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td id="xdx_8B0_z93q0wS3pcT3" style="display: none; text-align: left; padding-left: 0pt">Schedule of segment reporting information</td><td> </td> <td style="text-align: left"> </td><td id="xdx_490_20240701__20250630_zDi6HAwDsoYd" style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_495_20230701__20240630_zgpugqYq5XJ" style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 0pt"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">For the Year Ended</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">For the Year Ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 0pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 0pt"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_40B_ecustom--ClinicalStudies_zZWOC2c50NI" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left; padding-left: 0pt">Clinical studies</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">3,660,000</td><td style="white-space: nowrap; width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">11,081,000</td><td style="white-space: nowrap; width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_ecustom--ClinicalTeams_zjvMykJGQT95" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 0pt">Clinical teams</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,479,000</td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,873,000</td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0pt">Chemistry, manufacturing and controls</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">834,000</td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,066,000</td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--OtherResearchAndDevelopmentExpenses_zdqy3g4zGFA4" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0pt">Other research and development expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">294,000</td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,081,000</td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr id="xdx_400_ecustom--SellingGeneralAndAdministrativeExpenses_zhgaBk6ZZX28" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0pt">Selling, general and administrative expenses</td><td> </td> <td style="text-align: left"></td><td style="text-align: right">8,570,000</td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"></td><td style="text-align: right">8,850,000</td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AdjustmentForAmortization_zdEZjaB1kQXg" style="font-size: 10pt; vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-left: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Amortization of intangible assets</p></td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right" title="Selling, general and administrative expenses"> 229,000</td><td style="font-size: 10pt; white-space: nowrap; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> 229,000</td><td style="font-size: 10pt; white-space: nowrap; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--OtherIncome_zT3XXASM0nz2" style="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 1pt; text-align: left; padding-left: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Other income, net</p></td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Selling, general and administrative expenses"> (524,000</td><td style="font-size: 10pt; padding-bottom: 1pt; white-space: nowrap; text-align: left">) </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"> (59,000</td><td style="font-size: 10pt; padding-bottom: 1pt; white-space: nowrap; text-align: left">) </td></tr> <tr id="xdx_405_ecustom--NetLoss_znXrplHjq7sh" style="font-size: 10pt; vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-bottom: 2.5pt; text-align: left; padding-left: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Net loss</p></td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$ </td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Selling, general and administrative expenses"> (17,542,000</td><td style="font-size: 10pt; padding-bottom: 2.5pt; white-space: nowrap; text-align: left">) </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$ </td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"> (32,121,000</td><td style="font-size: 10pt; padding-bottom: 2.5pt; white-space: nowrap; text-align: left">) </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <table cellpadding="0" cellspacing="0" id="xdx_88B_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zNyNDAR8uhke" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Segment Reporting (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td id="xdx_8B0_z93q0wS3pcT3" style="display: none; text-align: left; padding-left: 0pt">Schedule of segment reporting information</td><td> </td> <td style="text-align: left"> </td><td id="xdx_490_20240701__20250630_zDi6HAwDsoYd" style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_495_20230701__20240630_zgpugqYq5XJ" style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 0pt"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">For the Year Ended</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">For the Year Ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 0pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 0pt"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_40B_ecustom--ClinicalStudies_zZWOC2c50NI" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left; padding-left: 0pt">Clinical studies</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">3,660,000</td><td style="white-space: nowrap; width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">11,081,000</td><td style="white-space: nowrap; width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_ecustom--ClinicalTeams_zjvMykJGQT95" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 0pt">Clinical teams</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,479,000</td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,873,000</td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0pt">Chemistry, manufacturing and controls</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">834,000</td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,066,000</td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--OtherResearchAndDevelopmentExpenses_zdqy3g4zGFA4" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0pt">Other research and development expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">294,000</td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,081,000</td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr id="xdx_400_ecustom--SellingGeneralAndAdministrativeExpenses_zhgaBk6ZZX28" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0pt">Selling, general and administrative expenses</td><td> </td> <td style="text-align: left"></td><td style="text-align: right">8,570,000</td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"></td><td style="text-align: right">8,850,000</td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AdjustmentForAmortization_zdEZjaB1kQXg" style="font-size: 10pt; vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-left: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Amortization of intangible assets</p></td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right" title="Selling, general and administrative expenses"> 229,000</td><td style="font-size: 10pt; white-space: nowrap; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> 229,000</td><td style="font-size: 10pt; white-space: nowrap; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--OtherIncome_zT3XXASM0nz2" style="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 1pt; text-align: left; padding-left: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Other income, net</p></td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Selling, general and administrative expenses"> (524,000</td><td style="font-size: 10pt; padding-bottom: 1pt; white-space: nowrap; text-align: left">) </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"> (59,000</td><td style="font-size: 10pt; padding-bottom: 1pt; white-space: nowrap; text-align: left">) </td></tr> <tr id="xdx_405_ecustom--NetLoss_znXrplHjq7sh" style="font-size: 10pt; vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-bottom: 2.5pt; text-align: left; padding-left: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Net loss</p></td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$ </td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Selling, general and administrative expenses"> (17,542,000</td><td style="font-size: 10pt; padding-bottom: 2.5pt; white-space: nowrap; text-align: left">) </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$ </td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"> (32,121,000</td><td style="font-size: 10pt; padding-bottom: 2.5pt; white-space: nowrap; text-align: left">) </td></tr> </table> 3660000 11081000 4479000 8873000 294000 1081000 8570000 8850000 229000 229000 -524000 -59000 -17542000 -32121000 <p id="xdx_808_eus-gaap--SubsequentEventsTextBlock_zu9MPwbAcwTe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="margin-top: 0; margin-bottom: 0"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.5in; font-size: 10pt"><b>14.</b></td> <td style="font-size: 10pt"><b><span><span id="xdx_827_zN1l05iuqXM7">Subsequent Events</span></span></b></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 11, 2025, the Company closed an underwritten public offering of (i) <span id="xdx_909_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250801__20250811_zerSH9JyYuy4" title="Number of shares issued">5,620,000</span> units (the “Units”), with each Unit consisting of one share of common stock and one warrant (the “Warrants”) and (ii) <span id="xdx_909_ecustom--NumberOfPrefundedUnits_c20250801__20250811_zCxNmaSJyP26" title="Number of pre-funded units">380,000</span> pre-funded units (the “Pre-Funded Units”), with each Pre-Funded Unit consisting of one pre-funded warrant and one Warrant. The underwriter also exercised its over-allotment option in part and purchased an additional <span id="xdx_906_ecustom--AdditionalWarrantsPurchased_c20250801__20250811_zKVdbGuPyoRh" title="Additional warrants purchased">667,300</span> Warrants. The offering resulted in net proceeds of approximately $10.4 million, after deducting underwriting discounts and commissions and other estimated offering expenses. Each Unit was sold to the public at a price of $2.00 per Unit and each Pre-Funded Unit was sold to the public at a price of $1.999 per Pre-Funded Unit (which represents the public offering price of each Unit less the $0.0001 per share nominal exercise price for each Pre-Funded Warrant). On August 8, 2025, the Warrants commenced trading on The Nasdaq Capital Market under the symbol “BIVIW.” Each Warrant is immediately exercisable, entitles the holder to purchase one share of common stock at an exercise price of $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250811_zsplSbYBXxai" title="Warrant exercise price">2.50</span> per share and expires five years from the date of issuance. Each Pre-Funded Warrant is immediately exercisable, entitles the holder to purchase one share of common stock and may be exercised at any time until exercised in full. </span></p> 5620000 380000 667300 2.50 13098976 17544547 2173684 2104050 1607032 1049897 16879692 20698494 282910 339653 6308 178341 345711 345711 17514621 21562199 1611312 2200320 82398 74464 1693710 2274784 213319 275430 1907029 2550214 0.001 0.001 10000000 10000000 0 0 0 0 0.0001 0.0001 800000000 800000000 7544675 7541839 1917061 1914224 754 192 384221988 371156068 -368615121 -352144246 29 29 15607592 19011985 17514621 21562199 57344 57344 172033 172033 3176945 1344991 10382794 8042379 2151088 1585869 6377450 6188703 5385377 2988204 16932277 14403115 -5385377 -2988204 -16932277 -14403115 7290 3771 5967 4998 13923 327722 121045 197494 518869 674087 115078 199786 504946 350136 -5270299 -2788418 -16427331 -14052979 43544 369465 -5270299 -2788418 -16470875 -14422444 -0.70 -1.51 -2.35 -10.68 -0.70 -1.51 -2.35 -10.68 7543923 1850722 7019677 1350352 7543923 1850722 7019677 1350352 621640 62 349738841 -2633 -27 -334232661 15506215 118898 118898 301491 301491 341 1500 33450 33450 162794 16 2259047 2259063 12024 1 -1 325041 -325041 -4152032 -4152032 798299 79 352776767 -2633 -27 -338709734 14067085 385328 385328 265804 265804 381 223130 22 2901319 2901341 422 825600 83 13415467 13415550 44424 -44424 -7112529 -7112529 1847832 184 369789109 -2633 -27 -345866687 23922579 338412 338412 345372 345372 6743 7 -5 -203 -2 -2788418 -2788418 1854575 191 370472888 -2836 -29 -348655105 21817945 1917061 192 371156068 -2836 -29 -352144246 19011985 268388 268388 270559 270559 5620000 562 10457067 10457629 3255 43544 -43544 -5087557 -5087557 7540316 754 382195626 -2836 -29 -357275347 24921004 197336 197336 216169 216169 3255 -6069475 -6069475 7543571 754 382609131 -2836 -29 -363344822 19265034 1561366 1561366 51491 51491 1104 -5270299 -5270299 7544675 754 384221988 -2836 -29 -368615121 15607592 -16427331 -14052979 172033 172033 538219 912667 2027090 842638 33450 11820 -111212 25758 56743 49448 3771 69634 557135 365135 -589008 -1111072 -54177 -43807 -14903200 -13417738 10457629 15674613 2901341 850000 5000000 10457629 12725954 -4445571 -691784 17544547 23843798 13098976 23152014 13923 178932 43544 369465 <p id="xdx_80D_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_z8t7GKqOLqo8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0pt"></td><td style="width: 20pt; text-align: left"><b>1.</b></td><td style="text-align: justify"><b><span id="xdx_822_zqz6cR0ll9Yl">Background Information</span></b></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">BioVie Inc. (the “Company” or “we” or “our”) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Neurodegenerative Disease Programs</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company acquired the biopharmaceutical assets of NeurMedix, Inc. (“NeurMedix”) a privately held clinical-stage pharmaceutical company and a related party in June 2021. The acquired assets included NE3107 (or “bezisterim”). Bezisterim, the approved generic name for NE3107 is an investigational, novel, orally administered small molecule that is thought to inhibit inflammation-driven insulin resistance and major pathological inflammatory cascades with a novel mechanism of action. There is emerging scientific consensus that both inflammation and insulin resistance may play fundamental roles in the development of Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), and bezisterim could, if approved by the U.S. Food and Drug Administration (“FDA”), represent an entirely new medical approach to treating these devastating conditions affecting an estimated 6 million Americans suffering from AD, 1 million Americans suffering from PD, and approximately 20 million adults in the US suffering from Long COVID, with millions more affected worldwide.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With respect to the mechanism of action, we believe Bezisterim inhibits activation of inflammatory action extracellular single regulated kinase (“ERK”) and nuclear factor kappa-light-chain-enhancer of activated B cells (“NFκB”) (including interactions with tumor necrosis factor (“TNF”) signaling and other relevant inflammatory pathways) that lead to neuroinflammation and insulin resistance. By binding to ERK and selectively modulating NFκB activation and TNF-α production without interfering with their homeostatic functions, we believe that bezisterim may offer clinical improvements in several disease indications, including PD, AD and long COVID.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Parkinson’s Disease </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is conducting a Phase 2b clinical trial of bezisterim as a potential first-line therapy for patients with newly diagnosed PD. The trial is designed to evaluate the safety and efficacy of bezisterim on motor and non-motor symptoms in patients with PD who have not been treated with carbidopa/levodopa. The Phase 2b study is a multicenter, randomized, double-blind, placebo-controlled trial with a hybrid decentralized design, and is expected to span approximately 20 weeks from initial screening through safety follow-up for each participant. The trial commenced in April 2025 and completed enrollment of 60 patients in December 2025. The Company currently expects to report topline results from the trial in mid-year 2026, although the timing of results is subject to change and there can be no assurance that the trial will yield favorable results or support further development.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Phase 2 study of bezisterim for the treatment of PD (NCT05083260) that we completed in December 2022, was a double-blind, placebo-controlled, safety, tolerability, and pharmacokinetics study in PD participants treated with carbidopa/levodopa and bezisterim. Forty-five patients with a defined L-dopa “off state” were randomized 1:1 to placebo: bezisterim 20 mg twice daily for 28 days. This trial was launched with two design objectives: 1) the primary objective was safety and a drug-drug interaction study as requested by the FDA to measure the potential for adverse interactions of bezisterim with carbidopa/ levodopa; and 2) the secondary objective was to determine if preclinical indications of promotoric activity and apparent enhancement of levodopa activity could be seen in humans. Both objectives were met.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Long COVID Program</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Long COVID is a condition in which symptoms of COVID-19, the acute respiratory disease caused by the SARS-CoV-2 virus, persist for an extended period, generally three months or more. Common symptoms include lingering loss of smell and taste, extreme fatigue, and “brain fog,” though persistent cardiovascular and respiratory problems, muscle weakness, and neurologic issues have also been documented.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In April 2024, the Company was awarded a clinical trial grant of $13.1 million from the U.S. Department of Defense (“DOD”), awarded through the Peer Reviewed Medical Research Program of the Congressionally Directed Medical Research Programs. In August 2024, U.S. Army Medical Research and Development Command, Office of Human Research Oversight (“OHRO”) approved the Company’s plan to evaluate bezisterim for the treatment of neurological symptoms that are associated with long COVID and the FDA authorized our Investigational New Drug (“IND”) application for bezisterim allowing the Company to study a novel, anti-inflammatory approach for the treatment of the debilitating neurocognitive symptoms associated with long COVID. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Phase 2 ADDRESS-LC study is a randomized (1:1), placebo-controlled, multicenter trial evaluating the efficacy, safety and tolerability of bezisterim in adult participants with long COVID who have cognitive impairment sequelae and fatigue. Individuals who have been diagnosed with long COVID and have neurocognitive dysfunction and self-reported fatigue may meet qualification criteria. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2026, the total cost incurred was approximately $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIEJhY2tncm91bmQgSW5mb3JtYXRpb24gKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_908_eus-gaap--CostsAndExpenses_pp0n6_c20250701__20260331__srt--ProductOrServiceAxis__custom--LongCOVIDProgramMember_z30mf52imnI" title="Costs and expenses">9.4</span> million and as of May 4, 2026 the total cost reimbursed was $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIEJhY2tncm91bmQgSW5mb3JtYXRpb24gKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_90A_eus-gaap--CostsAndExpenses_pp0n6_c20260501__20260504__srt--ProductOrServiceAxis__custom--LongCOVIDProgramMember_zIdThd5or492" title="Costs and expenses">9.4</span> million. Grant reimbursements recognized for the corresponding research and development expenses in the accompanying condensed statements of operations totaled approximately $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIEJhY2tncm91bmQgSW5mb3JtYXRpb24gKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_903_eus-gaap--OtherResearchAndDevelopmentExpense_pp0n6_c20260101__20260331__srt--ProductOrServiceAxis__custom--LongCOVIDProgramMember_zgPXuMauYnI4" title="Research and development expense">3.1</span> million and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIEJhY2tncm91bmQgSW5mb3JtYXRpb24gKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_904_eus-gaap--OtherResearchAndDevelopmentExpense_pp0n6_c20250101__20250331__srt--ProductOrServiceAxis__custom--LongCOVIDProgramMember_zPWUwh9FCUG3" title="Research and development expense">2.5</span> million for the three months ended March 31, 2026 and 2025, respectively. Grant reimbursements recognized for the corresponding research and development expenses in the accompanying condensed statements of operations totaled approximately $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIEJhY2tncm91bmQgSW5mb3JtYXRpb24gKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_905_eus-gaap--OtherResearchAndDevelopmentExpense_pp0n6_c20250701__20260331__srt--ProductOrServiceAxis__custom--LongCOVIDProgramMember_zAc2JKYnaJsg" title="Research and development expense">4.1</span> million and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIEJhY2tncm91bmQgSW5mb3JtYXRpb24gKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_90F_eus-gaap--OtherResearchAndDevelopmentExpense_pp0n6_c20240701__20250331__srt--ProductOrServiceAxis__custom--LongCOVIDProgramMember_zUSuSH4zLoRb" title="Research and development expense">2.9</span> million for the nine months ended March 31, 2026 and 2025, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Alzheimer’s Disease</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In AD, BioVie has conducted both Phase 2 and Phase 3 trials. Preliminary data from these trials suggest improvements in cognition and biomarkers, supporting further trials to evaluate its potential as a therapy for the six million Americans living with AD.<b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Liver Cirrhosis Program</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In liver disease, our investigational drug candidate BIV201 (continuous infusion terlipressin) was granted both FDA Fast Track status and FDA Orphan Drug designation for ascites (due to all etiologies except cancer), which is the most common complication related to liver cirrhosis and represents a significant unmet medical need. BIV201 is being evaluated as a treatment option for patients suffering from life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism. U.S. treatment costs for liver cirrhosis, including ascites and other complications, are estimated at more than $5 billion annually and have an estimated 50% mortality rate within 6 to 12 months.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">After receiving guidance from the FDA regarding the design of Phase 3 clinical testing of BIV201 for the treatment of patients with cirrhosis and ascites, the Company is now targeting a broader ascites patient population. The Company is currently finalizing the protocol design for the Phase 3 study of BIV201 with a focus on demonstrating clinical benefit through a composite primary endpoint of complications and disease progression in patients with cirrhosis and ascites who have recently recovered from acute kidney injury (“AKI”). Ascites is a common complication of advanced liver cirrhosis involving the accumulation of large volumes of fluid in the abdomen, often exceeding five liters, due to liver and kidney dysfunction. BIV201 is administered in a continuous infusion of terlipressin as a patent-pending liquid formulation with patents issued in the U.S., China, Japan, Chile and India to date. Terlipressin is used in over 40 countries to treat complications of liver cirrhosis, including Type 1 hepatorenal syndrome and bleeding esophageal varices, and was approved in the U.S. in 2022 to improve kidney function in adults with hepatorenal syndrome experiencing a rapid reduction in kidney function; it is not currently approved in Japan.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The BIV201 development program was initiated by LAT Pharma LLC. On April 11, 2016, BioVie acquired LAT Pharma LLC and the rights to its BIV201 development program and currently owns all development and marketing rights to this drug candidate. Pursuant to the Agreement and Plan of Merger entered into on April 11, 2016, between predecessor entities, LAT Pharma LLC and NanoAntibiotics, Inc., BioVie is obligated to pay a low single digit royalty on net sales of BIV201 (continuous infusion terlipressin) to be shared among LAT Pharma Members, PharmaIn Corporation, and The Barrett Edge, Inc.</p> 9400000 9400000 3100000 2500000 4100000 2900000 <p id="xdx_807_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zZczUbsgHbAh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0pt"></td><td style="width: 20pt; text-align: left"><b>2.</b></td><td style="text-align: justify"><b><span id="xdx_829_zDyrNq04R2bb">Liquidity and Going Concern</span></b></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s operations are subject to a number of factors that can affect its operating results and financial conditions. Such factors include, but are not limited to: the results of clinical testing and trial activities of the Company’s products, the Company’s ability to obtain regulatory approval to market its products; competition from products manufactured and sold or being developed by other companies; the price of, and demand for, Company products; the Company’s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products; and the Company’s ability to raise capital. The Company’s financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As of March 31, 2026, the Company had working capital of approximately $<span id="xdx_900_ecustom--WorkingCapital_iI_pp0n6_c20260331_zxYZaHbdz0Yd" title="Working capital">15.2</span> million, cash and cash equivalents of approximately $<span id="xdx_909_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0n6_c20260331_z3mPwOSHWHVe" title="Cash and cash equivalent">13.1</span> million, stockholders’ equity of approximately $<span id="xdx_905_ecustom--StockholderEquities_iI_pp0n6_c20260331_z7ssV7FT9Hv" title="Stockholders' equity">15.6</span> million, and an accumulated deficit of approximately $<span id="xdx_900_ecustom--AccumulatedDeficit_iI_pp0n6_c20260331_zA07Sn6yFzf4" title="Accumulated deficit">368.6</span> million. The Company is in the pre-revenue stage and no revenues are expected in the foreseeable future. The Company’s future operations are dependent on the success of the Company’s ongoing development and commercialization efforts, as well as its ability to secure additional financing as needed. Projected cash flows could be extended if further measures are taken to delay planned expenditures in our research protocols and slow the progress in the Company’s development and launch of next phase clinical programs.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The future viability of the Company is largely dependent upon its ability to raise additional capital to finance its operations. Management expects that future sources of funding may include sales of equity, obtaining loans, or other strategic transactions. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Although management continues to pursue the Company’s strategic plans, there is no assurance that the Company will be successful in obtaining sufficient financing on terms acceptable to the Company, if at all, to fund continuing operations. These circumstances raise substantial doubt on the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p> 15200000 13100000 15600000 368600000 <p id="xdx_80A_eus-gaap--SignificantAccountingPoliciesTextBlock_zauO38RdI9Sb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0pt"></td><td style="width: 20pt; text-align: left"><b>3.</b></td><td style="text-align: justify"><b><span id="xdx_826_zBeE9YckLWV5">Significant Accounting Policies</span></b></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_84C_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zltomNctMeKk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i><span id="xdx_864_zbfUv3R23A23">Basis of Presentation – Interim Financial Information</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These unaudited interim condensed financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (the “SEC”) for Interim Reporting. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim condensed financial statements furnished reflect all adjustments (consisting of normal recurring accruals) that are, in the opinion of management, considered necessary for a fair presentation of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. The condensed balance sheet at June 30, 2025, was derived from audited annual financial statements but does not contain all the footnote disclosures from the annual financial statements. These unaudited interim condensed financial statements should be read in conjunction with the Company’s audited financial statements for the fiscal years ended June 30, 2025 and 2024 in our Annual Report on Form 10-K filed with the SEC on August 15, 2025 (the “2025 Form 10-K”). A summary of significant accounting policies can also be found in those audited financial statements in the 2025 Form 10-K.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_84B_ecustom--ReverseStockSpliteUpPolicyTextBlock_zVwYWhnuy4Y4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span id="xdx_86A_z8bh3tMPumCf">Reverse stock split</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company effected a <span id="xdx_903_eus-gaap--StockholdersEquityReverseStockSplit_c20250701__20260331_zuQVSdCmpvz3" title="Reverse split">1:10 reverse stock split</span> of the issued and outstanding shares of its Common Stock on July 7, 2025 which was approved by the board of directors prior to shareholders’ approval at the special meeting on June 23, 2025. All historical share and earnings per share amounts presented have been retroactively adjusted to reflect the reverse stock split. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_840_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zH8AeT4wNaxa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span id="xdx_861_zdG2uri7TGZd">Cash and cash equivalents </span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash and cash equivalents consisted of cash deposits and money market funds held at a bank and funds held in a brokerage account which included a U.S. treasury money market fund and U.S. Treasury Bills with original maturities of three months or less.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_84B_ecustom--ConcentrationOfCreditRiskinTheFinancialServiceIndustryPolicyTextBlock_zNizyuulM6L3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span id="xdx_86D_zflQdrQKTAe2">Concentration of Credit Risk in the Financial Service Industry</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2026, the Company had cash deposited in a certain financial institution in excess of federally insured levels. The Company regularly monitors the financial stability of these financial institutions and believes that it is not exposed to any significant credit risk in cash and cash equivalents. However, if liquidity and financial stability concerns arise with respect to banks and financial institutions, either nationally or in specific regions, the Company’s ability to access cash or enter into new financing arrangements may be threatened, which could have a material adverse effect on its business, financial condition and results of operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">  <i> </i></p> <p id="xdx_847_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zCc1dUkipZ7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span id="xdx_86D_zxbWhIcxJA4">Fair value measurement of assets and liabilities</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We determine the fair values of our financial instruments based on the fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value assumes that the transaction to sell the asset or transfer the liability occurs in the principal or most advantageous market for the asset or liability and establishes that the fair value of an asset or liability shall be determined based on the assumptions that market participants would use in pricing the asset or liability. The classification of a financial asset or liability within the hierarchy is based upon the lowest level input that is significant to the fair value measurement. The fair value hierarchy prioritizes the inputs into three levels that may be used to measure fair value:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 1 - Inputs are unadjusted quoted prices in active markets for identical assets or liabilities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 2 - Inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 3 - Inputs are unobservable inputs based on our assumptions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s financial instruments include cash, accounts payable, and the carrying value of the operating lease liabilities. The carrying amounts of cash and accounts payable approximate their fair value, due to the short-term nature of these items. The carrying amounts of operating lease liabilities approximate their fair values since they bear interest at rates which approximate market rates for similar debt instruments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_84B_eus-gaap--EarningsPerSharePolicyTextBlock_zIxZCx49E381" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span id="xdx_86F_zP3U0EWNlRH3">Net Loss per Common Share</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic net loss per common share is computed by dividing the net loss attributable to Common Stockholders by the weighted average number of shares of Common Stock outstanding during the period. Diluted net loss per common share is computed by dividing the net loss attributable to Common Stockholders by the weighted average number of shares of Common Stock outstanding and potentially outstanding shares of Common Stock during the period to reflect the potential dilution that could occur from common shares issuable through stock options, warrants, restricted stock units, and convertible debentures. For the three and nine months ending March 31, 2026 and 2025, such amounts were excluded from the diluted loss since their effect was considered anti-dilutive due to the net loss for the periods presented.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The weighted average number of common shares outstanding for the three and nine months ended March 31, 2026 of <span id="xdx_904_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20260101__20260331_pd" title="Weighted average number of common shares outstanding, basic"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20260101__20260331_pd" title="Weighted average number of common shares outstanding, diluted">7,543,923</span></span> and <span id="xdx_906_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250701__20260331_pd" title="Weighted average number of common shares outstanding, basic"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250701__20260331_pd" title="Weighted average number of common shares outstanding, diluted">7,019,677</span></span>, respectively, includes the weighted average effect of the pre-funded warrants issued in connection with the August 2025 Offering, the exercise of which requires nominal consideration for the delivery of the shares of common stock (see Note 6).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The table below shows the potential shares of common stock, presented based on amounts outstanding at each period end, which were excluded from the computation of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zcouF8SpJTwk" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Significant Accounting Policies (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td><span id="xdx_8B7_z9spc3L66cv7" style="display: none">Schedule of dilutive securities were excluded from the computation of diluted loss per share</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">March 31, 2026</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">March 31, 2025</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left">Stock Options</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250701__20260331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zrdj0zda1A5k" title="Total">2,785,363</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240701__20250331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_z8nq5Absymsb" title="Total">88,713</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250701__20260331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z2rzWGUlFEDf" title="Total">7,902,037</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240701__20250331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zONYa2Rad2wc" title="Total">960,057</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Restricted Stock Units</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250701__20260331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zLTuSE42IlI1" title="Total">1,099</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240701__20250331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zcfNN78Lps29" title="Total">10,904</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 3.5pt"> </td><td style="font-weight: bold; padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 3.5pt double; font-weight: bold; text-align: right"><span id="xdx_90C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250701__20260331_zR1D4O42zNaj" title="Total">10,688,499</span></td><td style="padding-bottom: 3.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 3.5pt double; font-weight: bold; text-align: right"><span id="xdx_904_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240701__20250331_zueaTcGERnw2" title="Total">1,059,674</span></td><td style="padding-bottom: 3.5pt; font-weight: bold; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_843_ecustom--GrantProgramPolicyTextBlock_zTVHrN5tVCjj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span id="xdx_86F_zr5fXTyPkmCj">Grant program</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company records expenses related to the DOD Long Covid Program as incurred. The reimbursements of such expenses are recognized as a credit against the respective expense account upon receipt, or when it is probable the reimbursement will be received.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_846_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zoNNbdOPgdhg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span id="xdx_861_zNYaDUj3hXsj">Segment Reporting</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company operates as one operating segment with a focus on its efforts to develop drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. The Company's Chief Executive Officer (“CEO”), as the chief operating decision maker, manages and allocates resources to the operations of the Company based on the line items included within these financial statements. This enables the CEO to assess the overall level of available resources and determine how best to deploy these resources across functions, clinical trials, and development projects in line with the long-term company-wide strategic goals. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_84C_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zltomNctMeKk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i><span id="xdx_864_zbfUv3R23A23">Basis of Presentation – Interim Financial Information</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These unaudited interim condensed financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (the “SEC”) for Interim Reporting. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim condensed financial statements furnished reflect all adjustments (consisting of normal recurring accruals) that are, in the opinion of management, considered necessary for a fair presentation of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. The condensed balance sheet at June 30, 2025, was derived from audited annual financial statements but does not contain all the footnote disclosures from the annual financial statements. These unaudited interim condensed financial statements should be read in conjunction with the Company’s audited financial statements for the fiscal years ended June 30, 2025 and 2024 in our Annual Report on Form 10-K filed with the SEC on August 15, 2025 (the “2025 Form 10-K”). A summary of significant accounting policies can also be found in those audited financial statements in the 2025 Form 10-K.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_84B_ecustom--ReverseStockSpliteUpPolicyTextBlock_zVwYWhnuy4Y4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span id="xdx_86A_z8bh3tMPumCf">Reverse stock split</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company effected a <span id="xdx_903_eus-gaap--StockholdersEquityReverseStockSplit_c20250701__20260331_zuQVSdCmpvz3" title="Reverse split">1:10 reverse stock split</span> of the issued and outstanding shares of its Common Stock on July 7, 2025 which was approved by the board of directors prior to shareholders’ approval at the special meeting on June 23, 2025. All historical share and earnings per share amounts presented have been retroactively adjusted to reflect the reverse stock split. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 1:10 reverse stock split <p id="xdx_840_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zH8AeT4wNaxa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span id="xdx_861_zdG2uri7TGZd">Cash and cash equivalents </span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash and cash equivalents consisted of cash deposits and money market funds held at a bank and funds held in a brokerage account which included a U.S. treasury money market fund and U.S. Treasury Bills with original maturities of three months or less.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_84B_ecustom--ConcentrationOfCreditRiskinTheFinancialServiceIndustryPolicyTextBlock_zNizyuulM6L3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span id="xdx_86D_zflQdrQKTAe2">Concentration of Credit Risk in the Financial Service Industry</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2026, the Company had cash deposited in a certain financial institution in excess of federally insured levels. The Company regularly monitors the financial stability of these financial institutions and believes that it is not exposed to any significant credit risk in cash and cash equivalents. However, if liquidity and financial stability concerns arise with respect to banks and financial institutions, either nationally or in specific regions, the Company’s ability to access cash or enter into new financing arrangements may be threatened, which could have a material adverse effect on its business, financial condition and results of operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">  <i> </i></p> <p id="xdx_847_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zCc1dUkipZ7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span id="xdx_86D_zxbWhIcxJA4">Fair value measurement of assets and liabilities</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We determine the fair values of our financial instruments based on the fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value assumes that the transaction to sell the asset or transfer the liability occurs in the principal or most advantageous market for the asset or liability and establishes that the fair value of an asset or liability shall be determined based on the assumptions that market participants would use in pricing the asset or liability. The classification of a financial asset or liability within the hierarchy is based upon the lowest level input that is significant to the fair value measurement. The fair value hierarchy prioritizes the inputs into three levels that may be used to measure fair value:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 1 - Inputs are unadjusted quoted prices in active markets for identical assets or liabilities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 2 - Inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 3 - Inputs are unobservable inputs based on our assumptions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s financial instruments include cash, accounts payable, and the carrying value of the operating lease liabilities. The carrying amounts of cash and accounts payable approximate their fair value, due to the short-term nature of these items. The carrying amounts of operating lease liabilities approximate their fair values since they bear interest at rates which approximate market rates for similar debt instruments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_84B_eus-gaap--EarningsPerSharePolicyTextBlock_zIxZCx49E381" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span id="xdx_86F_zP3U0EWNlRH3">Net Loss per Common Share</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic net loss per common share is computed by dividing the net loss attributable to Common Stockholders by the weighted average number of shares of Common Stock outstanding during the period. Diluted net loss per common share is computed by dividing the net loss attributable to Common Stockholders by the weighted average number of shares of Common Stock outstanding and potentially outstanding shares of Common Stock during the period to reflect the potential dilution that could occur from common shares issuable through stock options, warrants, restricted stock units, and convertible debentures. For the three and nine months ending March 31, 2026 and 2025, such amounts were excluded from the diluted loss since their effect was considered anti-dilutive due to the net loss for the periods presented.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The weighted average number of common shares outstanding for the three and nine months ended March 31, 2026 of <span id="xdx_904_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20260101__20260331_pd" title="Weighted average number of common shares outstanding, basic"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20260101__20260331_pd" title="Weighted average number of common shares outstanding, diluted">7,543,923</span></span> and <span id="xdx_906_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250701__20260331_pd" title="Weighted average number of common shares outstanding, basic"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250701__20260331_pd" title="Weighted average number of common shares outstanding, diluted">7,019,677</span></span>, respectively, includes the weighted average effect of the pre-funded warrants issued in connection with the August 2025 Offering, the exercise of which requires nominal consideration for the delivery of the shares of common stock (see Note 6).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The table below shows the potential shares of common stock, presented based on amounts outstanding at each period end, which were excluded from the computation of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zcouF8SpJTwk" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Significant Accounting Policies (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td><span id="xdx_8B7_z9spc3L66cv7" style="display: none">Schedule of dilutive securities were excluded from the computation of diluted loss per share</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">March 31, 2026</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">March 31, 2025</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left">Stock Options</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250701__20260331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zrdj0zda1A5k" title="Total">2,785,363</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240701__20250331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_z8nq5Absymsb" title="Total">88,713</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250701__20260331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z2rzWGUlFEDf" title="Total">7,902,037</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240701__20250331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zONYa2Rad2wc" title="Total">960,057</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Restricted Stock Units</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250701__20260331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zLTuSE42IlI1" title="Total">1,099</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240701__20250331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zcfNN78Lps29" title="Total">10,904</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 3.5pt"> </td><td style="font-weight: bold; padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 3.5pt double; font-weight: bold; text-align: right"><span id="xdx_90C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250701__20260331_zR1D4O42zNaj" title="Total">10,688,499</span></td><td style="padding-bottom: 3.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 3.5pt double; font-weight: bold; text-align: right"><span id="xdx_904_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240701__20250331_zueaTcGERnw2" title="Total">1,059,674</span></td><td style="padding-bottom: 3.5pt; font-weight: bold; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> 7543923 7543923 7019677 7019677 <table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zcouF8SpJTwk" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Significant Accounting Policies (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td><span id="xdx_8B7_z9spc3L66cv7" style="display: none">Schedule of dilutive securities were excluded from the computation of diluted loss per share</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">March 31, 2026</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">March 31, 2025</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left">Stock Options</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250701__20260331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zrdj0zda1A5k" title="Total">2,785,363</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240701__20250331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_z8nq5Absymsb" title="Total">88,713</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250701__20260331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z2rzWGUlFEDf" title="Total">7,902,037</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240701__20250331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zONYa2Rad2wc" title="Total">960,057</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Restricted Stock Units</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250701__20260331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zLTuSE42IlI1" title="Total">1,099</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240701__20250331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zcfNN78Lps29" title="Total">10,904</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 3.5pt"> </td><td style="font-weight: bold; padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 3.5pt double; font-weight: bold; text-align: right"><span id="xdx_90C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250701__20260331_zR1D4O42zNaj" title="Total">10,688,499</span></td><td style="padding-bottom: 3.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 3.5pt double; font-weight: bold; text-align: right"><span id="xdx_904_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240701__20250331_zueaTcGERnw2" title="Total">1,059,674</span></td><td style="padding-bottom: 3.5pt; font-weight: bold; text-align: left"> </td></tr> </table> 2785363 88713 7902037 960057 1099 10904 10688499 1059674 <p id="xdx_843_ecustom--GrantProgramPolicyTextBlock_zTVHrN5tVCjj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span id="xdx_86F_zr5fXTyPkmCj">Grant program</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company records expenses related to the DOD Long Covid Program as incurred. The reimbursements of such expenses are recognized as a credit against the respective expense account upon receipt, or when it is probable the reimbursement will be received.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_846_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zoNNbdOPgdhg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span id="xdx_861_zNYaDUj3hXsj">Segment Reporting</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company operates as one operating segment with a focus on its efforts to develop drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. The Company's Chief Executive Officer (“CEO”), as the chief operating decision maker, manages and allocates resources to the operations of the Company based on the line items included within these financial statements. This enables the CEO to assess the overall level of available resources and determine how best to deploy these resources across functions, clinical trials, and development projects in line with the long-term company-wide strategic goals. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_80B_eus-gaap--IntangibleAssetsDisclosureTextBlock_zfMXgqKLCYHh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0pt"></td><td style="width: 20pt; text-align: left"><b>4.</b></td><td style="text-align: justify"><b><span id="xdx_828_zjikHKe38Cbd">Intangible Assets</span></b></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company’s intangible assets consist of intellectual property acquired from LAT Pharma, Inc. and are amortized over their estimated useful lives.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following is a summary of the Company’s intangible assets:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zsWdp97mTJej" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Intangible Assets (Details)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B6_zurUhP3eZfA4" style="display: none">Schedule of intangible assets</span></td><td> </td> <td colspan="2" id="xdx_495_20260331_zreVbDylrhFg"> </td><td> </td><td> </td> <td colspan="2" id="xdx_496_20250630_za53CLqNwiFj"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0d_maFLIANzEUZ_zB99LPVVU6h1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left">Intellectual Property</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,293,770</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,293,770</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0d_di_msFLIANzEUZ_zKqhix8m0ofg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: Accumulated Amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,287,462</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,115,429</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pp0d_mtFLIANzEUZ_zlJoM2jFm7Wb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 3.5pt">Intellectual Property, net</td><td style="padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right">6,308</td><td style="padding-bottom: 3.5pt; text-align: left"> </td><td style="padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right">178,341</td><td style="padding-bottom: 3.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Amortization expense was $<span id="xdx_903_eus-gaap--AmortizationOfIntangibleAssets_c20260101__20260331_pp0p" title="Amortization expenses"><span id="xdx_90D_eus-gaap--AmortizationOfIntangibleAssets_c20250101__20250331_pp0p" title="Amortization expenses">57,344</span></span> in each of the three-month periods ended March 31, 2026 and 2025. Amortization expense was $<span id="xdx_906_eus-gaap--AmortizationOfIntangibleAssets_c20250701__20260331_pp0p" title="Amortization expenses"><span id="xdx_900_eus-gaap--AmortizationOfIntangibleAssets_c20240701__20250331_pp0p" title="Amortization expenses">172,033</span></span> in each of the nine-month periods ended March 31, 2026 and 2025. The Company amortizes intellectual property over the expected original useful lives of <span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20260331_zp8JRGZ5ZTrf" title="Useful life">10</span> years and the remaining amortization expense for the year ending June 30, 2026 is $<span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetsNet_c20260331_pp0p" title="Remaining amortization expense">6,308</span>. </p> <table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zsWdp97mTJej" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Intangible Assets (Details)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B6_zurUhP3eZfA4" style="display: none">Schedule of intangible assets</span></td><td> </td> <td colspan="2" id="xdx_495_20260331_zreVbDylrhFg"> </td><td> </td><td> </td> <td colspan="2" id="xdx_496_20250630_za53CLqNwiFj"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0d_maFLIANzEUZ_zB99LPVVU6h1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left">Intellectual Property</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,293,770</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,293,770</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0d_di_msFLIANzEUZ_zKqhix8m0ofg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: Accumulated Amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,287,462</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,115,429</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pp0d_mtFLIANzEUZ_zlJoM2jFm7Wb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 3.5pt">Intellectual Property, net</td><td style="padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right">6,308</td><td style="padding-bottom: 3.5pt; text-align: left"> </td><td style="padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right">178,341</td><td style="padding-bottom: 3.5pt; text-align: left"> </td></tr> </table> 2293770 2293770 2287462 2115429 6308 178341 57344 57344 172033 172033 P10Y 6308 <p id="xdx_808_eus-gaap--FairValueDisclosuresTextBlock_zb8mMXZRT956" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0pt"></td><td style="width: 20pt; text-align: left"><b>5.</b></td><td style="text-align: justify"><b><span id="xdx_824_zjxpbquHsNp1">Fair Value Measurements</span></b></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Financial assets</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2026, investments in U.S. Treasury Bills were valued through use of quoted prices and are classified as Level 1. The following table presents information about our assets that are measured at fair value on a recurring basis using the above input categories. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_z9Sgq9J3Y29b" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Fair Value Measurements (Details 1)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span id="xdx_8B8_ztXTYXe9PVS2" style="display: none">Measured at fair value on a recurring basis</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="14" style="font-weight: bold; text-align: center">Fair Value Measurements at</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Level 1</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Level 2</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Level 3</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Total</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Cash</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_909_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20260331__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p" title="Total">2,130,109</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_90A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20260331__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl2136">-</span></span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_90B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20260331__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl2138">-</span></span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_909_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20260331__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_pp0p" title="Total">2,130,109</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">U.S. Treasury Bills due in 3 months or less at purchase</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20260331__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p" title="Total">10,968,867</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20260331__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl2144">-</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20260331__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl2146">-</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20260331__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember_pp0p" title="Total">10,968,867</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 3.5pt">Total</td><td style="padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right"><span id="xdx_902_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p" title="Total">13,098,976</span></td><td style="padding-bottom: 3.5pt; text-align: left"> </td><td style="padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right"><span id="xdx_905_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl2152">-</span></span></td><td style="padding-bottom: 3.5pt; text-align: left"> </td><td style="padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right"><span id="xdx_904_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl2154">-</span></span></td><td style="padding-bottom: 3.5pt; text-align: left"> </td><td style="padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right"><span id="xdx_90C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20260331_pp0p" title="Total">13,098,976</span></td><td style="padding-bottom: 3.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="14" style="font-weight: bold; text-align: center">Fair Value Measurements at</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Level 1</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Level 2</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Level 3</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Total</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Cash</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_90E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iI_pp0d_c20250630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zsfSNeewYNBa" title="Total">3,978,271</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_900_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iI_pp0d_c20250630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z0ccceuY2wxd" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl2160">-</span></span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_907_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iI_pp0d_c20250630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zW7nJHINdBS8" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl2162">-</span></span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_909_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iI_pp0d_c20250630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_zkLMpd7XBhNi" title="Total">3,978,271</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">U.S. Treasury Bills due in 3 months or less at purchase</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iI_pp0d_c20250630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_ziNwoQ7QmWbh" title="Total">13,566,276</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iI_pp0d_c20250630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z7hpatIANW04" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl2168">-</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iI_pp0d_c20250630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zUXd1ZnwNgYc" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl2170">-</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iI_pp0d_c20250630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember_z4pQN7cliWE9" title="Total">13,566,276</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 3.5pt">Total</td><td style="padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right"><span id="xdx_905_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z4zSQzB68VFc" title="Total">17,544,547</span></td><td style="padding-bottom: 3.5pt; text-align: left"> </td><td style="padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right"><span id="xdx_90C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zIaoz9wXyjX4" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl2176">-</span></span></td><td style="padding-bottom: 3.5pt; text-align: left"> </td><td style="padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right"><span id="xdx_907_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zIwoFPy9YVv2" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl2178">-</span></span></td><td style="padding-bottom: 3.5pt; text-align: left"> </td><td style="padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right"><span id="xdx_904_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iI_pp0d_c20250630_zBcixbaoFFj8" title="Total">17,544,547</span></td><td style="padding-bottom: 3.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A3_zYJj9WOABWql" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_z9Sgq9J3Y29b" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Fair Value Measurements (Details 1)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span id="xdx_8B8_ztXTYXe9PVS2" style="display: none">Measured at fair value on a recurring basis</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="14" style="font-weight: bold; text-align: center">Fair Value Measurements at</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Level 1</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Level 2</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Level 3</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Total</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Cash</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_909_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20260331__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p" title="Total">2,130,109</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_90A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20260331__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl2136">-</span></span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_90B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20260331__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl2138">-</span></span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_909_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20260331__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_pp0p" title="Total">2,130,109</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">U.S. Treasury Bills due in 3 months or less at purchase</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20260331__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p" title="Total">10,968,867</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20260331__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl2144">-</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20260331__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl2146">-</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20260331__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember_pp0p" title="Total">10,968,867</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 3.5pt">Total</td><td style="padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right"><span id="xdx_902_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p" title="Total">13,098,976</span></td><td style="padding-bottom: 3.5pt; text-align: left"> </td><td style="padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right"><span id="xdx_905_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl2152">-</span></span></td><td style="padding-bottom: 3.5pt; text-align: left"> </td><td style="padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right"><span id="xdx_904_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl2154">-</span></span></td><td style="padding-bottom: 3.5pt; text-align: left"> </td><td style="padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right"><span id="xdx_90C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20260331_pp0p" title="Total">13,098,976</span></td><td style="padding-bottom: 3.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="14" style="font-weight: bold; text-align: center">Fair Value Measurements at</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Level 1</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Level 2</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Level 3</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Total</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Cash</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_90E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iI_pp0d_c20250630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zsfSNeewYNBa" title="Total">3,978,271</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_900_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iI_pp0d_c20250630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z0ccceuY2wxd" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl2160">-</span></span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_907_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iI_pp0d_c20250630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zW7nJHINdBS8" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl2162">-</span></span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_909_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iI_pp0d_c20250630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_zkLMpd7XBhNi" title="Total">3,978,271</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">U.S. Treasury Bills due in 3 months or less at purchase</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iI_pp0d_c20250630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_ziNwoQ7QmWbh" title="Total">13,566,276</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iI_pp0d_c20250630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z7hpatIANW04" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl2168">-</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iI_pp0d_c20250630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zUXd1ZnwNgYc" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl2170">-</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iI_pp0d_c20250630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember_z4pQN7cliWE9" title="Total">13,566,276</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 3.5pt">Total</td><td style="padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right"><span id="xdx_905_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z4zSQzB68VFc" title="Total">17,544,547</span></td><td style="padding-bottom: 3.5pt; text-align: left"> </td><td style="padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right"><span id="xdx_90C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zIaoz9wXyjX4" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl2176">-</span></span></td><td style="padding-bottom: 3.5pt; text-align: left"> </td><td style="padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right"><span id="xdx_907_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iI_pp0d_c20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zIwoFPy9YVv2" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl2178">-</span></span></td><td style="padding-bottom: 3.5pt; text-align: left"> </td><td style="padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right"><span id="xdx_904_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iI_pp0d_c20250630_zBcixbaoFFj8" title="Total">17,544,547</span></td><td style="padding-bottom: 3.5pt; text-align: left"> </td></tr> </table> 2130109 2130109 10968867 10968867 13098976 13098976 3978271 3978271 13566276 13566276 17544547 17544547 <p id="xdx_804_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z0DDQeJdC532" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0pt"></td><td style="width: 20pt; text-align: left"><b>6.</b></td><td style="text-align: justify"><b><span id="xdx_825_z6ixbryoPvVk">Equity Transactions</span></b></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Equity Transactions with Acuitas (former related party)</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 15, 2022, the Company entered into a securities purchase agreement with Acuitas Group Holdings, LLC (“Acuitas”), the Company’s largest stockholder, pursuant to which Acuitas agreed to purchase from the Company, in a private placement, (i) an aggregate of <span id="xdx_90F_eus-gaap--CommonStockSharesIssued_c20220715__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AcuitasGroupHoldingsLLCMember_pd" title="Common stock, shares issued">36,364</span> shares of the Company’s Common Stock, at a price of $165.00 per share (the “PIPE Shares”), and (ii) a warrant to purchase 72,728 shares of Common Stock (“PIPE Warrant Shares”), at an original exercise price of $182.00, with a term of exercise of five years.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of the Company’s subsequent capital raises, the warrants’ down round features (the “ratchet adjustment”) resulted in deemed dividends recognized in the accompanying condensed statements of changes in stockholders’ equity for the three months ended September 30, 2025 and 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the three months ended September 30, 2024, the deemed dividend of $<span id="xdx_90A_eus-gaap--Dividends_pp0p0_c20240701__20240930__us-gaap--AwardTypeAxis__custom--WarrantsMember_zBziQBBXhmh2" title="Deemed dividend">325,041</span> was recognized based on ratchet adjustments from the September 25, 2024 capital raises, that reduced the exercise prices from $<span id="xdx_90A_eus-gaap--SharePrice_iI_c20240930__us-gaap--AwardTypeAxis__custom--WarrantsMember__srt--RangeAxis__srt--MaximumMember_zBIQjkZMVbTe" title="Stock price">100.00</span> to $<span id="xdx_90E_eus-gaap--SharePrice_iI_c20240930__us-gaap--AwardTypeAxis__custom--WarrantsMember__srt--RangeAxis__srt--MinimumMember_zL3Yu0PK6l8a" title="Stock price">15.30</span> per share. The fair value of the PIPE Warrant Shares were estimated using the Black Scholes Method with the following inputs at September 2024, the stock price of $12.00, exercise price of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240930__us-gaap--AwardTypeAxis__custom--WarrantsMember__srt--RangeAxis__srt--MinimumMember_z02cKU6CgD0a" title="Exercise price">15.30</span> and $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240930__us-gaap--AwardTypeAxis__custom--WarrantsMember__srt--RangeAxis__srt--MaximumMember_zTBiLyOV1yBl" title="Exercise price">100.00</span>, remaining term of <span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240930__us-gaap--AwardTypeAxis__custom--WarrantsMember_zJDCGeKLHXg2" title="Remaining term">2.9</span> years, risk free rate of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20240701__20240930__us-gaap--AwardTypeAxis__custom--WarrantsMember_z7sQefkZYCA3" title="Risk free rate">3.5%</span> and volatility of <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20240701__20240930__us-gaap--AwardTypeAxis__custom--WarrantsMember_zVzi2UBfutF" title="Volatility">93.0%</span>, resulting in a $<span id="xdx_90D_eus-gaap--Dividends_pp0p0_c20240701__20240930__us-gaap--AwardTypeAxis__custom--WarrantsMember_zG6RONY7TAJi" title="Deemed dividend">325,041</span> deemed dividend.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The October 22, 2024 capital raise further reduced the exercise prices from $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241022__us-gaap--AwardTypeAxis__custom--WarrantsMember__srt--RangeAxis__srt--MaximumMember_zSJb5GRAj8tk" title="Exercise price">15.30 </span>per share to $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241022__us-gaap--AwardTypeAxis__custom--WarrantsMember__srt--RangeAxis__srt--MinimumMember_zJA3t5RTL6K3" title="Exercise price">13.70 </span>per share which drove an additional ratchet adjustment in the second quarter of fiscal year 2025. For the three months ended December 31, 2024, the Company calculated the difference in fair value of the PIPE Warrant Shares between the stated exercise price and the reduced exercise price and recorded $<span id="xdx_905_eus-gaap--Dividends_pp0d_c20241001__20241231__us-gaap--AwardTypeAxis__custom--WarrantsMember_zN87EmNskcVb" title="Deemed dividend">44,424</span> as a deemed dividend in the accompanying condensed statement of changes in stockholders’ equity. The fair value of the PIPE Warrant Shares were estimated using the Black Scholes Method with the following inputs, the stock price of $<span id="xdx_902_eus-gaap--SharePrice_iI_c20241231__us-gaap--AwardTypeAxis__custom--WarrantsMember_zAtG4240HeTf" title="Stock price">33.60</span>, exercise price of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--AwardTypeAxis__custom--WarrantsMember__srt--RangeAxis__srt--MaximumMember_zHNkpYNUZPDl" title="Exercise price">15.30</span> and $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--AwardTypeAxis__custom--WarrantsMember__srt--RangeAxis__srt--MinimumMember_z9titNn1avJg" title="Exercise price">13.70</span>, remaining term of <span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--AwardTypeAxis__custom--WarrantsMember_zV4RTaOOVIod" title="Remaining term">2.8</span> years, risk free rate of <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20240101__20241231__us-gaap--AwardTypeAxis__custom--WarrantsMember_zR7OQ0xEMV55" title="Risk free rate">3.99%</span> and volatility of <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20240101__20241231__us-gaap--AwardTypeAxis__custom--WarrantsMember_z00s5hirBI84" title="Volatility">94.0%</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the three months ended September 30, 2025, the deemed dividend of $<span id="xdx_908_eus-gaap--Dividends_pp0d_c20250701__20250930__us-gaap--AwardTypeAxis__custom--WarrantsMember_zMyMxuyGFIZ6" title="Deemed dividend">43,544</span> was recognized from the ratchet adjustment resulting from the August 2025 capital raise, which reduced the exercise price from $<span id="xdx_906_eus-gaap--SharePrice_iI_c20250930__us-gaap--AwardTypeAxis__custom--WarrantsMember__srt--RangeAxis__srt--MaximumMember_zIllF4ZO6MZb" title="Stock price">13.70</span> to $<span id="xdx_90A_eus-gaap--SharePrice_iI_c20250930__us-gaap--AwardTypeAxis__custom--WarrantsMember__srt--RangeAxis__srt--MinimumMember_zzQ3XwvDAmGd" title="Stock price">2.50 </span>per share. The fair value of the PIPE Warrant Shares was estimated using the Black Scholes Method with the following inputs, the stock price of $<span id="xdx_901_eus-gaap--SharePrice_iI_c20250930__us-gaap--AwardTypeAxis__custom--WarrantsMember_zSKIwXSOBvO2" title="Stock price">1.79</span>, exercise price of $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250930__us-gaap--AwardTypeAxis__custom--WarrantsMember__srt--RangeAxis__srt--MaximumMember_z3HQWAFdOzy3" title="Exercise price">13.70</span> and reduced exercise price of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250930__us-gaap--AwardTypeAxis__custom--WarrantsMember__srt--RangeAxis__srt--MinimumMember_z9kIHvRCbq87" title="Exercise price">2.50,</span> remaining term of <span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250930__us-gaap--AwardTypeAxis__custom--WarrantsMember_zDYDDusUUlx" title="Remaining term">2.0</span> years, risk free rate of <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20250701__20250930__us-gaap--AwardTypeAxis__custom--WarrantsMember_zKwtwULCOZS1" title="Risk free rate">3.8%</span> and volatility of <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20250701__20250930__us-gaap--AwardTypeAxis__custom--WarrantsMember_zcNFQ4Q824B8" title="Volatility">94.0%</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Issuance of common stock for cash</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 11, 2025, the Company closed an underwritten public offering of (i) <span id="xdx_901_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250801__20250811_pd" title="Number of shares issued">5,620,000</span> units (the “Units”), with each Unit consisting of one share of common stock and one warrant (the “Warrants”) and (ii) <span id="xdx_90C_ecustom--NumberOfPrefundedUnits_c20250801__20250811_pd" title="Number of pre-funded units">380,000</span> pre-funded units (the “Pre-Funded Units”), with each Pre-Funded Unit consisting of one pre-funded warrant and one Warrant. The underwriter also exercised its over-allotment option in part and purchased an additional <span id="xdx_908_ecustom--AdditionalWarrantsPurchased_c20250801__20250811_pd" title="Additional warrants purchased">667,300</span> Warrants. The offering resulted in net proceeds of approximately $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pp0n6_c20250801__20250811_zfW3ffLiy9W4" title="Proceeds from offering">10.5</span> million, after deducting underwriting discounts and commissions and other estimated offering expenses. <span id="xdx_90F_ecustom--SharePriceDescription_c20250801__20250811_z3VdapfEqNG" title="Share price description">Each Unit was sold to the public at a price of $2.00 per Unit and each Pre-Funded Unit was sold to the public at a price of $1.999 per Pre-Funded Unit (which represents the public offering price of each Unit less the $0.0001 per share nominal exercise price for each Pre-Funded Warrant). </span>On August 8, 2025, the Warrants commenced trading on The Nasdaq Capital Market under the symbol “BIVIW.” Each Warrant is immediately exercisable, entitles the holder to purchase one share of common stock at an exercise price of $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20250811_pd" title="Exercise price">2.50</span> per share and expires five years from the date of issuance. Each Pre-Funded Warrant is immediately exercisable, entitles the holder to purchase one share of common stock, and may be exercised at any time until exercised in full. Additionally, upon closing, the Company issued the underwriter warrants to purchase 300,000 shares of Common Stock exercisable at a per share price of $2.50, which was equal to 125% of the public offering price per share. The underwriter’s Warrants are exercisable during a five-year period commencing 180 days from August 11, 2025.<i> </i>  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Stock Options</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table summarizes the activity relating to the Company’s stock options for the nine months ended March 31, 2026:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">  </p> <table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zNHpXVAreV43" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity Transactions (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span id="xdx_8B3_ziLO94k6F0n5" style="display: none">Schedule of summarizes the activity relating to the Company’s stock options</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted-Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Remaining Average Contractual Term</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Outstanding at June 30, 2025</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20250701__20260331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zKj6aQfO8nl5" title="Options outstanding at beginning">84,872</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20250701__20260331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zxSsJmqYS9te" title="Weighted average exercise price, options outstanding at beginning">286.20</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250701__20260331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zWbFnTOiEmv2" title="Weighted remaining average contractual term, beginning">6.2</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_pp0d_c20250701__20260331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_z80uFSyFLzCi" title="Aggregate intrinsic value, outstanding at beginning"><span style="-sec-ix-hidden: xdx2ixbrl2261">-</span></span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Options Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20250701__20260331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_znWI4sfsEoea" title="Options granted">2,706,550</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20250701__20260331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_znf2RBoHDTqe" title="Weighted average exercise price, options granted">1.31</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_ecustom--SharebaseCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20250701__20260331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_z67ZApZz28H1" title="Weighted remaining average contractual term, options granted">7.6</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20250701__20260331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zRzY4uWIkejc" title="Aggregate intrinsic value. options granted">243,590</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Options Expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20250701__20260331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zrtZK0vky70e" title="Options expired">(6,059</span></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20250701__20260331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pd" title="Weighted average exercise price, Options expired">1,091.98</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">0.0</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 3.5pt">Outstanding at March 31, 2026</td><td style="padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; text-align: left"> </td><td style="border-bottom: Black 3.5pt double; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20250701__20260331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zpUshpyQoii9" title="Options outstanding at ending">2,785,363</span></td><td style="padding-bottom: 3.5pt; text-align: left"> </td><td style="padding-bottom: 3.5pt"> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20250701__20260331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_z9KXdhwIsLDb" title="Weighted average exercise price, options outstanding at ending">7.62</span></td><td style="padding-bottom: 3.5pt; text-align: left"> </td><td style="padding-bottom: 3.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20250701__20260331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zGYtiLkjyoAh" title="Weighted remaining average contractual term, ending">7.6</span></td><td style="padding-bottom: 3.5pt; text-align: left"> </td><td style="padding-bottom: 3.5pt"> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iE_pp0d_c20250701__20260331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_z61PBF4M3MU" title="Aggregate intrinsic value, outstanding at ending">243,590</span></td><td style="padding-bottom: 3.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 3.5pt">Exercisable at March 31, 2026</td><td style="padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; text-align: left"> </td><td style="border-bottom: Black 3.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_c20260331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pd" title="Options exercisable">1,606,299</span></td><td style="padding-bottom: 3.5pt; text-align: left"> </td><td style="padding-bottom: 3.5pt"> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20260331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pd" title="Weighted average exercise price, options exercisable">10.51</span></td><td style="padding-bottom: 3.5pt; text-align: left"> </td><td style="padding-bottom: 3.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250701__20260331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zq5YCHDuIJ57" title="Weighted average remaining contractual term, options exercisable">7.4</span></td><td style="padding-bottom: 3.5pt; text-align: left"> </td><td style="padding-bottom: 3.5pt"> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c20260331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pp0p" title="Aggregate intrinsic value. options exercisable">139,018</span></td><td style="padding-bottom: 3.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AA_zMZKOdxVCxfc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recorded stock-based compensation expense relating to the vesting of stock options of approximately $<span id="xdx_90D_eus-gaap--ShareBasedCompensation_pn3n3_dm_c20260101__20260331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zP6PGpKRG1kk" title="Stock based compensation expense - stock options">1.6</span> million and $<span id="xdx_90E_eus-gaap--ShareBasedCompensation_pp0d_c20250101__20250331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zsH2Pg8qrjOl" title="Stock based compensation expense - stock options">338,000</span> for the three months ended March 31, 2026 and 2025, respectively. The Company recorded stock-based compensation expense relating to the vesting of stock options of approximately $<span id="xdx_90A_eus-gaap--ShareBasedCompensation_pn3n3_dm_c20250701__20260331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_z1NUKEB6zrud" title="Stock based compensation expense - stock options">2.0 </span>million and $<span id="xdx_90E_eus-gaap--ShareBasedCompensation_pp0d_c20240701__20250331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zSuR1dUT0h3d" title="Stock based compensation expense - stock options">843,000</span> for the nine months ended March 31, 2026 and 2025, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of each option on the date of grant is estimated using the Black-Scholes option pricing model. The pricing model reflects the following weighted-average assumptions for the nine months ended March 31, 2026 and 2025:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zX9qGDI7cgXi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity Transactions (Details 1)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt"><span id="xdx_8B1_zIO1QGuLt8Rb" style="display: none">Schedule of assumptions used</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2025</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left; padding-left: 5.4pt">Expected life of options (in years)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250701__20260331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_ziL3hgle0Q1g" title="Expected life of options (in years)">5</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240701__20250331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zZMos1pVsjKb" title="Expected life of options (in years)">4</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20250701__20260331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zZW5ba1n0IX4" title="Expected volatility">89.31</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20240701__20250331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zGIfz9vY9RB7" title="Expected volatility">93.44</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.4pt">Risk free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20250701__20260331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zvWLiThBEf9b" title="Risk free interest rate">3.69</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20240701__20250331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zFVRUZQdQ5t4" title="Risk free interest rate">4.34</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt">Dividend Yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20250701__20260331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zHhkb9lp3Li6" title="Dividend Yield">0</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20240701__20250331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zqWE5VdVokC7" title="Dividend Yield">0</span></td><td style="text-align: left">%</td></tr> </table> <p id="xdx_8AE_zawEjCdoqNW9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 5, 2026 (the “Grant Date”), directors’ annual compensation was approved and the directors were granted stock options to purchase a total of <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20251230__20260105__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zZcsDDE6UVK8" title="Number of stock option granted">355,000</span> shares of common stock, at an exercise price of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260105__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zbyv41jfAYI1" title="Exercise price">1.31</span> per share, the closing stock price on the grant date. The stock options vest from the beginning of service on November 11, 2025 in four equal installments on February 11, 2026, May 11, 2026, August 11, 2026 and the earlier of November 11, 2026 or the 2026 annual shareholders' meeting.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 5, 2026 (the “Grant Date”), the Company awarded bonus and retention incentive stock options to certain directors and employees to purchase a total of <span id="xdx_90B_ecustom--NumberOfAwardedBonusAndRetentionIncentiveStockOptions_c20260102__20260105__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zoat4qHQB7nl" title="Number of awarded bonus and retention incentive stock options">812,700</span> and <span id="xdx_900_ecustom--NumberOfAwardedBonusAndRetentionIncentiveStockOptions_c20260102__20260105__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zQFALGubhvwa" title="Number of awarded bonus and retention incentive stock options">1,538,850</span>, respectively; shares of common stock, at an exercise price of $1.31 per share, the closing stock price on the Grant Date. The directors’ stock options vested <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_c20251230__20260105__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zGh4OrjdXhM9" title="Stock option vested">75%</span> on the Grant Date with the remaining balance vesting in equal installments on the first, second and third Grant Date anniversary. The employees’ stock options vested <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_c20251230__20260105__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zJ4eUFB8Oing" title="Stock option vested">55%</span> on grant date with the remaining balance vesting in equal installments on the first, second and third Grant Date anniversary.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Restricted stock units:</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 2, 2025 (the “Grant Date”), the Company awarded a total of <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20250901__20250902__srt--TitleOfIndividualAxis__custom--ConsultantMember_pd" title="Stock issued during period for service">1,500</span> Restricted Stock Units (“RSUs”) to a consultant at the grant date fair value of $<span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue1_c20250901__20250902__srt--TitleOfIndividualAxis__custom--ConsultantMember_pd" title="Rsu granted, grant date fair value">1.58</span> per RSU. The RSUs vest in five equal installments beginning on the Grant Date and over the following four calendar quarters beginning December 31, 2025.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes vesting of restricted stock units:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_zLOokuatzz7h" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity Transactions (Details 2)"> <tr style="vertical-align: bottom; background-color: White"> <td><span id="xdx_8B5_zi9HjbiIFAV9" style="display: none">Schedule of vesting of restricted stock units</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Grant Date Fair Value Per Share</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%">Unvested at June 30, 2025</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">7,213</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_iS_c20250701__20260331_zDPWw69ifc9k" title="Weighted average exercise price, beginning">116.41</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20250701__20260331_zJmeQeQ4Mcr2" title="Number of shares, granted">1,500</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20250701__20260331_zG0woJOINwL3" title="Weighted average exercise price, granted">1.58</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Vested</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_di_c20250701__20260331_zXL3ZTYzOOmh" title="Number of shares, vested">(7,614</span></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20250701__20260331_zSMLkgypKTh" title="Weighted average grant date fair value per share, vested">83.67</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Unvested at March 31, 2026</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_c20250701__20260331_zhLWMdk6Haqk" title="Number of shares unvested at ending">1,099</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20250701__20260331_zBGKEcBFhpGl" title="Weighted average grant date fair value per share unvested at ending">187.02</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AD_z6cIXYMu87Al" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The total stock-based compensation expense from restricted stock units for the three months ended March 31, 2026 and 2025 was approximately $<span id="xdx_907_eus-gaap--ShareBasedCompensation_pp0d_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zcJnyiOF5nwi" title="Stock based compensation expense - stock options">51,000</span> and $<span id="xdx_90F_eus-gaap--ShareBasedCompensation_pp0d_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z9h9HDl6jDY9" title="Stock based compensation expense - stock options">321,000</span>, respectively.  The total stock-based compensation expense from restricted stock units for the nine months ended March 31, 2026 and 2025 was approximately $<span id="xdx_900_eus-gaap--ShareBasedCompensation_pp0d_c20250701__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zulVho85POUj" title="Stock based compensation expense - stock options">538,000</span> and $<span id="xdx_904_eus-gaap--ShareBasedCompensation_pp0d_c20240701__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zGLRVm5bYxCl" title="Stock based compensation expense - stock options">888,000</span>, respectively.  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Stock Warrants</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table summarizes the warrants activity during the nine months ended March 31, 2026:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_zMq0FypC8mP2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity Transactions (Details 3)"> <tr style="vertical-align: bottom; background-color: White"> <td><span id="xdx_8BC_zoibB1cX7cS2" style="display: none">Summary of warrants activity</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Life (Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Outstanding and exercisable at June 30, 2025</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20250701__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zXKPMKb8akP6" title="Number of shares, beginning">960,098</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_iS_c20250701__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zgaNdpfBwqal" title="Weighted average exercise price, beginning">35.02</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20240701__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zNffW0lv7UB2" title="Weighted average remaining life (Years)">4.1</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_pp0d_c20250701__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zeztyPGVUA7a" title="Aggregate intrinsic value, beginning"><span style="-sec-ix-hidden: xdx2ixbrl2366">-</span></span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20250701__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zrenwG7TQFph" title="Number of shares, granted">6,967,300</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20250701__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pd" title="Weighted average exercise price, granted">2.50</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20250701__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZi198dbmpv5" title="Weighted average remaining life (Years), granted">5.0</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Canceled</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iP3us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20250701__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z7XH15lWcr9e" title="Number of shares, canceled">(25,001</span></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_iP3us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20250701__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zkJqMQohA8" title="Weighted average grant date fair value per share, canceled">150.00</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_c20250701__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pd" title="Number of shares, expired">(360</span></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20250701__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zW84eX83rh29" title="Weighted average exercise price, expired">1,250.00</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Outstanding and exercisable at March 31, 2026</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20250701__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zB8EVMkcSoT" title="Number of shares, ending">7,902,037</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_iE_c20250701__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zkZdKKhcsmyj" title="Weighted average exercise price, ending">5.82</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250701__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPnFIivS0zuc" title="Weighted average remaining life (Years)">4.2</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iE_pp0d_c20250701__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJ8aE6UfSYQh" title="Aggregate intrinsic value, ending"><span style="-sec-ix-hidden: xdx2ixbrl2388">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AC_zKGqGu9TGGQ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The table below shows the expiration of the warrants outstanding as of March 31, 2026:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_z8bVSWPr9Fed" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity Transactions (Details 4)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span id="xdx_8B3_zZ0Jm6MgjNq" style="display: none">Schedule of expiration of the warrants outstanding</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expiring June 30,</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 85%; text-align: left">2027</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_907_eus-gaap--ClassOfWarrantOrRightOutstanding_c20260331__us-gaap--AwardDateAxis__custom--Year2027Member_pd" title="Total outstanding warrants">3,610</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2028</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_c20260331__us-gaap--AwardDateAxis__custom--Year2028Member_pd" title="Total outstanding warrants">72,728</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2029</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--ClassOfWarrantOrRightOutstanding_c20260331__us-gaap--AwardDateAxis__custom--Year2029Member_pd" title="Total outstanding warrants">90,508</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2030</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightOutstanding_c20260331__us-gaap--AwardDateAxis__custom--Year2030Member_pd" title="Total outstanding warrants">767,891</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">2031</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightOutstanding_c20260331__us-gaap--AwardDateAxis__custom--Year2031Member_pd" title="Total outstanding warrants">6,967,300</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Total outstanding warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightOutstanding_c20260331_pd" title="Total outstanding warrants">7,902,037</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A8_zDz8k5bvBP0k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The warrants table excludes <span id="xdx_907_ecustom--PrefundedWarrants_c20250701__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJC1NbnHM64d" title="Prefunded warrants">380,000</span> prefunded warrants with an exercise price of $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zSZ8PH5i7NDd" title="Exercise price">0.0001</span> and no expiration.  None of the prefunded warrants were exercised during the nine months ended March 31, 2026.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 36364 325041 100.00 15.30 15.30 100.00 P2Y10M24D 0.035 0.930 325041 15.30 13.70 44424 33.60 15.30 13.70 P2Y9M18D 0.0399 0.940 43544 13.70 2.50 1.79 13.70 2.50 P2Y 0.038 0.940 5620000 380000 667300 10500000 Each Unit was sold to the public at a price of $2.00 per Unit and each Pre-Funded Unit was sold to the public at a price of $1.999 per Pre-Funded Unit (which represents the public offering price of each Unit less the $0.0001 per share nominal exercise price for each Pre-Funded Warrant). 2.50 <table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zNHpXVAreV43" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity Transactions (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span id="xdx_8B3_ziLO94k6F0n5" style="display: none">Schedule of summarizes the activity relating to the Company’s stock options</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted-Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Remaining Average Contractual Term</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Outstanding at June 30, 2025</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20250701__20260331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zKj6aQfO8nl5" title="Options outstanding at beginning">84,872</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20250701__20260331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zxSsJmqYS9te" title="Weighted average exercise price, options outstanding at beginning">286.20</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250701__20260331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zWbFnTOiEmv2" title="Weighted remaining average contractual term, beginning">6.2</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_pp0d_c20250701__20260331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_z80uFSyFLzCi" title="Aggregate intrinsic value, outstanding at beginning"><span style="-sec-ix-hidden: xdx2ixbrl2261">-</span></span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Options Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20250701__20260331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_znWI4sfsEoea" title="Options granted">2,706,550</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20250701__20260331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_znf2RBoHDTqe" title="Weighted average exercise price, options granted">1.31</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_ecustom--SharebaseCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20250701__20260331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_z67ZApZz28H1" title="Weighted remaining average contractual term, options granted">7.6</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20250701__20260331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zRzY4uWIkejc" title="Aggregate intrinsic value. options granted">243,590</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Options Expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20250701__20260331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zrtZK0vky70e" title="Options expired">(6,059</span></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20250701__20260331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pd" title="Weighted average exercise price, Options expired">1,091.98</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">0.0</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 3.5pt">Outstanding at March 31, 2026</td><td style="padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; text-align: left"> </td><td style="border-bottom: Black 3.5pt double; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20250701__20260331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zpUshpyQoii9" title="Options outstanding at ending">2,785,363</span></td><td style="padding-bottom: 3.5pt; text-align: left"> </td><td style="padding-bottom: 3.5pt"> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20250701__20260331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_z9KXdhwIsLDb" title="Weighted average exercise price, options outstanding at ending">7.62</span></td><td style="padding-bottom: 3.5pt; text-align: left"> </td><td style="padding-bottom: 3.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20250701__20260331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zGYtiLkjyoAh" title="Weighted remaining average contractual term, ending">7.6</span></td><td style="padding-bottom: 3.5pt; text-align: left"> </td><td style="padding-bottom: 3.5pt"> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iE_pp0d_c20250701__20260331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_z61PBF4M3MU" title="Aggregate intrinsic value, outstanding at ending">243,590</span></td><td style="padding-bottom: 3.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 3.5pt">Exercisable at March 31, 2026</td><td style="padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; text-align: left"> </td><td style="border-bottom: Black 3.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_c20260331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pd" title="Options exercisable">1,606,299</span></td><td style="padding-bottom: 3.5pt; text-align: left"> </td><td style="padding-bottom: 3.5pt"> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20260331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pd" title="Weighted average exercise price, options exercisable">10.51</span></td><td style="padding-bottom: 3.5pt; text-align: left"> </td><td style="padding-bottom: 3.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250701__20260331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zq5YCHDuIJ57" title="Weighted average remaining contractual term, options exercisable">7.4</span></td><td style="padding-bottom: 3.5pt; text-align: left"> </td><td style="padding-bottom: 3.5pt"> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c20260331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pp0p" title="Aggregate intrinsic value. options exercisable">139,018</span></td><td style="padding-bottom: 3.5pt; text-align: left"> </td></tr> </table> 84872 286.20 P6Y2M12D 2706550 1.31 P7Y7M6D 243590 6059 1091.98 2785363 7.62 P7Y7M6D 243590 1606299 10.51 P7Y4M24D 139018 1600000 338000 2000000.0 843000 <table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zX9qGDI7cgXi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity Transactions (Details 1)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt"><span id="xdx_8B1_zIO1QGuLt8Rb" style="display: none">Schedule of assumptions used</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2025</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left; padding-left: 5.4pt">Expected life of options (in years)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250701__20260331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_ziL3hgle0Q1g" title="Expected life of options (in years)">5</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240701__20250331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zZMos1pVsjKb" title="Expected life of options (in years)">4</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20250701__20260331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zZW5ba1n0IX4" title="Expected volatility">89.31</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20240701__20250331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zGIfz9vY9RB7" title="Expected volatility">93.44</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.4pt">Risk free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20250701__20260331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zvWLiThBEf9b" title="Risk free interest rate">3.69</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20240701__20250331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zFVRUZQdQ5t4" title="Risk free interest rate">4.34</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt">Dividend Yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20250701__20260331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zHhkb9lp3Li6" title="Dividend Yield">0</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20240701__20250331__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zqWE5VdVokC7" title="Dividend Yield">0</span></td><td style="text-align: left">%</td></tr> </table> P5Y P4Y 0.8931 0.9344 0.0369 0.0434 0 0 355000 1.31 812700 1538850 0.75 0.55 1500 1.58 <table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_zLOokuatzz7h" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity Transactions (Details 2)"> <tr style="vertical-align: bottom; background-color: White"> <td><span id="xdx_8B5_zi9HjbiIFAV9" style="display: none">Schedule of vesting of restricted stock units</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Grant Date Fair Value Per Share</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%">Unvested at June 30, 2025</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">7,213</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_iS_c20250701__20260331_zDPWw69ifc9k" title="Weighted average exercise price, beginning">116.41</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20250701__20260331_zJmeQeQ4Mcr2" title="Number of shares, granted">1,500</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20250701__20260331_zG0woJOINwL3" title="Weighted average exercise price, granted">1.58</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Vested</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_di_c20250701__20260331_zXL3ZTYzOOmh" title="Number of shares, vested">(7,614</span></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20250701__20260331_zSMLkgypKTh" title="Weighted average grant date fair value per share, vested">83.67</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Unvested at March 31, 2026</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_c20250701__20260331_zhLWMdk6Haqk" title="Number of shares unvested at ending">1,099</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20250701__20260331_zBGKEcBFhpGl" title="Weighted average grant date fair value per share unvested at ending">187.02</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> 116.41 1500 1.58 7614 83.67 1099 187.02 51000 321000 538000 888000 <table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_zMq0FypC8mP2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity Transactions (Details 3)"> <tr style="vertical-align: bottom; background-color: White"> <td><span id="xdx_8BC_zoibB1cX7cS2" style="display: none">Summary of warrants activity</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Life (Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Outstanding and exercisable at June 30, 2025</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20250701__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zXKPMKb8akP6" title="Number of shares, beginning">960,098</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_iS_c20250701__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zgaNdpfBwqal" title="Weighted average exercise price, beginning">35.02</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20240701__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zNffW0lv7UB2" title="Weighted average remaining life (Years)">4.1</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_pp0d_c20250701__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zeztyPGVUA7a" title="Aggregate intrinsic value, beginning"><span style="-sec-ix-hidden: xdx2ixbrl2366">-</span></span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20250701__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zrenwG7TQFph" title="Number of shares, granted">6,967,300</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20250701__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pd" title="Weighted average exercise price, granted">2.50</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20250701__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZi198dbmpv5" title="Weighted average remaining life (Years), granted">5.0</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Canceled</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iP3us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20250701__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z7XH15lWcr9e" title="Number of shares, canceled">(25,001</span></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_iP3us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20250701__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zkJqMQohA8" title="Weighted average grant date fair value per share, canceled">150.00</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_c20250701__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pd" title="Number of shares, expired">(360</span></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20250701__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zW84eX83rh29" title="Weighted average exercise price, expired">1,250.00</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Outstanding and exercisable at March 31, 2026</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20250701__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zB8EVMkcSoT" title="Number of shares, ending">7,902,037</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_iE_c20250701__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zkZdKKhcsmyj" title="Weighted average exercise price, ending">5.82</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250701__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPnFIivS0zuc" title="Weighted average remaining life (Years)">4.2</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iE_pp0d_c20250701__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJ8aE6UfSYQh" title="Aggregate intrinsic value, ending"><span style="-sec-ix-hidden: xdx2ixbrl2388">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> 960098 35.02 P4Y1M6D 6967300 2.50 P5Y -25001 150.00 -360 1250.00 7902037 5.82 P4Y2M12D <table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_z8bVSWPr9Fed" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity Transactions (Details 4)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span id="xdx_8B3_zZ0Jm6MgjNq" style="display: none">Schedule of expiration of the warrants outstanding</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expiring June 30,</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 85%; text-align: left">2027</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_907_eus-gaap--ClassOfWarrantOrRightOutstanding_c20260331__us-gaap--AwardDateAxis__custom--Year2027Member_pd" title="Total outstanding warrants">3,610</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2028</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_c20260331__us-gaap--AwardDateAxis__custom--Year2028Member_pd" title="Total outstanding warrants">72,728</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2029</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--ClassOfWarrantOrRightOutstanding_c20260331__us-gaap--AwardDateAxis__custom--Year2029Member_pd" title="Total outstanding warrants">90,508</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2030</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightOutstanding_c20260331__us-gaap--AwardDateAxis__custom--Year2030Member_pd" title="Total outstanding warrants">767,891</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">2031</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightOutstanding_c20260331__us-gaap--AwardDateAxis__custom--Year2031Member_pd" title="Total outstanding warrants">6,967,300</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Total outstanding warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightOutstanding_c20260331_pd" title="Total outstanding warrants">7,902,037</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> 3610 72728 90508 767891 6967300 7902037 380000 0.0001 <p id="xdx_800_eus-gaap--LesseeOperatingLeasesTextBlock_zCi8QTCIymf5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0pt"></td><td style="width: 20pt; text-align: left"><b>7.</b></td><td style="text-align: justify"><b><span id="xdx_822_zBI9CXtDXLVe">Leases</span></b></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Office Leases </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company pays an annual rent of $<span id="xdx_900_eus-gaap--PaymentsForRent_pp0d_c20250701__20260331__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--OfficeLeasesMember_zHfB4Y7RnZu1" title="Annual rent">2,200</span> for its headquarters at 680 W Nye Lane, Suite 201, Carson City Nevada 89703. The rental agreement was for a one-year term, commenced on October 1, 2022 and has been subsequently renewed at each annual maturity date at the same rate.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s San Diego office lease at 5090 Shoreham Place Suite 206, San Diego, CA 92122 was amended on February 12, 2024 for a larger space. The current monthly base rate for the office space is $<span id="xdx_903_ecustom--MonthlyRent_pp0d_c20240201__20240212__us-gaap--StatementOperatingActivitiesSegmentAxis__custom--OfficeLeasesMember_zbmCJf0SYFX2" title="Monthly rent">10,024</span>, with annual increases of four percent. The term of the lease is 60 months.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Total operating lease expense for the three months ended March 31, 2026 and 2025 of approximately $<span id="xdx_908_eus-gaap--OperatingLeaseCost_c20260101__20260331_pp0p" title="Operating lease cost">35,000</span> and $<span id="xdx_90A_eus-gaap--OperatingLeaseCost_c20250101__20250331_pp0p" title="Operating lease cost">32,000</span>, respectively, and for the nine months ended March 31, 2026 and 2025 of approximately $<span id="xdx_902_eus-gaap--OperatingLeaseCost_c20250701__20260331_pp0p" title="Operating lease cost">99,000</span> and $<span id="xdx_900_eus-gaap--OperatingLeaseCost_c20240701__20250331_pp0p" title="Operating lease cost">95,000</span>, respectively, were included in the accompanying condensed statements of operations as a component of general and administrative expenses.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The right-of-use asset, net and current and long-term portion of the operating lease liabilities included in the accompanying condensed balance sheets are as follows: </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"> </p> <table cellpadding="0" cellspacing="0" id="xdx_89B_ecustom--LesseeOperatingLeaseLiabilityTableTextBlock_zhOpq7yskOQ9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"><span id="xdx_8BD_zGssZv3wgUcg" style="display: none">Schedule of operating lease liabilities</span></td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left"> </td><td id="xdx_49F_20260331_zuhL1aHAloGh" style="text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left"> </td><td id="xdx_499_20250630_zAu0gPVvlVYi" style="text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; font-weight: bold">Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0d_zwauQkHC48u4" style="vertical-align: bottom; background-color: White"> <td style="width: 70%; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Operating lease right-of-use asset, net</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 12%; text-align: right">282,910</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 12%; text-align: right">339,653</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-decoration: underline; font-weight: bold">Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0d_maOLLzedc_zmS9xeMylp5l" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 9pt">Current portion of operating lease liability</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">82,398</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">74,464</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0d_maOLLzedc_zg3wna5nHQO7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Operating lease liability, net of current portion</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">213,319</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">275,430</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--OperatingLeaseLiability_iTI_pp0d_mtOLLzedc_zcG0UorjKAdl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 3.5pt; padding-left: 9pt">Total operating lease liability</td><td style="padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right">295,717</td><td style="padding-bottom: 3.5pt; text-align: left"> </td><td style="padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right">349,894</td><td style="padding-bottom: 3.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A9_z00kFBNbKkt1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At March 31, 2026, the future estimated minimum lease payments under non-cancelable operating leases are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_896_ecustom--ScheduleOfFutureEstimatedMinimumLeasePaymentsUnderNonCancelableOperatingLeases_zc4IZLXvb2D9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details 1)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span id="xdx_8BA_z2M9GLQvgaK9" style="display: none">Schedule of future estimated minimum lease payments under non-cancelable operating leases</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_49D_20260331_zMLggdHwIgjh" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0d_maLOLLPzZfV_zpJEgbWsNDli" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; width: 85%">Year ending June 30, 2026 (Remaining 3 months)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">31,124</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0d_maLOLLPzZfV_z7PM0HJN6Zf5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">126,313</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pp0d_maLOLLPzZfV_z14J0e506nY9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2028</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">130,734</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pp0d_maLOLLPzZfV_zABeZRBoPrFa" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">2029</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">77,796</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0d_mtLOLLPzZfV_zK9nDf3hitZi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total minimum lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">365,967</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0d_di_zAK9AUzDaTk3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less amount representing interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(70,250</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--OperatingLeaseLiability_iI_pp0d_zWlicW4EPWQk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Present value of future minimum lease payments</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">295,717</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A3_zw5n0lVIAyWh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Total cash paid for amounts included in the measurement of lease liabilities were $<span id="xdx_900_ecustom--CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities_c20250701__20260331_pp0p" title="Cash paid for amounts included in measurement of operating lease liabilities">90,917</span> and $<span id="xdx_902_ecustom--CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities_c20240701__20250331_pp0p" title="Cash paid for amounts included in measurement of operating lease liabilities">87,843</span> for the nine months ended March 31, 2026 and 2025, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The weighted average remaining lease term and discount rate as of March 31, 2026 and June 30, 2025 were as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_895_ecustom--ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock_zowIIdrL1rRj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details 2)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 9pt"><span id="xdx_8BE_zB5HhOy9Rmdk" style="display: none">Schedule of weighted average remaining lease term and discount rate</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Weighted average remaining lease term (Years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 70%; text-align: left; padding-left: 9pt">Operating lease</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_90F_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20261231_zElN8RY1UFee" title="Weighted average remaining lease term (Years) Operating leases">2.8</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20250630_zyU8GJX8VGHe" title="Weighted average remaining lease term (Years) Operating leases">3.6</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Weighted average discount rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 9pt">Operating lease</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20261231_z5CSmpSpCnGh" title="Weighted average discount rate Operating leases">15.00</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20250630_z0p7SM91gCwa" title="Weighted average discount rate Operating leases">15.00</span></td><td style="text-align: left">%</td></tr> </table> <p id="xdx_8A6_z9kDvErbFWc8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> 2200 10024 35000 32000 99000 95000 <table cellpadding="0" cellspacing="0" id="xdx_89B_ecustom--LesseeOperatingLeaseLiabilityTableTextBlock_zhOpq7yskOQ9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"><span id="xdx_8BD_zGssZv3wgUcg" style="display: none">Schedule of operating lease liabilities</span></td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left"> </td><td id="xdx_49F_20260331_zuhL1aHAloGh" style="text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left"> </td><td id="xdx_499_20250630_zAu0gPVvlVYi" style="text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; font-weight: bold">Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0d_zwauQkHC48u4" style="vertical-align: bottom; background-color: White"> <td style="width: 70%; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Operating lease right-of-use asset, net</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 12%; text-align: right">282,910</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 12%; text-align: right">339,653</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-decoration: underline; font-weight: bold">Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0d_maOLLzedc_zmS9xeMylp5l" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 9pt">Current portion of operating lease liability</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">82,398</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">74,464</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0d_maOLLzedc_zg3wna5nHQO7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Operating lease liability, net of current portion</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">213,319</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">275,430</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--OperatingLeaseLiability_iTI_pp0d_mtOLLzedc_zcG0UorjKAdl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 3.5pt; padding-left: 9pt">Total operating lease liability</td><td style="padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right">295,717</td><td style="padding-bottom: 3.5pt; text-align: left"> </td><td style="padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right">349,894</td><td style="padding-bottom: 3.5pt; text-align: left"> </td></tr> </table> 282910 339653 82398 74464 213319 275430 295717 349894 <table cellpadding="0" cellspacing="0" id="xdx_896_ecustom--ScheduleOfFutureEstimatedMinimumLeasePaymentsUnderNonCancelableOperatingLeases_zc4IZLXvb2D9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details 1)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span id="xdx_8BA_z2M9GLQvgaK9" style="display: none">Schedule of future estimated minimum lease payments under non-cancelable operating leases</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_49D_20260331_zMLggdHwIgjh" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0d_maLOLLPzZfV_zpJEgbWsNDli" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; width: 85%">Year ending June 30, 2026 (Remaining 3 months)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">31,124</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0d_maLOLLPzZfV_z7PM0HJN6Zf5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">126,313</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pp0d_maLOLLPzZfV_z14J0e506nY9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2028</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">130,734</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pp0d_maLOLLPzZfV_zABeZRBoPrFa" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">2029</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">77,796</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0d_mtLOLLPzZfV_zK9nDf3hitZi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total minimum lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">365,967</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0d_di_zAK9AUzDaTk3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less amount representing interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(70,250</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--OperatingLeaseLiability_iI_pp0d_zWlicW4EPWQk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Present value of future minimum lease payments</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">295,717</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> 31124 126313 130734 77796 365967 70250 295717 90917 87843 <table cellpadding="0" cellspacing="0" id="xdx_895_ecustom--ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock_zowIIdrL1rRj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details 2)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 9pt"><span id="xdx_8BE_zB5HhOy9Rmdk" style="display: none">Schedule of weighted average remaining lease term and discount rate</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Weighted average remaining lease term (Years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 70%; text-align: left; padding-left: 9pt">Operating lease</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_90F_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20261231_zElN8RY1UFee" title="Weighted average remaining lease term (Years) Operating leases">2.8</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20250630_zyU8GJX8VGHe" title="Weighted average remaining lease term (Years) Operating leases">3.6</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Weighted average discount rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 9pt">Operating lease</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20261231_z5CSmpSpCnGh" title="Weighted average discount rate Operating leases">15.00</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20250630_z0p7SM91gCwa" title="Weighted average discount rate Operating leases">15.00</span></td><td style="text-align: left">%</td></tr> </table> P2Y9M18D P3Y7M6D 0.1500 0.1500 <p id="xdx_804_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zEg449fHrpRh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0pt"></td><td style="width: 20pt; text-align: left"><b>8.</b></td><td style="text-align: justify"><b><span id="xdx_82B_z1eEpphkezsc">Commitments and Contingencies</span></b></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Royalty Agreements</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Agreement and Plan of Merger entered into on April 11, 2016, by and between our predecessor entities, LAT Pharma and NanoAntibiotics, Inc., the Company is obligated to pay a low single digit royalty on net sales of BIV201 (continuous infusion terlipressin) to be shared by the members of LAT Pharma Members, PharmaIn Corporation, and The Barrett Edge, Inc.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Technology Transfer Agreement entered into on July 25, 2016, by and between the Company and the University of Padova (Italy), the Company was obligated to pay a 5% on net sales (capped at a maximum of $200,000 per year) of all terlipressin products covered by US Patent No. 11364277, expiring in 2036 and the European Patent No. EP3347032, expiring in 2036 and pending patent applications in the U.S., Europe, China and Japan, related to the administration of terlipressin as a continuous infusion for the treatment of ascites.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Intellectual Property Rights Agreement entered into on April 18, 2019, by and between the Company and DOCUCHEM SLU, the Company is obligated to pay DOCUCHEM SLU $25,000 on the issuance of the U.S. patent for terlipressin and $50,000 each calendar year in which the gross sales in the U.S. of a product covered by a claim of an issued U.S. patent as directed to terlipressin exceeds $10,000,000.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Shareholder class action complaint and shareholder derivative complaints</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 19, 2024, a purported securities class action complaint, captioned <i>Eric Olmstead v. BioVie Inc. et al.</i>, No. 3:24-cv-00035, was filed in the U.S. District Court for the District of Nevada, naming the Company and certain of its officers as defendants. On February 22, 2024, a second, related putative securities class action was filed in the same court asserting similar claims against the same defendants, captioned <i>Way v. BioVie Inc. et al.</i>, No. 2:24-cv-00361. On April 15, 2024, the court consolidated these two actions under the caption <i>In re BioVie Inc. Securities Litigation</i>, No. 3:24-cv-00035 (the “Securities Class Action”), appointed the lead plaintiff, and approved selection of the lead counsel. On June 21, 2024, the lead plaintiff filed an amended complaint, alleging that the defendants made material misrepresentations and/or omissions of material fact relating to the Company’s business, operations, compliance, and prospects, including information related to the NM101 Phase 3 study and trial of bezisterim (NE3107) in mild to moderate probable AD, in violation of Sections 10(b) and 20(a) of the Exchange Act, and Rule 10b-5 promulgated thereunder. The class action is on behalf of purchasers of the Company’s securities during the period from December 7, 2022 through November 28, 2023, and seeks unspecified monetary damages on behalf of the putative class and an award of costs and expenses, including attorney’s fees. The defendants filed a motion to dismiss the amended complaint on August 21, 2024, and on March 27, 2025, the court denied that motion. The parties are now engaged in fact discovery. On February 13, 2026, Plaintiffs filed a motion for class certification and a motion for leave to file a second amended complaint. Defendants opposed the motion for leave to amend, and that motion is now fully briefed and pending before the court. Defendants’ opposition to the motion for class certification is due June 15, 2026.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Three shareholder derivative lawsuits piggy-backing on the Securities Class Action were filed in the United States District Court for the District of Nevada, allegedly on behalf of the Company, by three putative stockholders: Andrew Hulm on December 30, 2024; William Settel on April 28, 2025 and Cline Wilkerson on September 11, 2025, (collectively the “Related Derivative Lawsuits”). Each Related Derivative Lawsuit names the same current and former officers and directors as defendants and alleges essentially the same claims: that the defendants breached their fiduciary duties by causing or failing to prevent the securities violations alleged in the Securities Class Action, and related claims for unjust enrichment, waste of corporate assets, gross mismanagement, and abuse of control. On September 29, 2025, at the request of the parties, the court consolidated all three Related Derivative Lawsuits under the caption <i>In re BioVie Inc</i>. <i>Derivative Litigation</i>, Case No. 3:24-cv-0602-CSD (the “Consolidated Derivative Action”). On January 27, 2026, at the request of the parties, the court stayed the Consolidated Derivative Action pending resolution of a summary judgment motion by defendants in the Securities Class Action.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company believes that the claims are without merit and intends to defend vigorously against them, but there can be no assurances as to the outcome.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_806_ecustom--EmployeeBenefitPlanTextBlock_z0yxfR6QRLD4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0pt"></td><td style="width: 20pt; text-align: left"><b>9.</b></td><td style="text-align: justify"><b><span id="xdx_827_zaVRTF7neZT1">Employee Benefit Plan</span></b></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company sponsors an employee benefit plan subject to Section 401(K) of the Internal Revenue Service Code (the “401K Plan”) pursuant to which, all employees meeting eligibility requirements are able to participate.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to certain limitations in the Internal Revenue Code, eligible employees are permitted to make contributions to the 401K Plan on a pre-tax salary reduction basis and the Company will match 5% of the first 5% of an employee’s contributions to the 401K Plan. The Company made contributions into the plan of approximately $<span id="xdx_900_eus-gaap--DefinedBenefitPlanContributionsByEmployer_c20260101__20260331_pp0p" title="Employee's contributions">49,700</span> and $<span id="xdx_906_eus-gaap--DefinedBenefitPlanContributionsByEmployer_c20250101__20250331_pp0p" title="Employee's contributions">46,800</span>, for the three months ended March 31, 2026 and 2025, respectively. The Company made contributions into the plan of approximately $<span id="xdx_90D_eus-gaap--DefinedBenefitPlanContributionsByEmployer_c20250701__20260331_pp0p" title="Employee's contributions">124,900</span> and $<span id="xdx_903_eus-gaap--DefinedBenefitPlanContributionsByEmployer_c20240701__20250331_pp0p" title="Employee's contributions">108,800</span>, for the nine months ended March 31, 2026 and 2025, respectively.</p> 49700 46800 124900 108800 <p id="xdx_807_eus-gaap--SegmentReportingDisclosureTextBlock_zfDqks3eCPbk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0pt"></td><td style="width: 20pt; text-align: left"><b>10.</b></td><td style="text-align: justify"><b><span id="xdx_828_zP2EmMqMhSx8">Segment Reporting</span></b></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company operates as one operating segment with a focus on its efforts to develop drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. The Company's CEO, as the chief operating decision maker, manages and allocates resources to the operations of the Company based on the line items included within these condensed financial statements and segment performance is evaluated based on net loss. This enables the CEO to assess the overall level of available resources and determine how best to deploy these resources across functions, clinical trials, and development projects in line with the long-term company-wide strategic goals. The measurement of segment assets is reported on the condensed balance sheet as total assets. All of the Company’s tangible assets are held in the United States.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table presents selected financial information with respect to the Company’s single operating segment and its significant segment approximated expenses for the nine months ended March 31, 2026 and 2025:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_88F_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zkHvvdBvoGGj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Segment Reporting (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span id="xdx_8B0_zmF0eTFgPT1e" style="display: none">Schedule of segment reporting information</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_490_20250701__20260331_zrjHr3IOVQy6" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_495_20240701__20250331_zk3pzzCI7aZc" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Nine months ended</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Nine months ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_40C_ecustom--ClinicalStudies_pp0d_maNLz0rl_zCtIa2jmzq7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left">Clinical studies</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">6,602,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">4,097,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_ecustom--ClinicalTeams_msNLz0rl_zd4sU3N9IzMe" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Clinical teams</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,255,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,968,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--ChemistryManufacturingAndControls_iP3custom--ClinicalTeams_msNLz0rl_zqaT2Il3WMt2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Chemistry, manufacturing and controls</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">142,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">726,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--OtherResearchAndDevelopmentExpenses_msNLz0rl_z66qd77JZpmc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other research and development expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">384,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">251,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_ecustom--SellingGeneralAndAdministrativeExpenses_msNLz0rl_zH5kV3K09FF7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">General and administrative expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,377,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,189,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AdjustmentForAmortization_msNLz0rl_z9qe2OTMgOjc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Amortization of intangible assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">172,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">172,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--OtherIncome_pp0d_maNLz0rl_z9rI4OL1ttVa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Other income, net</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(505,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(350,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40D_ecustom--NetLoss_pp0d_zaHOTcnwDPKf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 3.5pt">Net loss</td><td style="padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right">(16,427,000</td><td style="padding-bottom: 3.5pt; text-align: left">)</td><td style="padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right">(14,053,000</td><td style="padding-bottom: 3.5pt; text-align: left">)</td></tr> </table> <table cellpadding="0" cellspacing="0" id="xdx_88F_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zkHvvdBvoGGj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Segment Reporting (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span id="xdx_8B0_zmF0eTFgPT1e" style="display: none">Schedule of segment reporting information</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_490_20250701__20260331_zrjHr3IOVQy6" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_495_20240701__20250331_zk3pzzCI7aZc" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Nine months ended</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Nine months ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_40C_ecustom--ClinicalStudies_pp0d_maNLz0rl_zCtIa2jmzq7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left">Clinical studies</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">6,602,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">4,097,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_ecustom--ClinicalTeams_msNLz0rl_zd4sU3N9IzMe" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Clinical teams</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,255,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,968,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--ChemistryManufacturingAndControls_iP3custom--ClinicalTeams_msNLz0rl_zqaT2Il3WMt2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Chemistry, manufacturing and controls</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">142,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">726,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--OtherResearchAndDevelopmentExpenses_msNLz0rl_z66qd77JZpmc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other research and development expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">384,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">251,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_ecustom--SellingGeneralAndAdministrativeExpenses_msNLz0rl_zH5kV3K09FF7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">General and administrative expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,377,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,189,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AdjustmentForAmortization_msNLz0rl_z9qe2OTMgOjc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Amortization of intangible assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">172,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">172,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--OtherIncome_pp0d_maNLz0rl_z9rI4OL1ttVa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Other income, net</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(505,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(350,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40D_ecustom--NetLoss_pp0d_zaHOTcnwDPKf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 3.5pt">Net loss</td><td style="padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right">(16,427,000</td><td style="padding-bottom: 3.5pt; text-align: left">)</td><td style="padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right">(14,053,000</td><td style="padding-bottom: 3.5pt; text-align: left">)</td></tr> </table> 6602000 4097000 3255000 2968000 142000 726000 384000 251000 6377000 6189000 172000 172000 -505000 -350000 -16427000 -14053000